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1. GENERAL INTRODUCTION
The aim of this doctoral thesis is to investigate the use, the benefits, the risks and possible 
discontinuation of the most prevalent (psychotropic) drug in older nursing home residents for 
its most frequent indication: benzodiazepines and Z-drugs used for insomnia.
1.1 BENZODIAZEPINES WITHIN POLYPHARMACY IN OLDER PEOPLE
Age-related pharmacokinetic- and dynamic alterations make older adults more sensitive to 
their medications and also more susceptible for adverse effects [1]. Moreover, with aging, mul-
tiple pathologies can emerge, which require a complex treatment approach as there is not 
just one specific organ failure. This often results in polypharmacy (5 or more medications per 
day) and a complex medication regimen [2]. Moreover, older people can develop functional 
and cognitive impairment which additionally impedes the (pharmacological) treatment.
The Belgian health survey in 2008 showed that polypharmacy is frequent (40%) in people 
aged 75 or more [3]. Also in other countries, medication use among older adults is high and 
even increased in the last years [4, 5]. This increase in concomitant medication use can be ex-
plained by the rise of preventive medicine and the occurrence of the “prescribing cascade”, 
where one medication causes adverse effects which are countered with another medication 
[5]. 
Older adults living in residential care have even higher polypharmacy compared to older 
adults living at home [3, 6, 7]. However, these frail (and often cognitively impaired) residents 
have an increased susceptibility to adverse medication effects [8]. Psychotropic drugs, such as 
hypnotics, anxiolytics, antidepressants and antipsychotics dominate the medication chart of 
these older adults [6, 9, 10]. Moreover, use of multiple psychotropic drugs is common. In Belgian 
nursing homes, 47% of the residents took two or more psychotropic drugs in 2006 [11] and in 
Norwegian nursing homes, this was 33% in 2009 [9]. This high prevalence of psychotropic drug 
use increases the risk of side-effects in this frail older population.
Benzodiazepines, together with the related Z-drugs, are the most recurring group of drugs in 
terms of chronic prescribing and in terms of inappropriate psychotropic polypharmacy (in-
cluded in explicit criteria for detecting inappropriate prescribing such as the Beers criteria [12, 
13], STOPP criteria [14], Priscus list [15], Rancourt [16] and Laroche criteria [17]). Prescribing patterns 
vary widely between countries but long-term use is common [18]. 
In the UK and the US, the prevalence is somewhat lower [7, 19] due to special warnings (OBRA-
87 in the US[20] and a warning to prescribing physicians on dependence in the UK in ’88[21]), 
and to government initiatives in the late ‘80s and ‘90s such as the exclusion of BZD coverage 
in Medicare in the US[22] and the New York State triplicate prescription policy[23] which con-
stituted a barrier to accessing BZDs. These policies reduced BZD prescribing, though a shift 
towards other (psychotropic) medications could not be totally avoided[24, 25]. Some saw an 
increased use in the nonbenzodiazepine sedatives and even barbiturates (early ‘90s)[23, 26]. In 
order to avoid prescribing BZDs, sedative antidepressants such as trazodone are increasingly 
prescribed to treat insomnia problems[27, 28]. However, the evidence for trazodone for insom-
nia without depressive symptoms in older people is rather scarce and controversial[29].
In Belgium, the consumption of benzodiazepine and Z-drugs is high[30] -485 million DDD in 
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2012 as reported by de Algemene Pharmaceutische Bond)- especially among older adults (in 
2008, 13% used an anxiolytic BZD and 10% used a hypnotic BZD in the past 24h [3]). In com-
parison to other European countries, Belgium together with France, Portugal and Sweden 
are large consumers of these drugs (rapport ANSM 2013)[31]. In the neighbouring country, 
the Netherlands, the consumption is lower and decreased due to the cancellation of the 
reimbursement in 2009 [32]. There are several possible hypothesis that can explain why the 
Belgian consumption is high.  Though BZD/Zs are not reimbursed by the health care system, 
the out-of-pocket cost is relatively low. Furthermore, there is the global medicalization of 
psycho-social problems [33].The patient’s expectation together with the lack of communica-
tion and motivational techniques can pressure the physician to prescribe medications [34, 35]. 
Cultural aspects such as religious background have also been shown to impact the cross-na-
tional differences in medication use (difference in antibiotic use [36]). Although the physician is 
the only person allowed to prescribe medication, the final decision is the result of a complex 
interaction between patient and physician [37]. In comparison to the UK and US, there was a 
relative late start of federal campaigns to increase the awareness of BZD/Z consumption in 
Belgium (public campaigns and educational programs for physicians and pharmacists were 
launched after 2001). Moreover, in Belgium the patient is free  to choose both his general 
practitioner (GP) and pharmacist and can easy switch or consult multiple caregivers. The re-
muneration of the GP is based on a fee-for-service principle which can influence the already 
complex patient-doctor relationship.
In general, the use of benzodiazepine and Z-drugs (BZD/Z) is linked to older age [38, 39], with the 
highest prevalence in older adults in residential care [40]. 
Benzodiazepines have several pharmacological actions, but are mainly used to treat sleep 
problems and anxiety [41]. Though BZD/Zs are effective and relatively safe medication when 
used acutely, many national and international guidelines [41-44] warn for chronic BZD/Z use 
because of the lack of effectiveness after 4 weeks, the increased risk of dependence, and 
side-effects [45-47]. BZD/Zs have reinforcing effects which can result in abuse liability (nonmed-
ical use). However, the abuse for recreational purpose is rare in older adults [48, 49].
A remarkable contradiction between recommendations against long-term use of BDZ/Z drugs 
and their high prevalence, especially in older adults, raises several questions: are the guide-
lines too strict; is the evidence of associated risk not convincing; are prescribers reluctant; or 
is it too difficult to overcome habitual prescribing in this older population?
1.2 BENZODIAZEPINES, AN OVERVIEW
The benzodiazepines (BZDs) are a group of psychoactive drugs with sedative, hypnotic 
(sleep-inducing), anxiolytic, anticonvulsant (anti-epileptic), muscle relaxant and amnesic ac-
tion. Since their development in the mid ’50s by Leo Sternbach and his colleagues at Roche, 
they quickly replaced the less safe barbiturates and became a frequently prescribed drug for 
anxiety and/or insomnia [50, 51]. 
The more recently developed benzodiazepine receptor agonists (Z-drugs), zolpidem, zopi-
clone, eszopiclone and zaleplon entered the market in the late ‘80s. They work similar as the 
BZDs, though they are mainly indicated for hypnotic use. Since the ‘80s, several guidelines 
and campaigns warned for the detrimental effects of BZDs (tolerance and dependence) and 
the newer Z-drugs were promoted as more selective and with less side-effects, despite the 
lack of evidence[52]. Consequently, Z-drugs were increasingly prescribed, while the use of ben-
zodiazepine hypnotics decreased [53, 54]. Later research showed that Z-drugs have an equally 
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harmful risk profile as BZDs [54, 55]. 
Due to the BZDs’ differential kinetics and interaction with the receptor, they somewhat differ 
in usage. Short- and intermediate-acting benzodiazepines (duration of action around 24h or 
less) are preferred for the treatment of insomnia; longer-acting benzodiazepines (duration 
of action exceeding 24h) are recommended for the treatment of anxiety [41]. The Anatomical 
Therapeutic  Chemical (ATC) system from the World Health Organisation [56] classifies the 
BZDs and Z-drugs into Hypnotics (N05CD), Anxiolytics (N05BA) and Z-drugs (N05CF). This clas-
sification is not really instrumental to distinguish between clinical indications, as most BZDs 
have diverse pharmacological properties: sedative, anxiolytic, hypnotic, antiepileptic, muscle 
relaxant and amnesic.
1.2.1 Pharmacodynamics
BZDs interact with the gamma (γ )-aminobutyric acid (GABA) receptor, which is a part of the 
major inhibitory neurotransmitter system in the brain [57, 58]. There are three families of the 
GABA receptor: GABA
A
 and GABAB and GABAC(GABAA-ρ subclass) , but the BZDs only bind 
with the GABA
A
 receptor at a specific BZD site. BZDs facilitate the action of the neurotrans-
mitter GABA by increasing the influx of negatively charged chloride ions and enhance the 
neuronal inhibition of GABA, resulting in the hypnotic, anxiolytic, sedative, muscle relaxant 
action. The GABA
A 
receptor consists of 5 different  transmembrane subunits. There are sev-
eral possible subunits (α1-6, ß1-3, γ1-3, δ, ε, θ and π) that result in the heterogeneity of the 
GABA
A
 receptor [59]. The most common receptor type is composed of two α, two ß and one 
γ subunit [60]. Depending on the subtype of the GABA
A
 receptor, they are present in different 
locations throughout the brain, indicating that they have different functional properties. Each 
receptor complex has two GABA binding sites but only one BZD binding site (located between 
α and γ subunit [61]). Not all BZDs interact with the same type of GABA
A
 receptor or with equal 
affinity, which results in the more selective work profile of the BZDs [58].
More into detail, α1 containing GABA
A
 receptors are probably more sedative, amnesic and 
anticonvulsant. Muscle relaxation and anxiety reduction are primarily ascribed to α2 and pos-
sibly α3. Researchers are still not sure of the clinical relevance of pharmacodynamic differ-
ences among BZDs caused by the differential selectivity for the GABA
A
 subtypes.[59]. Clinicians 
more often use the pharmacokinetic properties to categorise BZDs.
The Z-drugs also interact with the GABA
A
 receptor similarly to the BZDs and at the same 
binding site (between the α and the γ subunit). Zolpidem has a preferential agonistic activity 
at the α1 subunit [62]. 
With aging, pharmacodynamics change: the atrophy of neurons, loss of receptors and altered 
receptor affinity leads to a changed sensitivity of the central nervous system (CNS) which 
increases the possibility of CNS side effects, such as confusion, increased postural sway and 
subsequent risk of falling [1, 63].
1.2.2 Pharmacokinetics
The pharmacokinetic properties of BZD/Zs describe their absorption, distribution, metabo-
lism, and excretion (i.e. what the body does to the drug). This pharmacokinetic profile deter-
mines the onset and the duration of action. The most common way to classify BZD/Z drugs is 
based on their elimination half-life (T
1/2
: the time needed to reduce the drug concentration 
in the plasma by half)[58]. In our studies, we categorize BZD/Zs according to half-life in short/
intermediate (T
1/2
<24h) and long-acting (T
1/2
≥24h) [41, 64]. However, these arbitrary cut-offs are 
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not universal and vary per country[65]. Some BZD/Zs produce active metabolites and this ex-
tends their duration of action (see box 1). 
BZD/Zs can be administered via oral, sublingual, intramuscular, intravenous, intranasal or rec-
tal route, of which the oral route is the most common. BZD/Zs are usually well absorbed by 
the gastrointestinal tract after oral administration. The lipid solubility of the BZD/Z increases 
the absorption and distribution. The fast absorption through the blood-brain barrier results 
in a quick onset of clinical effect. The increased distribution extends the plasma half-life. 
Most BZD/Zs and their metabolites are highly protein bound. They are widely distributed in 
the body and preferentially accumulate in lipid-rich areas such as the central nervous sys-
tem (CNS) and the adipose tissue. Most of the BZD/Zs are oxidatively metabolized by the 
cytochrome P450 enzymes in the liver (phase I metabolism), conjugated with glucuronide 
to make them more water soluble (phase II metabolism), and excreted almost entirely in the 
urine [58]. Long-term use and repeated daily doses result in accumulation in fatty tissue and 
possible hangover effects (residual drowsiness i.e., day-time somnolence and marked psych-
omotor and cognitive impairment)[66, 67]. 
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Aging has also some pharmacokinetic implications. While BZD/Z absorption is not really al-
tered, the reduced first-pass metabolism due to a reduction in liver mass and blood flow 
can lead to an altered clearance of drugs through the liver. The drug metabolizing enzymes 
and conjugation process is not really altered. However, multiple drug use can impede drug 
metabolisation. The body composition changes with a progressive reduction in total body 
mass resulting in a relative increase in body fat. Therefore, the lipid soluble BZD/Zs have an 
increased distribution and a prolonged half-life [1, 63].
1.2.3 Efficacy 
Benzodiazepines are considered to be acutely effective for the treatment of insomnia, anxie-
ty, epilepsy, muscle cramps, and as (pre) anaesthetic. 
The efficacy of BZD/Zs for insomnia will be addressed in section 1.3.
Anxiety disorder is an umbrella term that covers several different forms such as general-
ised anxiety (GAD), panic disorder, posttraumatic stress, social phobia (social anxiety disorder 
SAD), specific phobias and obsessive compulsive disorder (OCD)[68]. Anxiety disorders can ex-
ist in isolation but often co-exist with psychiatric disorders, most commonly depression [69]. 
BZD are efficacious in the acute treatment of GAD, SAD and panic disorder, but have limited 
effect on other anxiety conditions (OCD, agoraphobia, phobias) [70]. Because most anxiety 
disorders tend to be chronic for which long-term treatment is often necessary and because 
it rarely exists as a single condition, guidelines (NICE guideline on GAD and panic disorder in 
adults[71], national guideline[72], Trimbos guideline[73]) recommend use of psychological thera-
py or an antidepressant. Non-pharmacological therapy such as cognitive behavioural therapy 
(CBT) has proven to be effective in the long-term (>1 year) [69]. Tolerance and dependency 
problems of BZDs and the concurrence of depression are the reasons why antidepressants 
are the pharmacological choice for (chronic) anxiety [68]. Selective serotonine reuptake inhibi-
tors (SSRI’s) are preferred above tricyclic antidepressants because of their less severe side-ef-
fect risk. However, a recent review questions the superiority of antidepressants over BZDs in 
terms of efficacy and tolerability [74].
Epilepsy, more specifically status epilepticus (prolonged or repeated generalised, convulsive 
seizures) can be successfully treated with an acute administration of BZDs (diazepam, loraz-
epam, midazolam) (NICE clinical guidelines 2012[75]). Also muscle spasms can be effectively 
treated with BZDs (mainly diazepam and tetrazepam) [76]. Although they are not recommend-
ed for low back pain (NICE  2009[77]), some studies showed that tetrazepam was beneficial 
in improving pain [78]. However, muscle spasm can be seen as a protective mechanism that 
should not be inhibited by muscle relaxants. BZDs are not effective for muscle spasm in rheu-
matoid arthritis [79]. 
1.2.4 Tolerance 
BZDs and related Z-drugs are initially efficacious, but after 2 to 4 weeks, the effects fade and 
tolerance develops. Tolerance is defined as a decrease over time in the ability of the drug to 
produce the same degree of pharmacological effect [80].Tolerance is a major factor, impeding 
on the efficacy of long-term use. It appears at different rates and to a different degree for 
each of the BZD’s effects, including the side-effects [80, 81]. BZDs with short half-life are more 
likely to produce tolerance [82, 83]. Clinical studies showed that tolerance to the sedative and 
hypnotic effect occurs more quickly than for the anticonvulsant effect [80, 82]. Full tolerance to 
the anxiolytic effect has not been demonstrated [80]. Most clinical data do not support the ex-
istence of tolerance to the BZDs’ induced cognitive impairments (memory impairment)[57, 84]. 
The neuro-adaptive mechanism that underlies BZD tolerance is still unclear and several hy-
13
1.1
IN
TRO
D
U
CTIO
N
:    general introduction
potheses are possible: down-regulation of the GABA
A
 receptor is an obvious potential mech-
anism explaining both tolerance and withdrawal when stopped. However, there is increasing 
experimental evidence for different neuro-adaptive mechanisms: uncoupling of the linkage 
between GABA en BZD site on the receptor, intracellular changes (subunit gene turnover and 
changes in receptor gene expression), compensatory mechanism of glutamate receptors, in-
teraction with other neurotransmitters and neurosteroids [57]. 
Tolerance implies that a dose escalation is necessary in order to maintain the desired clinical 
effects. However, in most studies investigating prescribing of BZDs and Z drugs, such a dose 
escalation was not seen among low-dose users [85, 86]. Though hypnotic and anxiolytic effects 
fade, patients do not ask for a dose increase. This is also a reason to belief that there is a 
strong placebo effect and/or psychological dependence present. The minority of patients 
that do ask for a higher dose have specific personality traits [87] or severer psychiatric prob-
lems, and combine psychotropic medication [85]. 
1.2.5 Dependence and withdrawal symptoms
BZD/Zs dependence is multidimensional and includes both physical and psychological ele-
ments (WHO definition). The term addiction should be considered a synonym for depend-
ence, though in many contexts, the former term  has a different connotation (behaviour that 
is out of control). In the ‘60s the WHO recommended to abandon ‘addiction’ in favour of 
‘dependence’, which can exist in various degrees of severity. BZD/Z dependence/addiction is 
distinct from BZD/Z misuse, which implies nonmedical use, use for pleasurable purpose, and 
criminal use (out of scope in this thesis).
Physical dependence refers to the development of withdrawal symptoms in response to drug 
cessation or decrease in dose [88]. The main withdrawal effects are agitation, irritability, in-
creased sensitivity to light and sound, muscle cramps, headache, dizziness, nausea, loss of 
appetite, and also rebound insomnia or anxiety, which can be more intense than the initial 
symptoms for which the BZD/Z was started[89]. These symptoms can be mistakenly seen as 
the persistent efficacy of the BZD/Z and are often the reason to continue use. The duration 
of (chronic) use, the BZD/Z half-life (the longer the half-life, the longer the timespan of the 
appearance of withdrawal symptoms) and the dose all affect the start and duration of with-
drawal symptoms [81]. Rebound insomnia and anxiety are more intense in BZD/Zs with a short 
elimination half-life [83]. The rebound insomnia and tolerance are commonly perceived to be 
derived from the same compensatory mechanism by which the GABA
A
 receptor becomes less 
responsive to the continuing acute effects of BZDs due to several adaptation (see tolerance) 
[57, 80].
The most recommended clinical option to overcome withdrawal symptoms is supervised 
gradual tapering [90], though abrupt discontinuation of long-term low-dose treatment seems 
feasible [91].   
Psychological dependence is a more complex concept. Psychological dependence is a de-
pendency of the mind (cravings, irritability) and includes some form of loss of control (lack of 
respect for dose restrictions and treatment periods, compulsive drug-seeking behaviour e.g. 
forging prescriptions, going to multiple doctors for prescriptions). Psychological dependence 
is believed to be strongly associated with particular areas of the brain’s rewarding system 
(dopamine)[92]. Craving is regarded as an important aspect of dependence as this can be the 
reason why patients relapse after a discontinuation [93]. BZD/Zs craving is still a vague concept 
and appears in varying degrees. In some research [94] drug insistence (not wanting to discon-
tinue) is labelled craving. As shown in another study, the majority of the long-term BZD/Z 
users show minor signs of craving (positive evaluation of  initial effectiveness, fear of relapse 
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upon withdrawal)[95].
BZD/Z dependence (both physical and psychological) can lead to a ‘substance related and 
addictive disorder’ (as defined by the DSM-V criteria) and refers to problematic pattern of 
BZD/Z use leading to clinically significant impairment or distress[81].
1.2.6 Side-effects of benzodiazepine use
The acute side-effects of benzodiazepines and Z-drugs are inherent to their working mech-
anism. BZD/Z drugs induce sedation and muscle relaxation, which can cause impaired alert-
ness, drowsiness, impaired driving skills, and increased risk of falling[47, 96] . A common side 
effect of BZDs, especially of long-acting drugs, is the residual drowsiness i.e. day-time som-
nolence, and marked psychomotor and cognitive impairment [66, 97]. Depending on someone’s 
susceptibility, the BZD’s potency and dose, BZD/Zs can cause paradoxical effects such as in-
creased anxiety, seizures, and disinhibiting effects such as aggression [98, 99] (occurs in less than 
1% of patients). Other rare paradoxical effects related to the hypnotic use of BZD/Zs, include 
complex sleep-related behaviours (sleep walking, eating, driving and aggressive behaviour) 
[100, 101]. Upon acute use, BZD/Z drugs impair several areas of cognition (attention, reaction 
time and psychomotor functions) and cause anterograde amnesia [102, 103]. Cognitive and psy-
chomotor impairment can be detected even at ostensibly therapeutic doses (1 DDD). 
Although most BZDs and Z-drugs are often used chronically, the evidence on side-effects is as 
inconclusive as the evidence on the effectiveness. Cognitive impairment and incident demen-
tia has been linked to long-term BZD/Z use, but the  literature is inconclusive [104]. While some 
studies suggest a negative effect of chronic BZD/Z use on cognitive decline [105-108] and even an 
increased risk for dementia[109-112], others did not find an association [113-115], and some even 
found a protective effect of BZD use on cognition [116, 117]. These studies are not equally com-
parable with each other due to different methodological design (prospective cohort, whether 
or not controlled, nested case control), due to the used outcome measurements to evaluate 
cognition (ceiling effects, varying sensitivity to change) [118, 119] and due to the heterogeneity of 
the study population (some were psychiatric patients, some healthy adults,…).
Most of the abovementioned side-effects are not life-threatening, some fade due to tol-
erance, and some might be reversible [47]. However, several studies have postulated an in-
creased mortality risk (an association) in chronic BZD/Z users [120-124], while others failed to 
draw such conclusions [125, 126]. The inconsistent findings are mostly due to methodological 
limitations, the study design,  the duration of follow-up (2.5y till 20years), the heterogeneity 
in age ranges and heterogeneity in sample size, the type of hypnotic, and finally, the lack of 
distinction between indications (use for psychiatric disorders or for sleep disorders [125]).
1.3 BENZODIAZEPINES FOR SLEEP PROBLEMS
Benzodiazepines and Z-drugs are the most commonly used symptomatic treatment for sleep 
problems [127, 128]. The BZD/Zs that are used for this indication have fast absorption and distri-
bution rates, which result in rapid sleep induction and is particularly important since delayed 
sleep onset is a major complaint of sleep problems.
Sleep problems affect 10-15% of the general population and increase with growing age [128, 
129]. In the normal aging process, changes in the sleep structure occur with less restorative 
deep sleep (i.e. stage III of the nonrapid eye movement NREM) and a more fragmented sleep 
pattern [130]. In addition, comorbidities, medication use and sleep-related disorders (restless 
legs, periodic limb movement, sleep apnoea), all affect sleep quality and increase with age 
15
1.1
IN
TRO
D
U
CTIO
N
:    general introduction
[131]. In Belgium, more than one in four adults aged 65 or more experienced sleep problems 
(27% in the 2008 Health Interview Survey Belgium)[3].
Sleep problems are categorised into dyssomnia (restless legs, periodic limb movement, sleep 
apnoea, narcolepsy), into parasomnia (REM sleep behaviour disorder, night terrors, sleep 
waking) and into insomnia, of which the latter is the most common disorder and therefore 
the most researched. The diagnostic systems (such as the American Psychiatric Association 
DSM-V[132], the American Academy of Sleep Medicine International Classification of Sleep 
Disorder ICSD-2[133], the World Health Organisation International Classification of Diseases 
ICD-10), use different definitions for insomnia, which makes mutual comparison of insomnia 
research difficult [134]. Although all systems include daytime impairment in their criteria for 
insomnia, this requirement is not always fulfilled when BZD/Zs are prescribed in clinical prac-
tice. In this thesis, as well as in clinical practice, poor sleep and problems with initiating and 
maintaining sleep (even without daytime impairment) is often labelled as insomnia. 
Box 2. Diagnostic criteria for common insomnia types (adopted from the ICSD-2, 2005 of the American Academy of Sleep Medi-
cine, the WHO ICD-10 classification, and from the American Psychiatric Association’s DSM-V, 2013
INSOMNIA
Primary insomnia -        problems with initiating sleep, maintaining sleep, waking up too
         early, or nonrestorative sleep although there is adequate opportunity for sleep
AND
-        daytime impairment
EXCLUDE Sleep disturbance DUE TO underlying medical, psychiatric, or environmental problem
Psychophysiological 
insomnia
-        idem primary insomnia
AND
-        at least present for 1 month
AND
-        the patient has evidence of conditioned sleep difficulty and/or heightened arousal in bed
Comorbid insomnia -        sleep disturbance is comorbid with an underlying problem
Paradoxical (Pseudo) 
insomnia
-        complaints of insufficient and/or unsatisfying sleep
BUT
-        no daytime impairment
In terms of BZD/Z efficacy research, the most studied indication is primary insomnia (in-
somnia without any underlying problem or comorbidity). However, a majority of insomnia 
patients have sleep problems originating from an underlying disorder, such as cardio-meta-
bolic disorders, musculoskeletal conditions (arthritis, chronic back or neck pain), respiratory 
disorders, digestive disorders, chronic pain, all known as comorbid (or secondary) insomnia 
[135]. Psychiatric disorders (with anxiety disorder, depressive disorder, bipolar disorder and 
adjustment disorder) are the most common conditions comorbid with insomnia[135, 136]. In the 
older (nursing home) population, the aging process causes a fragmented sleep pattern, which 
is more vulnerable to the underlying comorbidities [131, 137]. Unfortunately, these patients are 
often either excluded in clinical research, either not recognised as such. Therefore, there is 
no effectiveness data available for this large patient group. 
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Insomnia is a clinical diagnosis based on the reporting of the patient. Therefore, clinical stud-
ies on the effectiveness of BZD/Zs should combine objective and subjective evaluation of 
sleep parameters. Next to the decrease in sleep latency and increase in total sleep duration, 
it is important to measure the feeling of being well rested and daytime fatigue. Therefore, in 
our studies we will use a subjective scale that measures different aspects of sleep quality (The 
Pittsburgh Sleep Quality Index- Buysse 1989[138]).
BZDs and Z-drugs are effective for short-term treatment of insomnia [139]. Systematic reviews 
showed that time to fall asleep is decreased and total sleep duration enhanced [127, 140-142]. Ob-
jective polysomnographic research showed also an altered sleep structure, with an increase 
in NREM, a decrease in deep sleep (SWS) and a prolonged REM latency. A meta-analysis in 
older people with insomnia [143] showed an improvement in sleep quality, an increased total 
sleep time (mean 25min), and a decreased number of night-time awakenings when using 
BZDs and/or Z-drugs compared to placebo. Though the effect sizes are significant, their mag-
nitude is small. Moreover, a meta-analysis indicated that the objective polysomnographic 
measurements show small improvement in sleep latency and sleep duration, while the pa-
tient’s reported subjective sleep latency (assessed with sleep diaries or questionnaires) was 
more optimistic[140]. This indicates that there may be an overestimation of the BZD’s effects 
on sleep outcome parameters [140]. Moreover, the selective reporting and publishing of pos-
itive studies and results also indicates that there is an overestimation favouring the BZD/Z 
drugs’ effects [141, 144]. In addition to the possible overestimation of the BZD/Z’s effects, several 
meta-analysis showed that placebo treatment also improves the sleep significantly [145, 146]. 
Because BZD/Zs are not free of side-effects, the overall risk/benefit balance must be taken 
into account. Moreover, all these studies investigated the effect of a short-term treatment. 
The maximum study duration for BZDs is 8 weeks[147]  and for Z-drugs it is 1 year [148, 149]. Al-
though the majority of BZD/Z users are chronic users, research on long-term BZD or Z-drug 
use is lacking. 
Till now, there is a lack of a credible evidence base for the long-term efficacy of BZD/Z use. 
Because of practical obstacles but also because long-term BZD/Z therapy is not concordant 
with the guidelines, it is difficult to initiate randomised controlled trials with incident users 
and follow the sleep longitudinal. The studies that did try to evaluate long-term effectiveness 
found a worse sleep quality in long-term users [46, 111, 150]. After taking into account both the 
short-term and long-term risks of BZD/Z use, and in the light of questionable effect of these 
drugs on sleep problems in the long-term, guidelines discourage chronic BZD/Z use.
1.4 BENZODIAZEPINES IN THE NURSING HOMES
The prevalence of BZD/Z use in older adults in residential care ranges from 28% to 55% in 
European [40, 151-153] and Australian nursing homes (32%)[154]. In the UK and US the prevalence 
is somewhat lower, 13% and 14% respectively [7, 19], due to special warnings (OBRA-87 and 
government initiatives) and a shift towards sedative antidepressants [27].
In Belgium, more than 50% of the older nursing home residents (PHEBE in 2006) received 
BZD/Z drugs. In nine out of ten residents, this use was longer than 3 months indicating chron-
ic use[11]. 
1.4.1 Belgian nursing home setting
Belgium has a mixed, public (community health services)/private (predominantly 
non-profit) health care system, with little difference in quality. The payment system is 
fee for service.  An essential principle of the Belgian health care system is the patient’s 
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freedom of choice of his primary and specialist care provider. When entering the nursing 
home, most of the residents retain their own GP, which leads to an average of 32 visiting 
GPs per nursing home. Although each nursing home has a medical coordinator who is a 
general practitioner to a certain extent trained in care for older people, the GP retains the 
responsibility for the treatment and the medication policy[155].
1.4.2 The high use and associated problems of benzodiazepines in the nursing homes 
Coming into a nursing home can be stressful and can provoke anxiety. Moreover, sleep 
problems are common in institutionalised settings. Not only because aging negatively 
affects sleep architecture, but also because environmental factors such as high level of 
noise, light and care routines can disrupt sleep [128]. Although one may expect that this 
is a place where a lot of BZD/Z drugs are initiated, most older adults enter the nursing 
home with already established BZD/Z use; the BZD or Z-drug is fixed on their medication 
list for years, even decades [114, 156, 157]. Often, the BZD/Z is initiated in primary care by their 
general physician [35] or during a hospital admission [158, 159]. The acute effectiveness, the 
establishment of dependency problems and the lack of reassessment leads to chronic 
continuation of these drugs. Although tolerance to the hypnotic and anxiolytic effects oc-
cur, aging increases the susceptibility towards the side-effects of medication. The atrophy 
of neurons and the intensified sensitivity of the central nervous system, together with 
pharmacokinetic alterations, which lead to BZD/Z accumulation, increases the possibility 
of confusion and CNS side-effects, hangover effects and subsequent risk of falling  [1, 160, 
161]. Often falls have no major consequences, but in older fragile adults this can cause 
injury and fractures, leading to hospitalisation and serious disability[162]. When BZD/Zs are 
used as sleep promoting agents, nocturia with frequent midnight visits to the bathroom 
increase fall risk [96]. It has been questioned whether there is an independent association 
between BZD/Z use and increased fall risk. Not only have falls a multifactorial aetiology 
(environmental, intrinsic muscle strength and extrinsic factors), but other psychotropic 
drugs are also associated with a 30-70% increased risk of falls [163-165]. 
This age group, with a higher risk of abovementioned side-effects, needs tailored pre-
scribing which includes de-prescribing[166]. Discontinuation of BZD/Z is widely advised, but 
has not reached global acceptance among prescribers, care givers and patients.
When confronting both the benefit and risk of BZD/Zs, their use seems to have drawbacks, 
especially for long-term use, and in this older population. Research on effectiveness and 
side-effects of chronic BZD/Z use remains inconclusive with few studies in the setting with 
the most abundant use, the nursing home setting.
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2     RESEARCH QUESTIONS
Although guidelines and national campaigns discouraged chronic benzodiazepine and Z-drug 
(BZD/Z) use, the Prescribing for Homes in the Elderly in BElgium (PHEBE) study in 2006 re-
vealed that the psychotropic drug use in the Belgian nursing homes was high (79%) and the 
BZD/Zs were the most abundant drugs on the medication chart (53%). This was the trigger 
for our research.
The research questions are:
1. What are the indications of the benzodiazepines and Z-drugs used in the 
 nursing home and at which dosages (chapter 2.1)? 
2. What is the proportion of antidepressants used for insomnia and anxiety in
 the nursing home and what are the dosages (chapter 2.2)?
3. What is the sleep quality of chronic BZD/Z use in nursing home residents and
 does it differ from nonusers (chapters 2.3 and 2.4)?
4.  What is the relationship between chronic BZD/Z use and cognitive 
 deterioration in nursing home residents? (chapter 2.5). 
5. Is it feasible to implement discontinuation in the nursing home 
 (chapter 2.6 and 2.7)?
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3     THESIS OUTLINE
In Chapter 2.1, we describe the indications and dosages of BZDs and Z-drugs in Belgian nurs-
ing homes in order to understand the highly prevalent use in this setting.
Antidepressants and benzodiazepines have overlapping indications and are both used for in-
somnia and anxiety (trazodone is becoming a popular sleeping aid). In Chapter 2.2, we inves-
tigate the indications and dosages of antidepressants for those overlapping indications. Both 
these studies (chapter 2.1 and 2.2) are based on a secondary analysis of a cross-sectional rep-
resentative study on medication consumption in the Belgian nursing homes (PHEBE-study).
In Chapters 2.3 and 2.4, we focus on the BZD/Z use for insomnia. For this indication, we want 
to contribute to the questionable benefit and provide information on chronic effect of BZD/Z 
use in terms of sleep quality (Chapter 2.3 and 2.4). We set up a prospective cohort study, 
comparing chronic BZD/Z users and nonusers and provide a cross-sectional analysis of the 
sleep quality using a validated sleep questionnaire (Pittsburgh Sleep Quality Index) in Chapter 
2.3. In Chapter 2.4, we analyse the temporal evolution of the sleep quality and the possible 
difference between chronic BZD/Z users and nonusers in a one-year follow-up.
In Chapter 2.5, we explore the worrisome link of BZD/Z use with cognitive decline. In the 
same cohort, we analyse whether chronic BZD/Z users have a different one-year evolution 
in cognition (as measured with the Mini Mental State Examination Score) compared to non-
users.
In the last two chapters, we want to analyse the feasibility of BZD/Z discontinuation in the 
nursing home setting. 
In Chapter 2.6, we explore barriers towards discontinuation pertaining to an individual resi-
dent in a cross-sectional survey among GPs and nurses.
In Chapter 2.7, we investigate the feasibility of discontinuation in a pilot study. In a small sam-
ple of cognitively competent residents we investigate overall feasibility and several outcome 
parameters such as change in sleep quality, quality of life and withdrawal effects.
Finally, we present our discussion and several implications for research and practice. 
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ABSTRACT
Objectives: 
(i) To describe the prevalence of benzodiazepine (BZD) and Z-drug use in Belgian nursing 
homes, with specific attention to indications and dosages.
(ii) To compare actual and recommended dosages of BZDs and Z-drugs for anxiety and in-
somnia.
(iii)To explore the risk profile for chronic BZD/Z use in institutionalised older adults.
Methods: Medication charts of 1730 residents from 76 nursing homes in Belgium were col-
lected and analysed, using the ATC classification. Drug name, indication and daily dosage 
were recorded. From authoritative international sources, we extracted for each drug and 
each indication a daily dosage recommended not to be exceeded in older adults for compar-
ison with observed actual dosages.
Results: Among the chronic BZD/Z users (50% of the residents), the leading indication was 
‘insomnia’ (59% of the users) followed by ‘anxiety’ (17%) and ‘unrest’ (10%). In the chronic 
prescriptions of BZD/Zs indicated for insomnia, the actual daily dose exceeded the geriatric 
upper limit: with lormetazepam in 95% ,zolpidem in 82%, zopiclone in 78% and lorazepam in 
35% of the prescriptions. In anxiety, daily doses also exceeded the limit but not to the same 
extent.
Multivariate analysis showed BZD/Z use was positively associated with pain (OR 1.58 CI95% 
1.27-1.97), constipation (OR 1.43 CI95% 1.16-1.76) and depression (OR 1.68 CI95% 1.35-
2.08). Residents with dementia were less likely to receive a BZD/Z (OR 0.60 CI95% 0.48-0.74).
Conclusion: Efforts to reduce the use of BZD/Zs in nursing homes should concentrate on 
insomnia, with interventions aimed at reducing too high prevalence of chronic use and too 
high daily dosages in this indication. 
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INTRODUCTION
Benzodiazepine utilisation in older adults is high, with intake rates varying from 28% to 55% 
in European nursing homes [1-4].  
  
Benzodiazepines are mainly indicated for the short-term treatment of insomnia and anxiety 
[5, 6]. Long-term use of benzodiazepines is discouraged in guidelines [5, 7, 8] because of the lack 
of effectiveness after 4 weeks [9, 10], the increased risk of dependence and abuse,  and with-
drawal syndromes [11, 12]. Moreover, it has been hypothesised that long-term use might have 
a detrimental effect on cognition and a potential acceleration of cognitive impairment [13-15].
 
High benzodiazepine utilisation in older adults is especially worrying, since age-related phar-
macokinetic-and dynamic alterations may lead to an increased risk of amnesia, confusion, 
sedation [16, 17], hangover effects [18, 19] and subsequent risk of falling [20].  
 
International drug formularies [21-23] recommend dose reduction when using ben-
zodiazepines in older adults. Moreover, in several attempts to develop prescrib-
ing quality indicators, upper limits for dosages in older adults have been estab-
lished for some benzodiazepines as part of lists with explicit criteria for inappropriate 
prescribing [24-26]. In addition, benzodiazepines are the most recurring group of drugs in 
terms of chronic prescribing and in terms of inappropriate psychotropic polypharmacy. 
Numerous studies have explored benzodiazepine utilisation in older adults, but they are 
often limited to the description of crude utilisation data, without looking deeper into ac-
tive substances, dosages and indications. Previous articles indicate the need for documen-
tation of indications to properly evaluate the appropriateness of psychotropic drug use  [27, 
28].  Therefore, the aim of this study was to describe the prevalence of benzodiazepine use in 
Belgian nursing homes, with attention to indications and dosages for each of the commonly 
used drugs. Furthermore, we compared actual dosages with recommended dosages  in older 
adults and explored the risk profile for chronic benzodiazepine use. 
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METHODS
Data for this secondary analysis study were obtained from a multicentre study, investigating 
the overall drug utilisation in Belgian nursing homes. A detailed description of the methods 
and findings of this study was published elsewhere [1, 29].  
Setting: 
Belgium has a mixed, public/private health care system. The system is fee for service.  An 
essential principle of the Belgian health care system is the patient’s freedom of choice be-
tween a wide range of independent care providers without listing system. In particular, the 
Belgian long-term residential care structure consists of residential and/or nursing homes for 
older people, which offer a home replacement with or without nursing care. Governance of 
nursing homes for older people is either public (community health services) or private (pre-
dominantly non-profit). Each nursing home has a medical coordinator who is a general prac-
titioner, additionally educated in care for older people. Most of the residents are still treated 
by their own GP, with an average of 32 visiting GPs per nursing home. Thereby, the GP has the 
responsibility for the treatment and medication policy. Periodic reassessment of the medica-
tion charts (i.e. a protocol for monitoring and discontinuation of therapy) is not mandatory.
Data collection: 
The PHEBE study (Prescribing in Homes for the Elderly in BElgium) was a cross-sectional, 
descriptive study of a representative, stratified random sample of 76 Belgian nursing homes. 
Data collection at resident level included administrative, clinical and medication data. To 
score the activities of daily living (ADL), we used the Katz scale[30] which is a mandatory in-
strument in Belgian nursing homes. The progression of disorientation as proxy for dementia 
severity was also scored by this instrument, ranging from a score 1 (no dementia) to 5 (severe 
dementia). 
For collecting clinical data, a checklist  with 28 items, focusing on clinical problems (i. e. dis-
eases with a clear cut diagnosis such as COPD, cardiovascular diseases,…) and on care prob-
lems (i.e problems with a predominant nursing care burden such as incontinence, pain, risk 
of falling,…) was sent to the general practitioner (GP) of each included resident. The 28-item 
checklist of clinical conditions was ad hoc designed for this study, with the items selected 
based on existing prescribing quality indicators for the elderly (BEERS, BEDNURS, ACOVE). It 
was pilot tested in two nursing homes.
The GP received a printout of the medication chart for verification of the medication use, and 
was asked to tick a predefined list of main indications for each medication. Residents consid-
ered by their GP as having a palliative status were excluded from the analysis.
Classification of benzodiazepines: 
Benzodiazepines (BZD), a group of psychoactive drugs with sedative, hypnotic, anxiolytic, 
anticonvulsant, muscle relaxant and amnesic action [5] were coded according to the Anatom-
ical Therapeutic and Chemical classification [31]. We investigated the benzodiazepines, availa-
ble on the Belgian pharmaceutical market of the ATC classes hypnotics (N05CD), anxiolytics 
(N05BA) and also the related Z-drugs (N05CF).  This classification is not strictly linked to the 
clinical indication, as most of the BZDs have a mix of different pharmacological actions, and 
Z-drugs act mainly hypnotic. Clonazepam (N03AE01) mostly used for the indications ‘restless 
legs’ and ‘epilepsy’, and tetrazepam (M03BX07), used as a muscle relaxant, were not included 
in this study. Duplicate use therapy was defined as the concomitant use of 2 or more differ-
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ent benzodiazepines or Z-drugs (BZD/Z). The focus of this study was chronic use, which was 
defined as daily use for at least 3 months. We analysed 2 levels of describing BZD/Z use: the 
prescription (medication) and the resident level. Indications were analysed at resident and 
prescription level and dosages at prescription level only. 
Indications and dosages: 
The indication of each BZD/Z drug was obtained from the GP who ticked an item on a prede-
fined list of indications: anxiety, insomnia, unrest, epilepsy, muscle tension and acute agita-
tion. Only the indications anxiety, insomnia and unrest were analysed in depth, as the other 
indications were not prevalent enough. Unrest is the symptom targeted by mild sedatives, 
intended to calm a restless patient. It is to be distinguished from the narcotic sedation used 
in palliative setting. When a physician ticked 2 or more indications for the same BZD/Z, we 
classified this as ‘multiple indications’. Only BZD/Zs with a minimum frequency of 15 prescrip-
tions were reported in this study. 
The daily dosage of each BZD/Z in each patient was recorded by summing the doses taken at 
the different moments of intake during one day. Comparison between prescribed daily dos-
ages of a BZD/Z for different indications was made when at least 5 prescriptions for each indi-
cation were present. We also analysed the different moments of intake to see fractionation.
Determination of the daily dose recommended not to be exceeded in older adults:
Reviewing several international pharmaceutical sources with dose recommendations for old-
er adults, we selected 3 international formularia [21-23] and 3 explicit criteria for inappropriate 
prescribing for older adults [24-26] that mentioned detailed information per active substance. 
These sources were the basis of selecting ‘the geriatric upper limit’  i.e. the daily dose rec-
ommended not to be exceeded in the geriatric population. We focused on specific doses 
associated with the indications ‘insomnia’ and ‘anxiety’ and selected the dose which was 
advised by the majority of the sources. Specific dose recommendations for sedative action in 
the indication ‘unrest’ were not found in these sources.
For lorazepam only, we found separate doses for insomnia and for anxiety.  For alprazolam, 
bromazepam and prazepam, our sources only mentioned a dose for the indication of anxiety. 
For the indication of insomnia, we found specific dose recommendations for lormetazepam, 
zolpidem and zopiclone.  The recommendations retrieved from the various sources, the se-
lected geriatric upper limit, and the relation with the Defined Daily Dose(DDD) and diazepam 
equivalent are presented in Box 1.  
To calculate the percentage of prescriptions exceeding the ‘geriatric upper limit’, we com-
pared the actual daily dosages for each prescription identified in the study with the geriatric 
upper limit.
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BOX 1: Recommended daily doses not to be exceeded in older adults
We based our selected dose adaptations on 3 formularia and 3 explicit criteria about inappropriate prescribing in the elderly:
formularia explicit criteria
Britisch National Formularium (BNF) (United Kingdom) BEERS 2003 (USA)
the Martindale 36ste edition (2009) Rancourt 2004 (Canada)
Informatorium medicamentorum 2009 (the Netherlands) Laroche 2007 (France)
Recommended daily doses were investigated for the most relevant BZD/Z and for the indications insomnia and anxiety.
ALPRAZOLAM BROMAZEPAM PRAZEPAM LORMETAZEPAM ZOLPIDEM ZOPICLONE
insomnia anxiety anxiety anxiety anxiety insomnia insomnia insomnia
BNF 1mg 2mg 0.75mg * * 0.5mg 5mg 3.75mg
Martindale 2mg 3mg 0.75mg 9mg 30mg 0.5mg 5mg 3.75mg
Inform. Medica 2mg 4mg 0.75mg 10mg 30mg 1mg * 3.75mg
BEERS * 3mg 2mg * * * * *
Rancourt * 3mg 0.75mg * * * * *
Laroche * 3mg 2mg * * 0.5mg 5mg 3.75mg
Geriatric upper 
limit (in mg/day)
2mg 3mg 0.75mg 10mg 30mg 0.5mg 5mg 3.75mg
 - DDD 0,8 1,2 0,75 1 1 0,5 0,5 0,5
- Diazepam 
equivalent
20mg 30mg 15mg 20mg 20mg 3,3mg 2,5mg 2,5mg
* the BZD has no recommended doses for this indication or the BZD/ Z is not listed in the formularium/explicit criteria
GERIATRIC UPPER LIMIT
RECOMMENDED DAILY DOSES NOT TO EXCEED IN OLDER ADULTS
Sources
LORAZEPAM
Geriatric upper limit expressed in
Statistics: 
The data were analysed using the statistical package SPSS version 18. The alpha level of sig-
nificance was set at p< 0.05. 
In a preliminary analysis investigating BZD and Z-drug use separately, we found no differences 
in residents characteristics. Consequently, all users were concatenated in one “BZD/Z” group 
for further analysis. 
We used descriptive statistics to explore indications and dosages. To detect differences in 
prescribed daily doses for different indications, we used non-parametric statistics (medians 
and the Mann-Whitney U test).  To explore a risk profile for BZD/Z use, we compared users 
and non-users. In univariate analysis, we used Chi² for dichotomous variables and independ-
ent T-tests for continuous variables. For multivariate analysis, we used a stepwise regression 
model with the statistically significant variables from the univariate analysis. To compare the 
characteristics of chronic users of BZD/Zs  in different indications (anxiety, insomnia, unrest), 
we used Chi² for dichotomous variables and one way ANOVA for continuous variables.
RESULTS
Description of the study population: 
Medication data and clinical information of 1730 residents were included in the analysis. The 
mean age was 85 (range 60-104) years and 78% was female. In 48% of the population, the 
treating physician diagnosed dementia and in 36% depression (Table 1). A combination of 
these two care problems was seen in 15% of the residents.
37
2.1
RESU
LTS:     Benzodiazepine use in Belgian nursing hom
es: a closer look into indications and dosages.
The residents used a mean of 7 chronic medications per resident, ranging from no medica-
tion (in less than 1% of the residents) to 22 medications. The most frequently used drugs 
were central nervous system drugs with benzodiazepines and Z-drugs (BZD/Z), antidepres-
sant, antipsychotic and anti-dementia drug prevalence in respectively 53%, 40%, 33% and 8% 
of all residents (Table 1).
Table 1. Description of the study population
RESIDENT CHARACTERISTICS Total population
n= 1730
Demografical charateristics
Age (mean+range) 84.8 (60-104)
Gender (% female) 78.1
Main clinical problems(%)
cardiovascular 75.7
Peptic ulcer 24.6
COPD 17.2
Diabetes 16.8
Renal failure 12.6
Hepatic problems 1.4
Main care problems(%)
Dementia 47.7
Insomnia 44.0
Constipation 41.9
Incontinence 35.9
Depression 35.7
Chronic pain 35.1
Risk of falling 45.5
Medication information
Number of (mean+range)
Medications 8.0 (0-22)
Chronic medications 7.1 (0-22)
Prevalence of overall psychotropic use(%) 77.5
Antipsychotics 32.9
Antidepressants 39.5
BZD/Z 53.1
Anti dementia drugs 7.5
Descriptive analysis on resident level: prevalence of BZD/Z users and indications:
The prevalence of BZD/Z drug utilisation among Belgian nursing home residents (n=1730) 
was 53 % (n=918). Chronic use was present in 50% (n=859) of the residents, and 3% used a 
BZD/Z only occasionally. The use of a single chronic BZD/Z was seen in 42% of the residents, 
while 8% had 2 to 3 chronic BZD/Zs on their medication chart (Table 2). 
Among the chronic users using a single BZD/Z (n=729), the indication was missing in 126 
residents.  An analysis of the characteristics of residents for whom the indication was missing 
revealed no significant differences. Hence,  the distribution of indications was extrapolated 
to the group of chronic users of a single BZD/Z. 
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The leading indication was insomnia (59%), followed by anxiety (17%), unrest (10%), and 
“other indications”(4%); the use of one BZD/Z for multiple indications was 10% (Table 2). 
When a resident received two or three chronic BZD/Zs, there was mostly a different indica-
tion for each of the prescribed BZD/Z, most often a mix of  anxiety,  insomnia or unrest.
Table 2. Prevalence of benzodiazepines and Z-drug use (BZD/Z) among 1730 nursing 
home residents and distribution of chronic users of a single BD/Z per indication.
Prevalence of BZD/ Z use (n=1730)
BZD/Z users 53.1%
Chronic BDZ/Z users 49.7%
Chronic users of a single BZD/Z 42.1%
Distribution of indications among single chronic BZD/Z users (n=603*)
Insomnia 58.7%
Anxiety 17.4%
Unrest 10.4%
Others** 3.6%
Multiple indications 9.8%
 *729 residents receiving a single chronic BZD/Z corrected for 126 missing indications
** Epilepsy, muscle spasm, panic attack
Descriptive analysis at prescription level: prevalence and dose analysis per indication: 
The 859 residents on chronic BZD/Zs received a total of 1001 chronic BZD/Z prescriptions for 
different indications (Table 3). 
On a total of 448 chronic prescriptions for insomnia, physicians prescribed 16 different BZD/Z 
drugs: 46% hypnotics (N05CD)  and 27% Z-drugs (N05CF), but also 27% anxiolytics (N05BA). 
The dominant sleeping pill was the hypnotic lormetazepam (38%), followed by zolpidem 
(23%). Of a total of 186 prescriptions to treat anxiety, physicians prescribed 13 different BDZ/
Zs, predominantly anxiolytics (alprazolam 36% and lorazepam 27%). On a total of 94 prescrip-
tions to treat unrest, 16 different BZD/Zs were prescribed with a wide spread of anxiolytics 
(but predominantly lorazepam 39%)  and also some typical hypnotics and Z-drugs (27%) (Ta-
ble 3).
When comparing the dosages on the prescriptions of an individual BZD/Z used for different 
indications, the prescribed daily dosages of prescriptions for insomnia were similar to the 
dosages of prescriptions for unrest, while for anxiety the daily dosages were higher (Table 3). 
For the treatment of anxiety, the daily dosage was divided into 2 to 4 administrations per day 
in 37% of these prescriptions. For the treatment of unrest, we saw fractionation in only 8% 
and no fractionation for insomnia as all prescriptions mentioned one dose at bedtime. 
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Table 3.  Distribution of prescriptions for chronic BZD/Z drug use and median prescribed daily doses per indication and per active substance.
ATC-DRUG CLASS Chronic prescriptions of BZD/Z Prescribed dialy doses (MEDIAN-RANGE) P value
TOTAL INSOMNIA ANXIETY UNREST INSOMNIA ANXIETY UNREST
***% (n=1001)  % (n=448) % (n=186) % (n=94) mg min-max mg min-max mg min-max
ANXIOLYTICS = N05BA 48.8 26.8 96.8 73.4
-lorazepam 22.1 19.6 26.9 39.4 1.0 0.25-2.50 2.0 0.50-7.50 1.25 0.50-2.50 0.035
-alprazolam 10.3 0.4 36.0 8.5 0.5 0.07-2.00 0.375 0.13-1.00 0.087
-bromazepam 4.1 4.0 4.8 5.3 4.5 3.00-6.00 6.0 3.00-12.00 0.196
-prazepam 3.3 0.0 11.8 0.0 30.0 5.00-40.00
other 9.0* 2.8 17.3 20.2
HYPNOTICS = N05CD 33.0 46.4 3.2 18.1
-lormetazepam 26.1 37.7 2.7 12.8 2.0 0.50-3.00 1.75 0.50-2.00 0.832
other 6.9** 8.7 0.5 5.3
Z-DRUGS = N05CF 18.3 26.8 0.0 8.5
-zolpidem 16.3 22.5 0.0 7.4 10.0 2.50-20.00 10.0 5.00-10.00 0.853
-zopiclone 1.9 4.0 0.0 1.1 7.5 3.75-7.50
-zaleplon 0.1 0.2 0.0 0.0
*other anxiolytics: oxazepam (2.1%); diazepam (2.0%); chlorazepate (1.9%); clotiazepam (1.5%) cloxazolam (1.1%); ethylloflazepam (0.2%), clobazan (0.1%), nordazepam (0.1%)
**other hypnotics: botizolam (2.6%); flunitrazepam (1.3%); triazolam (1.3%); flurazepam (0.9%); loprazolam (0.6%); nitrazepam (0.2%)
*** differences between Prescribed daily doses (Mann-Withney U); lorazepam differences only between insomia and anxiety
Compliance with ‘the Geriatric Upper Limit’: 
In Table 4 we give the percentage of prescriptions with a dose higher than ‘the geriatric upper 
limit’. In the prescriptions for insomnia, this limit was exceeded for lormetazepam in 95%, 
zolpidem in 82%,  zopiclone in 78% and for lorazepam in 35% of all chronic prescriptions. In 
the prescriptions for anxiety the ‘geriatric upper limit’ was also exceeded but not in such high 
percentages: for alprazolam in 30%, lorazepam in 12%, bromazepam in 11% and for praze-
pam in 5% of all chronic prescriptions.
Table 4. Percentage of prescriptions exceeding the Geriatric Upper Limit per indication.
INDICATION BZD/Z DOSAGES
Geriatric Upper 
Limit n**  %Exceeding***
INSOMNIA Lormetazepam 0.5mg 169 94.7
Zolpidem 5mg 101 82.2
Lorazepam 2mg 88 35.2
Zopiclone 3.75mg 18 77.8
ANXIETY Alprazolam 0.75mg 67 29.9
Lorazepam 3mg 50 12.0
Prazepam 30mg 22 4.5
Bromazepam 10mg 9 11.1
* Recommendations (see box)
** the number of chronic prescriptions for this specific drug for this indication
*** % of prescriptions for older adults exceeding the Geriatric Upper Limit
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Comparison between  BZD/Z users and non-users: 
Univariate analysis showed that BZD/Z users had a significantly higher usage of chronic med-
ications and antidepressants; a higher frequency of care problems such as constipation, de-
pression and chronic pain; and a lower frequency of dementia and incontinence. We found 
no association between BZD/Z use and the physicians’ perception of the risk of falling, nor 
with the frequency of clinical problems such as cardiovascular diseases, diabetes and COPD 
(Table 5).  
In multivariate analysis, BZD/Z use was more frequent in female residents (OR 1.32 95%CI 
1.03-1.68) and residents with chronic pain (OR 1.58 95%CI 1.27-1.97), constipation (OR 1.43 
95%CI 1.16-1.76) and depression (OR 1.68 95%CI 1.35-2.08), and less frequent in residents 
with incontinence (OR=0.71 95%CI 0.57-0.88) and dementia (OR=0.60 95%CI 0.48-0.74 (Ta-
ble 5). 
Table 5. Comparison of characteristics between chronic benzodiazepine or z-drug users and non-users (n=1730).
RESIDENT CHARACTERISTICS  BZD/Z user non user P value* UNIVARIATE ** MULTIVARIATE***
n=859 n=871 OR 95%CI OR 95%CI
Demographical
Age (mean+range)  84.5[60-104] 85.1[60-104] 0.165 0.99 0.98-1.00
Gender(% female) 80.3 75.7 0.021 1.31 1.04-1.65 1.32 1.03-1.68
Main clinical problems(%)
Cardiovascular 77.3 74.1 0.112 1.20 0.96-1.49
Peptic ulcer 24.9 24.3 0.766 1.03 0.83-1.29
COPD 18.5 15.9 0.156 1.20 0.99-1.54
Diabetes 15.9 17.8 0.303 0.88 0.68-1.13
Renal failure 11.8 13.4 0.326 0.87 0.65-1.15
Hepatic problems 1.6 1.2 0.441 1.38 0.61-3.12
Main care problems(%)
Constipation 46.8 36.9 p<0.001 1.50 1.24-1.82 1.43 1.16-1.76
Risk of falling 46.4 44.5 0.421 1.08 0.89-1.31
Depression 42.2 29.0 p<0.001 1.79 1.46-2.20 1.68 1.35-2.08
Chronic pain 42.1 27.9 p<0.001 1.89 1.54-2.31 1.58 1.27-1.97
Dementia 40.1 55.5 p<0.001 0.54 0.44-0.65 0.60 0.48-0.74
Incontinence 32.1 39.7 0.001 0.72 0.59-0.88 0.71 0.57-0.88
Medication information
Number of (mean+range)
Medications 9.0[0-22] 7.0[1-22] P<0.001 1.15 1.12-1.19
Chronic medications 7.7[0-22] 6.2[0-22] P<0.001 1.18 1.15-1.22
Use of psychotropics(%) 100.0 54.6 P<0.001
Antipsychotics 35.0 30.8 0.065 1.21 0.99-1.48
Antidepressants 48.3 32.4 P<0.001 1.95 1.61-2.37
* P value of the difference between user and non-user using χ² for categorical variables and independent t-test for continuous variables
**Odds Ratio: Risk of taking a BZD/Z
*** stepwise regression model (covariates: gender,constipation,depression,pain,dementia,incontinence) 
Comparison between BZD/Z users for the different indications: 
Depression, chronic medication, antidepressant and antipsychotic use were significantly 
more likely to be present when a resident took a BZD/Z for anxiety rather than for insomnia 
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and unrest. We found no significant differences in the risk profiles of residents with BZD/Z use 
for insomnia versus use for unrest (Table 6). 
Especially among users with the indication of insomnia, we observed a gradual decrease in 
BZD/Z use as dementia progressed (Fig. 1).
Relationship with institutional characteristics: 
BZD/Z drug use was not associated with institutional characteristics such as private or public 
facility, size, or staffing. 
Table 6. Comparison of  characteristics of chronic benzodiazepine and z-drug users for the indications ‘insomnia’, ‘anxiety’ 
and ‘unrest’.
RESIDENT CHARACTERISTICS Chronic BZD/Z user INSOMNIA
Chronic BZD/Z 
user ANXIETY
Chronic BZD/Z 
user UNREST P value **
(n= 354)* (n=105)* (n= 63)*
Demographical
Age (mean+range) 85.5 (60-102) 84.9 (60-99) 83.6 (60-103) 0.224
Gender(% female) 80.5 78.8 74.6 0.562
Main care problems(%)
Constipation 47.0 54.3 49.2 0.423
Risk of falling 48.0 51.9 50.8 0.752
Depression 36.3 61.2 28.3 P<0.001
Chronic pain 41.6 47.6 44.4 0.542
Dementia 36.0 43.1 41.9 0.343
Incontinence 31.5 28.8 33.3 0.811
Medication information
Number of (mean+range)
Medications 8.4 (1-20) 10.0 (2-21) 9.1 (3-17) P<0.001
Chronic medications 7.5 (1-16) 8.9 (2-21) 8.1 (3-15) P<0.001
Use of psychotropics(%)
Antipsychotics 25.4 38.1 34.9 0.024
Antidepressants 39.5 61.9 36.5 P<0.001
* residents receiving a single BZD/Z for this specific indication
**  P-value of differences using χ² for dichotomous variates and One-Way-Anova for continuous variates
Fig 1: Relation between indication for benzodiazepine and Z-drug use and increasing dementia
DEMENTIA STAGES (KATZ)
Stage 1: no dementia (n=542)
Stage 2 (n=402)
Stage 3 (n=438)
Stage 4 (n=264)
Stage 5: severe dementia (n=66)
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DISCUSSION
Originality of the study: 
In this observational cross-sectional study of chronic use of benzodiazepines and Z-drugs 
(BZD/Z) in Belgian nursing homes , the prevalence of usage of these drugs has been examined 
in depth per indication, and differences in dosing practices per indication have been analysed. 
We confirmed the high prevalence of chronic BZD/Z use (half of the residents) in this setting, 
as found in numerous other studies [2, 4, 32]. We found that insomnia was the main indication 
for chronic use, and was treated at higher dosages than recommended in older adults [21, 23, 25, 
26]. This finding is not striking, but our study is the first to scientifically confirm the assumption 
that insomnia is most prevalent for BZD/Z use. We were able to determine interesting ele-
ments for a risk profile of BZD/Z use in multivariate analysis, such as positive associations with 
female gender, obstipation, depression, chronic pain and polypharmacy (including polyphar-
macy with other psychotropics), and negative associations with dementia and incontinence. 
There was a puzzling absence of association with age, risk of falling, clinical problems, and 
institutional characteristics.  
This study in a large representative sample of Belgian nursing home residents provides 
long-awaited information on indications and dosages of benzodiazepines [33]. Actual daily 
dosages were compared to the geriatric upper limit, a pragmatic threshold determined from 
authoritative international pharmaceutical sources. 
Strenghts and limitations: 
One strength of our study was the substantial and representative sample of Belgian nursing 
home residents [29]. In neighbouring European countries [2-4] similar prevalence numbers of 
benzodiazepine use have been found.  In the United States [27], there is a lower use of ben-
zodiazepines  due to the safety warnings issued in the late ’80s and due to specific actions 
tackling the high use of these drugs (Medicare part D). Another strength of this study is that 
our data collection was based on reliable recording from primary sources,  namely medica-
tion charts and direct clinical information from the treating GP. Another strong aspect of this 
study was our attempt to list most of the existing recommendations for older adults regarding 
dosages of BZD/Zs. However, we did not use an explicit method to extract the geriatric upper 
limit and we limited ourselves to the most abundantly prescribed BZD/Zs in Belgium. This 
geriatric upper limit is a threshold based on a pragmatic analysis of different sources, and 
therefore not a gold standard nor a rigid criteria for inappropriate prescribing.
One limitation was that we did not use internationally validated criteria to evaluate (severity 
of) dementia. In this cross-sectional study, we were not able to investigate the distribution 
of the duration of chronic use, nor it was possible to investigate temporal changes and the 
relationship between process and outcome. Indications for BZD/Z drugs were collected by 
interviewing the GP, which may have influenced data reliability. To reduce the complexity of 
the analysis, we narrowed our in-depth analysis of indications to chronic users with only one 
BZD/Z and therefore only one indication and disregarded residents on multiple BZD/Zs (8% 
of all residents) or residents on a BZD/Z with more than one indication (10% of the residents 
on a single chronic BZD/Z). In addition, there was a large number of missing indication data 
(17%) which might reflect an uncertainty of the treating GPs when discriminating among the 
indications of anxiety, insomnia, and unrest. This pragmatic approach might have introduced 
some bias in the estimation of the prevalence.  
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Critical discussion of the main findings:
Insomnia
Our study showed that the number one indication for BZD/Z drugs in this setting was insom-
nia and to a far lesser extent anxiety and unrest. 
A striking finding was that almost all use of BDZ/Z drugs for insomnia was chronic, which is 
generally considered to be inappropriate [25, 34]. In order to avoid chronic prescribing, guide-
lines such as the British National Formulary and the Belgian drug code [21, 35] point out that 
before prescribing a hypnotic, the cause of the insomnia should be established and, where 
possible, underlying factors (such as depression or ‘restless legs’ ) should be treated [36, 37]. 
Establishing a good sleep hygiene is the first choice, but is not easy to implement in nursing 
homes. When a pharmacological treatment seems necessary, hypnotics should be reserved 
for short courses (<3weeks) in the acutely distressed and routine/chronic prescribing is un-
desirable [21].
With regard to the drug choice within the benzodiazepine drug class (with hypnotic, anxio-
lytic, -sedative, muscle-relaxant and  amnesic action) for the indication of insomnia, mainly 
hypnotic benzodiazepines and Z-drugs were used,  but also the anxiolytics lorazepam and 
bromazepam.
With regard to dosages for the different indications, we found that, especially in patients 
treated for insomnia, the daily dosages of the hypnotic benzodiazepines, of the Z-drugs, and 
of the anxiolytic lorazepam exceeded the geriatric upper limit. However, in terms of diazepam 
equivalence, the dosages were still considerably lower than the dosages used when treating 
patients with anxiety.
It is generally known that older adults need a dose reduction, but specific information about 
this reduction is hard to find. Most sources stay vague and point at a dose reduction of 50% 
and a slow titration. Hence, it is no surprise that there are no clear guidelines, and that GPs 
are not aware of geriatric optimal dosing. A comparison of the geriatric upper limit with the 
Defined Daily Dose (DDD)  revealed that the two values coincided for anxiety, but for insom-
nia, the geriatric upper limit was half the DDD (BOX 1). This may be one  methodological ex-
planation for the high prevalence of dosages exceeding the limit in prescriptions indicated for 
insomnia. Another explanation is that physicians titrate the dosage upwards when tolerance 
sets in, as expected for benzodiazepines use. Also, one culprit may be the unavailability of 
geriatric package dosages. Lormetazepam for example, is on the Belgian market in package 
doses of 1 or 2 mg, and consequently exceeds the required 0,5mg a day for older adults. This 
is also the case for the package dosages of zolpidem (only packages of 10mg on the market).
In our study, the hypnotic users, but especially the residents receiving a BZD to treat anxiety 
were more associated with having a depression and a prescription for an antidepressant. This 
chronic concomitant use of psychotropic drugs to treat depression is not appropriate in the 
geriatric population who has already an increased risk of interactions and adverse drug reac-
tions. On the one hand, it is not surprising we found an association between depression and 
BZD/Z use, because depression can be the reason of initiating a BZD/Z drug, definitely when 
depression is related to a disturbed sleep pattern and anxiety [38]. On the other hand, a study 
in 2007 revealed that the use of hypnotics was associated with an increased incidence of de-
pression, suggesting hypnotics may be contra indicated when there is a risk for depression [39].
Unexpectedly, we saw a gradual decrease in the use of sleeping pills when dementia pro-
gressed, although it is well known that patients with dementia often have nocturnally dis-
turbed sleep [40]. As a sleeping problem is frequently an explicit complaint, uttered by the 
patient [41], it is possible that prescribing sleeping pills is demand-driven. So, when residents 
with severe dementia lose the ability to express the need for sleeping pills, their prescription 
might not get renewed. 
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Anxiety 
In patients using only a single BZD/Z chronically, the single indication of anxiety was limited to 
less than 1 in 5 patients. However, this indication was also present in patients using multiple 
BDZ/Z drugs, or a single BZD/Z drug for multiple indications. Using BZDs chronically to treat 
mild anxiety is considered to be inappropriate [8]. At the onset of treatment of depression, a 
benzodiazepine could be used as an adjuvant, as the anti-anxiety effect of some antidepres-
sants can take 2 to 4 weeks  [42]. However, to avoid chronic use, this dual therapy should be 
tapered in time [43].
In this indication, the drugs of choice were exclusively the anxiolytic ATC-class drugs, used in 
daily dosages higher than the dosages used when indicated for insomnia, but closer to the 
geriatric upper limit (and to the DDD). It is logical daily dosages are higher for anxiety as they 
are more frequently dispensed during the day, unlike for sleeping pills, which are adminis-
tered once daily in the evening. 
The indication of anxiety was associated with a more intense polypharmacy, more antide-
pressants (and more depression), and more antipsychotics. Hence, efforts to withdraw from 
BDZ/Z drug usage should be seen in the broader context of mental health, and treatment of 
behavioural and psychological symptoms of dementia. 
Unrest 
A variety of benzodiazepines in different ATC classes were used to treat this indication. The 
prescribed daily doses of these BZD/Z drugs for the indication ‘unrest’ were similar to the 
prescribed daily doses of these BZD/Z drugs used for the treatment of insomnia. Further-
more, we observed no differences in characteristics between a resident using a BZD/Z drug 
for insomnia and unrest. Sedative action in this setting is considered to provide calming ef-
fects (different from the narcotic aim in palliative care context and different from control of 
acute agitation). This suggests  some semantic overlap between the terms “sedative” and 
“hypnotic” action, not only in literature but also in daily practice. 
Risk profile of BDZ/Z drug users
Our multivariate comparison of users versus non-users revealed a positive association with 
care problems such as obstipation and chronic pain, possible causes of irritation and sleep-
lessness leading to BZD/Z use. The negative association between incontinence and BZD/Z 
use might be explained by covariance with dementia and the use of nocturnal incontinence 
material.
The association with polypharmacy (more specifically psychotropic polypharmacy) calls for 
comprehensive approach to assure the quality of psychotropic pharmacotherapy of mental 
health in nursing homes [44].
In other studies an association was found between BZD/Z use and risk of falling [20, 45-47]. In this 
cross-sectional study we could not observe this, possibly because treating physicians failed 
to perceive the risk of falling as a consequence of BZD/Z use, or because of the multifactorial 
nature of this association.  
We did not find significant associations between BDZ/Z drug use and institutional character-
istics (including staffing), contradicting the popular belief that high hypnotic usage is associ-
ated with low staffing [48].  
Implications for practice and research: 
The contradiction between recommendations against long-term use of BZD/Zs,  and the high 
prevalence in older adults has already been discussed often but seldom explained.  Prescrib-
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ers seem to be convinced of the detrimental long-term effects of benzodiazepines in older 
adults [49], but it seems very hard to change habitual prescribing and to overcome the fear of 
possible relapse and withdrawal effects for both prescribers and caregivers and for patients 
[50].  
It is difficult to persuade patients and their physicians to stop chronic use of BDZ/Z drugs. 
However, a small intervention study in primary care showed that sending a letter from the 
physician to the BZD/Z user could have a positive impact on successful withdrawal [51, 52]. Moti-
vation together with gradual tapering seems to be the best strategy for discontinuation [11, 53].
Previous articles on BZDs supported non-pharmacological ways to address insomnia and to 
avoid the initiation of benzodiazepines use [54-56]. More efforts to motivate the residents as 
well as the care giving staff to do physical exercises and other activities to ameliorate the 
sleep quality of older adults must be made in order to reduce the persistent sleep problems 
and sleeping pill use [57, 58].
More emphasis should be given to at least avoiding high dosages during chronic use for older 
patients.  This study found that prescribers do not pay attention to reducing the dosage ac-
cording to existing recommendations, especially in patients treated for insomnia. We do not 
know whether this reluctance indirectly leads to a higher mortality [59], but several studies 
state the existence of adverse effects, such as cognitive impairment [14, 15] addictive properties 
and possible withdrawal effects. The pharmaceutical companies  should produce packages 
with appropriate dosages for older adults. But nurses and pharmacists could also play an 
important role in the correct administration of these drugs in older adults [60, 61].
Future research  on benzodiazepines should differentiate between insomnia and anxiety or 
other indications. Our findings suggest that insomnia, given its high prevalence as primary 
indication,  deserves priority. Efforts to reduce chronic use should concentrate on reducing 
initiation, chronic use and excessively high dosages for this indication.
Furthermore, there is a need to strengthen the evidence base regarding the absence of long-
term efficacy and the significance of adverse effects in order to persuade physicians, nurses, 
caregivers and patients of the positive risk benefit balance of discontinuation attempts.
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ABSTRACT
Background & objectives: Since antidepressants are prescribed for multiple indications, the 
use of an antidepressant cannot be equated with a diagnosis of depression. The objective of 
this study was to examine the quality of antidepressant prescribing in Belgian nursing homes, 
with a critical evaluation of indications and dosages: to see whether depression was appro-
priately treated in terms of drug choice, indication and whether there was underdosing.
Methods: Clinical and medication data was obtained from a cross-sectional study of a repre-
sentative stratified random sample of 1730 residents from 76 Belgian nursing homes (PHEBE 
study 2006). A 28-item checklist of clinical conditions was designed ad hoc for the PHEBE 
study and sent to the residents’ general practitioner (GP) to collect clinical information. We 
copied the medication chart, classified the drugs into codes with the Anatomical Therapeutic 
and Chemical classification system, and transferred the drug names and dosages into a data-
base. Information on indications was retrospectively obtained from the GPs, so that we could 
link the indication to each medication. Minimal effective doses (MED) of antidepressants to 
treat major depression were obtained from the literature to assess under-dosing. 
Results: The overall use of antidepressants in nursing homes was 39.5% (95%CI, 37.2-41.8). 
The physicians classified 34.2% (95% CI 32.0-36.4) of the residents as having depression and 
80.9% of these patients were treated with an antidepressant. Indications among the single 
antidepressant users (n= 551) were depression (66.2%), insomnia (13.4%), anxiety (6.2%) 
and neuropathic pain (1.6%). In the indication of ‘depression’, 74.8% used a Selective Ser-
otonine Reuptake Inhibitor (SSRI), predominantly citalopram, sertraline and escitalopram. 
Venlafaxine was used by 10.7% of the residents. Dosages for these antidepressants were 
equal to or higher than the MED. But when trazodone, amitriptyline or mirtazapine was used 
to treat depression, respectively 92.3%, 55.5% and 44.5% was dosed under the MED.  In 
the indication of insomnia, most of the time, trazodone (90.5%) or mirtazapine (5.4%) were 
used and in lower dosages than those required for depression treatment (<MED). Tricyclic 
antidepressants were predominantly used for the treatment of neuropathic pain and also at 
lower dosages. Of all the residents receiving a medication for anxiety, only 13.9% received an 
antidepressant (mostly a SSRI), and the remaining received a benzodiazepine. 
Conclusion: The number one indication for the use of an antidepressant was depression. 
Within this indication, mostly the recommended SSRIs were used, in dosages equal to or 
higher than the MED. Furthermore, we noticed that there was substantial use of sedative 
antidepressants for insomnia and that the physicians preferred to prescribe benzodiazepines 
over the recommended SSRIs to treat anxiety chronically.
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INTRODUCTION
The prevalence of late-life depression in nursing homes varies from 11% to 50% [1-5] and is 
generally higher than in community dwelling older adults [6]. Depression is often reported to 
be under-recognised and undertreated in older adults [3, 7]. However, the use of antidepres-
sants (ADs) has increased over the last decade [8] and this trend was also visible in the nursing 
home population [9, 10]. 
Depression often has an atypical presentation in older adults [11]. The poor recognition of 
clinical features of depression in old age and the overlap with symptoms of dementia or other 
co-morbidities makes a correct diagnosis difficult. 
Depression negatively affects daily activities [12] and the quality of life [13], causes high treat-
ment and societal costs[14, 15] and increases mortality [16]. Chronic diseases, pain and social 
deprivation are known risk factors for developing depression [17]. These elements are com-
mon in long-term care facilities. Moreover, transition from the community to a nursing home 
can trigger depression, which results in a high number of newly admitted residents develop-
ing depression [2, 18]. 
Depression is a treatable illness [19]; approximately 50-60% patients with a major depressive 
disorder are thought to improve clinically as a consequence of antidepressant treatment[20, 
21]. In addition, there are other indications to prescribe an antidepressant. Anxiety, panic dis-
orders, behavioural and psychological symptoms of dementia and neuropathic pain [22] are 
potential indications for antidepressants in the older population. In daily practice, antidepres-
sants are also prescribed for insomnia without concomitant depressive symptoms, although 
this indication is not mentioned in the official labelling [23].
In order to make a complete evaluation of the antidepressant prescribing attitudes and to 
evaluate the pharmacotherapy of depression, both indication and dosage information are 
necessary. Drug utilisation studies that evaluate the indication and dosages of these medi-
cations are scarce [24-26]. In these studies, indication analysis is mostly done by linking clinical 
diagnoses (ICD-9 or DSM IV) and medication databases. This does not automatically provide 
information on the reason or the indication for which each antidepressant was prescribed. 
Similar to the BEACH project in Australia [27], the PHEBE study (Prescribing in Homes for the 
Elderly in Belgium) was designed to include the indication per medication as reported by 
the prescribing general practitioner (GP). The PHEBE study was a cross-sectional, descriptive 
study of a representative stratified random sample of 76 Belgian nursing homes, investigating 
the overall drug utilisation in Belgian nursing homes in 2006. A detailed description of the 
methods and findings of this study was published elsewhere[28-30].
The main objective of this subanalysis of the data obtained in the PHEBE study was to examine 
the quality of antidepressant prescribing in Belgian nursing homes with a critical evaluation 
of indications and dosages: to see whether depression was appropriately treated in terms of 
drug choice, the indications and whether there was underdosing. An additional objective was 
to investigate the resident characteristics associated with antidepressant use.
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METHODS
Setting: 
Belgium has a mixed, public/private health care system. The system works on a fee for service 
base. The Belgian long-term residential care structure consists of residential and/or nursing 
homes for older people, which offer a home replacement with or without nursing care. Gov-
ernance of nursing homes for older people is either public (community health services) or 
private (predominantly non-profit) with little difference in quality. In Belgian nursing homes, 
residents are still supervised by their own GP, and this leads to an average of 32 GPs per 
nursing home.
Data collection: 
In the PHEBE study, data collection at resident level included administrative, clinical and med-
ication data. We obtained the medication data by copying the medication chart, transferring 
and coding it to a database. For collecting clinical data, we sent the GP a checklist with 28 
items, focusing on clinical problems (i.e. cardiovascular disease, COPD, peptic ulcer) as well 
as focusing on care problems (i.e. problems with a predominant nursing care burden, such as 
dementia, insomnia, depression,…). The 28-item checklist of clinical conditions was ad hoc 
designed for this study, with the items selected based on existing prescribing quality indica-
tors (BEERS[31], ACOVE[32], BEDNURS[33]) for older adults. The diagnosis of depression is in this 
study based on the clinical evaluation by the GP. In Belgium, the KATZ scale is a mandatory 
instrument in the nursing homes and it consist of two parts. The first part scores activities 
of daily living (ADL) and the second part scores disorientation in time and place. This second 
part is scored from 1 (no disorientation) to 5 (severe) and used as a proxy to estimate the 
severity of dementia in this study.  Residents receiving palliative care were excluded from 
analysis. 
Classification of Antidepressants: 
Antidepressants were classified according to the Anatomical Therapeutic Chemical system 
(ATC) [34]. According to the availability on the Belgian pharmaceutical market, we investigated 
the classes N06AA Tricyclic Antidepressants (TCA), N06AB Selective Serotonin Reuptake In-
hibitors (SSRI), N06AG Mono Amino Oxidase Inhibitors (MAO-I) and the class N06AX which 
includes serotonin-norepinephrine reuptake inhibitors and other antidepressants.
The SNRI, duloxetine, and bupropion are not included in the analysis because they were not 
yet commercialised in Belgium in 2006. Lithium, in ATC considered as an antipsychotic and 
mostly used to treat bipolar disorders, was excluded from analysis. Combination drugs of an 
antidepressant and an antipsychotic were also excluded. Duplicate use therapy was defined 
as the concomitant use of 2 or more ADs. Medication prescribed in short term and as-needed 
medications were excluded from analysis. We focused on chronic use (defined as daily use for 
at least 3 months).We analysed 2 levels of describing AD use: the prescription (medication) 
and the resident level. Indications were analysed at prescription and resident level and dos-
ages at prescription level only.
Indication and dosages: 
Data on indications were collected retrospectively: the GP received a printout of the resi-
dent’s medication chart for verification of the medication use, and he/she was asked to tick 
relevant indications from a predefined list for ADs: depression, posttraumatic stress, anxiety, 
insomnia, neuropathic pain or other.
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The prescribed daily dose (PDD) of each AD was recorded by summing the doses taken at the 
different moments of intake during one day. To interpret these doses, we chose the universal 
Defined Daily Dose (DDD), which is the assumed average maintenance dose per day for a 
drug used for its main indication in adults[34]. We described the distribution of the PDD using 
its median and range. To examine possible under-dosing in the treatment of depression, we 
used the Minimal Effective Dose (MED). The MED of an antidepressant serves as a threshold, 
below which all doses are not effective in treating major depressive episode [35]. The MED of 
the most common antidepressants were determined using the Prescribing guidelines [36] and 
Pharmacotherapy: A pathophysiologic Approach [37]. We considered under-dosing when the 
PDD of the antidepressant was under the MED.
Statistical analysis: 
The data was analysed using the statistical package SPSS version 18. The alpha level of signif-
icance was set at p< 0.05. We used descriptive statistics to explore indications and dosages. 
We examined the characteristics (demographical, clinical, medication and institutional infor-
mation) of the AD users and the nonusers, and also compared characteristics of the AD users 
for the different indications (respectively for depression and all other indications). To inves-
tigate differences, we used χ² for discontinue variables, t-tests for continuous variables or 
non-parametric statistics (Mann-Whitney U test) for skewed distributions.
In a second analysis, we explored a risk profile for AD use. We calculated the Odds ratios and 
the 95% confidence intervals in univariate and multivariate analysis. For multivariate analysis, 
we used a stepwise regression model including the statistical significant variables from the 
univariate analysis. 
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RESULTS
Study population characteristics: 
Medication data and clinical information of 1730 nursing home residents was included in the 
analysis. The mean age was 85 (range 60-104) yearsand 78.1% was female. The prevalence 
of depression was 34.2%[95% CI 32.0-36.4]. In 14.9% of the residents, a combination of de-
pression and dementia was noted. 
The mean number of chronic medication per resident was 7,and the number ranged from no 
medication (in less than 1% of the residents) to 22. The most frequently used drugs among 
the residents were the central nervous system drugs, with benzodiazepine, antidepressant, 
antipsychotic and anti-dementia drug use in respectively 53.1%, 39.5%, 32.9% and 8.3% of all 
residents. The demographical and clinical characteristics of the study population are shown 
in Table 1.
Table 1. Characteristics of the study population
RESIDENT CHARACTERISTICS total population
n= 1730
Demographical characteristics
Age (mean + range) 84.8 (60-104)
Gender (% female) 78.1
Main Clinical problems(%)
Cardiovascular 75.7
Peptic ulcer 24.6
COPD 17.2
Diabetes 16.8
Renal failure 12.6
Hepatic problems 1.4
Parkinson 8.3
Main Care problems(%)
Dementia 47.7
Depression 34.2
Insomnia 44.0
Risk of falling 45.5
Constipation 41.9
Chronic pain 35.1
Incontinence 35.9
Medication Information
Number of (mean + range)
Medications 8.0 (0-22)
Chronic Medications 7.1 (0-22)
Use of Psychotropics (%) 77.7
Benzodiazepines/z-drugs 53.1
Antidepressants 39.5
Antipsychotics 32.9
Use of Antidementia drugs(%) 8.3
Use of AntiParkinson drugs(%) 10.9
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Antidepressant use at Resident level: prevalence and indications: 
The prevalence of chronic AD utilisation among 1730 residents was 39.5%[95% CI 37.2-41.8]. 
The use of a single AD was seen in 32.6% , while the concomitant use of 2 to 4 ADs was found 
in 6.9%. Among the antidepressant users using a single AD (n=551), the leading indication 
for this use was depression (66.2%), followed by insomnia (13.4%), anxiety (6.2%) and pain 
(1.6%). We found the use of a single AD for ‘multiple indications’ in 11.6% of residents. This 
category was used largely for depression associated with another indication (Table 2). 
The physicians categorised 34.2% [95% CI 32.0-36.4] of the residents as depressed and 80.9% 
of these patients were treated with an AD; more specific indication analysis showed that 
73.1% of the residents with noted depression received an AD for that very indication (Table 
2). 
Table 2. Prevalence of Antidepressant (AD) use and Depression and the distribution of users per indication.
Prevalence n % 
total AD use (N=1730) 684 39.5 
single  AD use 565 32.6
multiple AD use 119 6.9
total prevalence of depression (N=1730) 591 34.2 
AD use among residents with depression (N=591) 478 80.9
AD use specific for the indication depression among residents with depression (N=591) 432 73.1
Indications among single AD users (N=551*) n %
Depression 365 66.2
Insomnia 74 13.4
Anxiety 34 6.2
Pain 9 1.6
Multiple indications 64 11.6
 depression+ insomnia 22 4.0
 depression+anxiety 23 4.2
 depression + pain 8 1.5
Other indications 5 0.9
*total residents receiving a single AD(n=565) corrected for 14 missing indications 
Table 3 shows which AD was most used for which indication. When the indication of the AD 
was depression, 74.8% of the residents took a SSRI, 10.7% venlafaxine and 8.2% mirtazapine. 
For the single indication ‘insomnia’ and for the combination of ‘insomnia and depression’, 
in respectively 90.5% and 53.3% trazodone was used. When the indication was ‘anxiety’, 
different AD classes were used, but mostly SSRIs (64.7%), trazodone (14.7%) and venlafaxine 
(8.8%). Of all residents receiving a medication for anxiety only 13.9% received an AD (mostly 
an SSRI) and the remaining patients received a benzodiazepine. The indication of neuropathic 
pain was mostly treated with TCA (66.7%) (Table 3). 
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Table 3. Distribution of Indications of (single) antidepressant (AD) use in Belgian nursing home residents (at resident level).
ANTIDEPRESSANT INDICATIONS for Antidepressant use among nursing home residents*
Depression Insomnia Anxiety Pain Multiple 
       n= 365      n= 74    n= 34    n=9      n=64
TCA (=N06AA) 8 (2.2%) 1 (1.4%) 2 (5.9%) 6 (66.7%) 4 (6.2%)
Amitriptyline 3 (0.8%) 2 (5.9%) 5 (55.6%)
SSRI (=N06AB) 273 (74.8%) 1 (1.4%) 22 (64.7%) 1 (11.1%) 30 (46.9%)
Citalopram 91 (24.9%) 1 (1.4%) 5 (14.7%) 1 (11.1%) 7 (10.9%)
Sertraline 67 (18.4%) 7 (20.6%) 9 (14.1%)
Escitalopram 60 (16.4%) 3 (8.8%) 3 (4.7%)
Paroxetine 39 (10.7%) 7 (20.6%) 10 (15.6%)
Fluoxetine 16 (4.4%) 1 (1.6%)
MAO-I (=N06AG) 1 (0.3%)
OTHERS (=N06AX) 83 (22.7%) 72 (97.3%) 10 (29.4%) 2 (22.2%) 30 (46.9%)
Trazodone 10 (2.7%) 67 (90.5%) 5 (14.7%) 1 (11.1%) 18 (28.1%)
Venlafaxine (=SNRI) 39 (10.7%) 3 (8.8%) 6 (9.4%)
Mirtazapine 30 (8.2%) 4 (5.4%) 1 (2.9%) 1 (11.1%) 4 (6.3%)
*n=551 (single AD users corrected for 14 missing indications); The indication ‘others’ is not shown (n=5)
AD used by less than 10 residents are not shown:
 TCA: dosulepine, imipramine,clomipramine,doxepine, nortriptyline, maprotiline
OTHERS:mianserine, reboxetine, hypericum perforatum and moclobemide (MAO-I)
TCA= Tricyclic Antidepressant; SSRI= selective serotonin reuptake inhibitor; MAO-I=monoamino oxidase inhibitor
Antidepressant use at Prescription level: prevalence and dose analysis: 
The most frequently prescribed class of all 814 AD prescriptions was SSRI (52.8%) with citalo-
pram, sertraline and escitalopram accounting for, respectively, 17.1%, 14.5% and 10.2%. Tra-
zodone, which is a serotonin modulator, was the most prescribed drug (22.9%). Venlafaxine 
was found in 8.2% and mirtazapine was found in 7.7% of all AD prescriptions. The TCA group 
accounted for 5.8% with amitriptyline (3.6%) as the most representative TCA drug. MAO-I 
prescriptions were negligible (0.1%) (Table 4). 
Of the 814 prescriptions, 72.5% were indicated for depression. Table 4 shows the frequency 
of use for all ADs and dosing information for the most common ADs for this indication. The 
amount of prescriptions with PDD below the MED for the treatment of depression was high 
for trazodone (92.3%), amitriptyline (55.5%) and mirtazapine (44.5%). We did not observe 
this underdosing when an SSRI or venlafaxine was prescribed.
When we used the DDD as a reference, we saw that for the indication of insomnia, the phy-
sicians prescribed daily dosages below the DDD (98.2%); this was also the case for the treat-
ment of (neuropathic) pain (87.5%). For anxiety, mostly, 1 DDD (53.8%) or less than 1 DDD 
was prescribed (46.2%).
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Characteristics associated with AD use: 
Univariate analysis showed that AD use was significantly associated with polypharmacy, pep-
tic ulcer and some care problems such as depression, insomnia, pain and constipation. We 
registered a gradual decrease in AD use from the age of 80 years. In a public nursing home 
and where the medication was dispensed through a hospital pharmacy, there was less AD 
use (Table 5).
In multivariate analysis, AD use was more frequent in younger residents (OR 0.97, 95% CI 0.96-
0.99), in residents with insomnia (OR 1.59, 95%CI 1.26-2.01) and in private nursing homes 
(OR 1.54, 95%CI 1.25-1.90). AD use was also more likely in residents with more chronic use 
of medications (OR 1.15 95%CI 1.11-1.19), concomitant use of benzodiazepines (OR 1.28, 
95%CI 1.00-1.62), antipsychotics (OR 1.26, 95%CI 1.01-1.57), anti-dementia medication (OR 
1.54, 95%CI 1.07-2.23) and antiparkinson medication (OR 1.58, 95%CI 1.14-2.18) (Table 5).
Table 5. Factors associated with Antidepressant use (AD).
CHARACTERISTICS NON user ANTIDEPRESSANT user RISK CALCULATION**
Total for depression for other indications UNIVARIATE MULTIVARIATE
N=1046 N= 684 N= 522 N= 162 p * OR(95% CI) OR(95% CI)
Demographical characteristics
Age (mean + range) 85.7 (60-104) 83.5 (60-102) 83.5 (60-102) 83.6 (60-102) 0.897 0.97(0.96-0.98) 0.97(0.96-0.99)
Gender (% female) 77.6 78.4 80.1 74.7 0.143 1.03(0.82-1.31)
Main Clinical problems(%)
Cardiovascular 75.0 75.8 77.4 74.7 0.477 1.09(0.81-1.26)
Peptic ulcer 22.1 27.8 29.6 24.7 0.230 1.33(1.07-1.67)
COPD 16.0 18.9 20.9 13.0 0.024 1.22(0.95-1.57)
Diabetes 16.3 17.4 18.7 14.8 0.264 1.06(0.82-1.37)
Renal failure 12.3 12.8 13.1 13.0 0.977 1.05(0.77-1.37)
Hepatic problems 1.2 1.6 1.5 1.9 0.780 1.25(0.56-2.80)
Parkinson 7.3 9.8 10.8 7.4 0.212 1.36(0.97-1.91)
Main Care problems(%)
Dementia 47.3 48.0 47.0 52.8 0.202 1.02(0.84-1.24)
Depression 11.5 70.3 84.2 29.2 p<0.001 18.07(13.99-23.34) ***
Insomnia 36.1 54.8 52.7 66.7 0.002 2.09(1.72-2.55) 1.59(1.26-2.01)
Risk of falling 43.9 47.8 48.6 45.6 0.516 1.17(0.97-1.42)
Constipation 39.1 45.3 45.1 49.7 0.306 1.27(1.04-1.54)
Chronic pain 32.6 38.3 40.8 32.7 0.066 1.27(1.04-1.55)
Incontinence 34.6 37.3 36.0 43.5 0.089 1.12(0.91-1.35)
Medication Information
Number of (mean + range)
Medications 7.1 (0-22) 9.2 (1-22) 9.5 (2-22) 8.9 (2-22) 0.012 1.15(1.12-1.18) ***
Chronic Medications 6.3 (0-22) 8.1 (0-22) 8.5 (2-21) 7.8 (2-19) 0.008 1.18(1.14-1.21) 1.15(1.11-1.19)
Use of Psychotropics (%)
Benzodiazepines/zdrugs 47.9 63.9 64.6 58.6 0.173 1.99(1.63-2.42) 1.28(1.00-1.62)
Antipsychotics 30.5 38.1 36.4 37.7 0.772 1.47(1.20-1.80) 1.26(1.01-1.57)
Use of Antidementia drugs 8.2 10.4 9.4 5.6 0.126 1.58(1.12-2.22) 1.54(1.07-2.23)
Use of AntiParkinson drugs 9.6 14.9 14.2 9.3 0.104 1.95(1.44-2.64) 1.58(1.14-2.18)
Institutional(%)
>90 beds 50.8 49.6 49.8 46.3 0.435 0.97(0.90-1.18)
ownership: private 51.1 60.6 62.1 56.2 0.180 1.47(1.21-1.78) 1.54(1.25-1.90)
linked with hospitalpharmacy 17.7 13.0 11.9 16.0 0.166 0.70(0.53-0.92)
*p value of difference between users for ‘depression’ and users for ‘other’ indications , using χ², t-test and Mann Whitney U 
**RISK calculation: Risk of receiving an Antidepressant expressed as Odds  Ratio (OR)
*** not included in multivariate analysis due to interacting effects
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Characteristics associated with Antidepressant use for the indication ‘depression’ and ‘other’ 
indications: Residents who received an AD for the indication of depression had more chronic 
obstructive pulmonary disease and had a significant greater usage of (chronic) medication in 
comparison with the residents that received an AD for other indications. The residents that 
received an AD for other indications were more likely to be classified by their physician as 
insomniacs (Table 5).
Depression and dementia:
In more than one third (34.4%) of the nursing home residents with some form of dementia, 
the GP recorded depression. The prevalence of noted depression as well as the use of an AD 
for the indication ‘depression’ decreased as dementia progressed. On the other hand, the 
proportion of AD use for other indications slightly increased in patients with more advanced 
dementia (Fig. 1). 
Fig 1: Antidepressant use in relation to increasing dementia (scored by the severity of disorientation 
axes in the KATZ scale)
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DISCUSSION
To our knowledge, our study is the first European study to collect indication and dosage in-
formation for each antidepressant directly from the treating physician. Based on our results, 
depression is not undertreated in Belgian nursing homes. More than one third of Belgian 
nursing home residents were classified as having depression and 81% of them were treated 
with an AD. The prescribing physicians used suitable drug classes according to the guidelines 
for depression in older people [38]. Underdosing was not seen in the treatment of depression 
with the most prevalent AD classes, but when ADs were used for other indications, we saw 
the use of lower doses.
There was a substantial use of ADs (mainly trazodone) for insomnia. Furthermore, we noticed 
physicians were more likely to prescribe a benzodiazepine rather than the preferred SSRIs to 
treat (chronic) anxiety. 
Strengths and limitations: 
Our sample proved to be representative both on the institutional and residential level[39]. 
Moreover, the large size of our sample makes it possible to extrapolate our findings to the 
entire Belgian nursing home setting.  Similar prevalence numbers for depression and AD use 
were found in European [1, 40] and American [9] studies, but for specific indication and dosage 
evaluation, no identical studies were available. The indications for AD prescribing were ret-
rospectively collected by interviewing the GP. As the GP is the prescriber of the AD, this ap-
proach gives us a clearer view of the use of ADs than linking clinical diagnoses and medication 
databases would have. This strength can be a limitation as well because of the retrospective 
aspect of the method. Our interpretation of underdosing and the MED as a threshold was 
established by using a strict methodology.           
A limitation of our study is that we did not collect information about alternative treatment 
strategies for depression such as psychotherapy, so we focused our discussion on the resi-
dents receiving an AD. Another limitation is that we did not use validated diagnostic criteria 
to evaluate the severity of depression and dementia, but we relied on the a posteriori clinical 
judgement of the treating physician. The physicians should have been aware that depression 
is not equal to depressive mood, but we do not know whether they had fully considered this. 
Moreover, we had no breakdown of various degrees of depression in our checklist of clinical 
diagnoses. The disorientation axes of the KATZ scale may not be an ideal dementia grading 
instrument as it can be influenced by other disorders (depression, delirium). However, we 
decided to use this tool for pragmatic reasons; use of this tool is mandatory in the Belgian 
context, and thus the data are readily available. In addition, in this cross-sectional study, we 
were not able to investigate the distribution of the duration of AD use; nor was it possible 
to investigate temporal changes and the relationship between process and outcome. Fur-
thermore, we reduced the complexity of the analysis by narrowing our in-depth analysis of 
indications to single AD users, and we disregarded residents on more than one AD (6.9% of 
all residents). 
Discussion of the main findings: 
According to our study, in more than one third of the Belgian nursing home residents the 
treating physician noted depression. This percentage is situated in the middle segment of 
the prevalence range 11%-50% reported in other studies in different Western countries [1, 
3-5]. Of all the residents classified as having depression, 81% was treated with an AD and 73% 
received an AD especially for the indication depression. Knowing that only major depression 
should be treated pharmacologically, our results do not support the hypothesis of under-
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treatment in the group of residents with noted depression. Other recent articles also indicate 
an AD treatment percentage of more than 80% [9, 40] for depressed residents, but these per-
centages are irrespective of indication. In addition to reporting that there is no undertreat-
ment, it could also be useful to examine the reason why about a third of all residents need 
pharmacological treatment of their depression.
In our study, more than one quarter of the AD prescriptions (28%) were not to treat depres-
sion. Other approved indications such as anxiety and neuropathic pain accounted for 7.8% of 
all AD use. Insomnia without depressive symptoms accounted for 13.4%.
Most of the ADs were prescribed at a dosage of 1 DDD or less and rarely exceeded 1 DDD. 
Possible depression underdosing in the nursing home population was checked by analysing 
the PDD in accordance with the MED. The SSRI group and venlafaxine were dosed above their 
MED. Trazodone, TCAs and mirtazapine were often dosed under their MED. It is important to 
keep in mind that when treating older adults, polypharmacy, polypathology, pharmacokinetic 
and –dynamic alterations can influence dosage response. The MED does not really consider 
these particular changes in determining the threshold. In the literature, there is not much 
guidance on antidepressant dosing in frail older adults; slow upwards titration and close 
monitoring of side-effects is recommended [41].
Antidepressants for the indication ‘depression’:
For the indication of depression in old age, SSRIs deserve a preference within the pharmaco-
logical approach [38, 42] and, as found in our study, were the most commonly prescribed ADs 
in Belgian nursing homes (citalopram, sertraline, escitalopram). Although SSRIs have a more 
appropriate side-effect profile and are safer in overdose for older adults than other antide-
pressants, still, physicians should prescribe these drugs with caution, because of the risk of 
drug-drug interactions and adverse effects such as hyponatraemia[43], upper gastrointestinal 
bleeding[44], insomnia, restless leg syndrome, agitation and the potential risk of serotonin 
syndrome[45, 46]. The Beers list [31] of inappropriate medications for use in older adults included 
fluoxetine, because of its long half-life and inhibition of cytochrome P 450 enzymes (mainly 
CYP2D6). In our study, this SSRI was prescribed only in 2% of the cases. 
In our study, venlafaxine was also frequently prescribed for depression. Together with the 
SSRIs, it is known for its stimulating properties that can cause sleeplessness [47]. Venlafaxine 
should be reserved as a second-line treatment for depression and is not indicated in patients 
with heart failure, coronary disease and uncontrolled hypertension [38]. 
Mirtazapine is also a relatively often prescribed AD for older adults because it has less an-
ticholinergic side effects (i.e. dry mouth, urinary retention, constipation) than TCAs [48]. 
TCAs, equally effective as SSRIs [49], are known for their toxicity in overdose [50] and their an-
ticholinergic side-effect profile. Therefore, they are not recommended as a first choice to 
treat depression in older adults. However, a recent cohort study concluded that SSRIs and the 
newer ADs were associated with a higher risk of adverse events, such as stroke, fracture and 
all-cause mortality, compared with TCAs  [40]. 
In our study, SSRIs and venlafaxine are prescribed above the MED. However, 45% of the mir-
tazapine, 96% of the trazodone and 56% of the TCA prescriptions are dosed under their MED, 
a possible precaution taken by prescribers aware of the sedative and/or anticholinergic prop-
erties of these drugs.
Antidepressants for ‘other’ indications: 
The most frequently prescribed AD in this setting was trazodone. It was predominately pre-
scribed at lower dosages for primary insomnia. The use of trazodone for sleep disturbance in 
adult and older patients is extensive in clinical practice [51].  In depressed adult patients, there 
is evidence for the efficacy of trazodone for sleep disturbance [52]. In non-depressed adult 
64
2.2
RESU
LTS:     The use of antidepressants in Belgian nursing hom
es: a focus on indications and dosages in the PH
EBE study
patients, trazodone might be effective in primary insomnia[53]. However, the evidence for its 
use for primary insomnia in older people is rather scarce [23] and controversial [54]. Trazodone 
has so far not received an indication as sleep-promoting agent in the official labelling. The 
side effects of trazodone are not very different from other (non)benzodiazepine hypnotics in 
terms of residual daytime impairments, but priapism and orthostatic hypotension are impor-
tant side effects of trazodone [55].
The amount of trazodone prescriptions intended for insomnia and not to treat depression 
is increasing [51, 56]. The (inter)national warnings and campaigns against the chronic use of 
benzodiazepines[57] [15] are a possible reason for the preferential prescribing of trazodone. 
Another consideration can be the relatively lower cost of trazodone in Belgium in compari-
son with (non)benzodiazepine hypnotics. Moreover, trazodone, unlike (non)benzodiazepines 
hypnotics, is reimbursed (75% of the cost) by the Belgium Health Care system. In order to 
maintain a healthy economic situation, it is important to ensure that no shift towards reim-
bursed sedative ADs takes place, particularly in the absence of convincing evidence. 
Another indication for which an AD can be prescribed is neuropathic pain. Our study con-
firmed the assumption that TCAs are mostly prescribed for the treatment of pain [22], and at 
doses lower than the DDD [24]. Although not licensed for this indication, amitriptyline, which 
was in our study the most prevalent agent, is considered first-line treatment for neuropathic 
pain in guidelines[58]. Duloxetine is also indicated for neuropathic pain and is registered for 
this indication [58]. 
Although the first pharmacological choice to treat anxiety disorders chronically is an SSRI 
[59, 60], in our study, physicians were more likely to prescribe a benzodiazepine on a chronic 
base than an AD. Benzodiazepines can be used for acute anxiety or can be co-administered 
for a short period of time (max 4 weeks) to overcome the delayed pharmacological effect of 
the AD  [59, 61, 62].  However, to avoid tolerance and dependence, this dual therapy should be 
tapered over time. 
Characteristics associated with antidepressant use: 
We found that older residents had lower AD use. This is also mentioned in other AD stud-
ies [9, 17] and with other medication groups. This can be partly explained by the increasing 
incidence of dementia in older residents and the growing inability of residents to utter spe-
cific complaints (e.g. feeling depressed) with deepening dementia. We also found that use 
of psychotropics and polypharmacy are inextricably linked, indicating the need for clinical 
practice guidelines and education focusing on initiation and reassessment of ADs and the 
use of psychotropic drugs in general. Antiparkinson drugs were significantly associated with 
AD use, which can be explained by the symptoms of parkinsonism: depression is a common 
neuropsychiatric manifestation in Parkinson’s disease. As ADs may have sedative properties 
and are often used for the treatment of insomnia, it was no surprise that insomnia was cor-
related with AD use, and more specifically with AD use for indications other than depression. 
Because in Belgium the differences in institutional characteristics between a private and pub-
lic nursing home are small, we cannot explain the association between the private nursing 
homes and the elevated likelihood of receiving an antidepressant.
Depression and dementia: 
In our study, in one third of the residents with noted dementia, depression was also reported. 
This is higher than the prevalence rate in other European countries [5, 63] and the United States 
[64]. When analyzing the different stages of disorientation (expression of dementia), we found 
that both the prevalence of depression and the antidepressant use decreased with worsen-
ing disorientation. This could indicate the difficulty of diagnosing depression in cognitively 
impaired residents and a possible under-treatment in this specific patient group. However, 
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a recent publication in the Lancet [65] suggested the absence of benefit of antidepressants in 
dementia compared with placebo and the increased risk of adverse events. The trial under-
scores the need to think about creative but evidence-based alternatives (such as psychoso-
cial interventions) for the management of depression in people with dementia. But because 
of organizational- and staffing problems, psychotherapy is not routinely available in Belgian 
nursing homes.
CONCLUSION
ADs were found to be used by 39.5% of the residents. Overall, the quality of AD prescribing 
in the Belgian nursing homes is relatively satisfactory. Most of the residents with reported 
depression were treated according to evidence-based recommendations with SSRIs (mainly 
citalopram, sertraline and escitalopram) in dosages equal to or higher than the MED. Ven-
lafaxine, not the first-choice drug in the older population, was used by 1/10 and in dosages 
equal to or higher than the MED. All other antidepressants (TCAs, mirtazapine, trazodone) 
used for depression were dosed under the MED. 
In the indication of anxiety, most of the time, the physicians did not prescribe the recom-
mended SSRIs; they preferred the chronic use of benzodiazepines. 
A controversial issue is the prescribing of sedative ADs (mostly trazodone) for insomnia 
(13.4%). A plausible explanation for this prescribing without clear evidence of efficacy and 
safety in frail older adults can be found in the reimbursed status of ADs in comparison with 
other sleeping pills.  
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ABSTRACT
Objectives: We aim to describe subjective sleep quality among chronic users of benzodi-
azepines and Z-drugs (BZD/Zs) in Belgian nursing homes, to compare it to nonusers, and to 
investigate determinants of bad sleep quality.
Methods: All mentally competent residents from 10 nursing homes were screened and com-
piled in a group of chronic BZD/Zs users or in a group of nonusers based on the medication 
chart. We collected demographic, functional, and medication characteristics and global and 
specific sleep parameters using the Pittsburgh Sleep Quality Index (PSQI). Linear regression 
was used to investigate which parameters were associated with sleep quality.
Results: Of the 300 residents, 178 (59%) were chronic BZD/Z users and 122 nonusers. The 
two groups did not differ in demographic and functional characteristics (mean age= 85.5 
years; range 57-100, 75% women). The users reported significantly more difficulties with fall-
ing asleep, had more midnight awakenings, felt less rested in the morning, and had a poorer 
self-perceived sleep quality compared to nonusers. Sleep duration and time to fall asleep did 
not differ.
The self-perceived sleep quality was mainly determined by difficulties during initiation of 
sleep. 
After controlling for demographic, medication and functional characteristics, BZD/Z use re-
mained strongly associated with bad sleep (r=0.173, p=0.003), and a study centre effect (dif-
ferences among nursing homes) was observed (r=0.229, p<0.001).
Conclusion: Our findings do not support long-term effectiveness of BZD/Zs; chronic users 
slept more poorly than nonusers (even more outspoken in users of long-acting BZDs). In fu-
ture longitudinal comparative studies of sleep quality, unexplained variability needs further 
assessment with medical, psychological and institutional parameters. 
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INTRODUCTION
Sleep problems are more frequent with growing age. In the normal aging process changes 
in the sleep structure occur, with less restorative deep sleep (i.e. stage III and IV of the non-
REM sleep). A fragmented sleep pattern with more midnight awakenings is associated with 
aging[1, 2]. In addition, comorbidities, medication use, psychological distress and sleep-related 
disorders (e.g. sleep apnoea, restless legs syndrome), all affect sleep quality and increase 
with age[3].
Benzodiazepines (BZDs) and related Z-drugs (BZD/Zs) are the most frequent used sympto-
matic treatment for sleep problems in the older population[4] and particularly in the nursing 
home setting[5]. In a previously published study, we reported that 50% of the Belgian nursing 
home population used BZD/Zs chronically[6]. 
Although BZD/Zs alter the sleep architecture by supressing deep sleep stages, they are ini-
tiated because of their ability to shorten the time to fall asleep and to increase total sleep 
duration[7, 8]. Due to their sedating action, the (short-term) adverse effects of BZD/Zs include 
decreased alertness with risk for falling and anterograde amnesia. After 4 weeks of contin-
uous BZD/Z use most patients engage in chronic use, while the hypnotic effect decreases 
due to tolerance[9]. Interruption of treatment can lead to withdrawal symptoms[10], and these 
symptoms are often the reason to continue use. 
Guidelines discourage chronic use because of both physical and psychological dependence 
as well as the unproven long-term effectiveness[11-13]. Moreover, it has been hypothesised 
that long-term use might have a detrimental effect on cognition and a potential acceleration 
of cognitive impairment[14]. The high prevalence of chronic BZD/Z users indicates that these 
guidelines are insufficiently implemented.
Long-term effectiveness is difficult to assess and requires long follow-up data[15]. Epidemio-
logical studies of the effects of chronic BZD/Z use on sleep quality are scarce. Ohayon et al.[16] 
reported few distinctions in the various dimensions of sleep quality between older drug-tak-
ing insomniacs and older nontreated insomniacs. A study among 516 older adults in Berlin[17] 
reported a higher rate of sleep related complaints among individuals taking sleep medication. 
Both studies did not focus on BZD and Z-drugs, and did not use a standardised method to 
evaluate sleep. Polysomnography is the objective tool for examining effectiveness of sleep 
medication[18]. However, the patient’s perception of sleep quality remains the determinant 
of most requests for prescribing hypnotics and is a common criterion by which the general 
physician and patient judge efficacy[19]. Therefore, a subjective tool such as the Pittsburgh 
Sleep Quality Index (PSQI)[20] has gained widespread acceptance to analyse sleep quality. It 
has undergone extensive psychometric evaluation and is often used in older adults[15, 21-23]. A 
Canadian study[15] in a large sample of community dwelling older adults that aimed to inves-
tigate the association between BZD use and overall sleep quality used this instrument and 
found a poorer sleep quality among BZD users. However, in this study the BZD use was self-re-
ported, there was no focus on chronic use and there were no other interfering co-medication 
reported. We found no study especially designed to compare sleep parameters in a well-de-
fined group of chronic BZD/Z users and a group of nonusers. Therefore, we set out to design 
a longitudinal study investigating sleep quality with the validated PSQI questionnaire. The 
aim of our study was to describe the sleep parameters of mentally competent nursing home 
residents as well as to investigate which sleep parameters are associated with self-perceived 
sleep quality, and which characteristics influence global sleep quality. More importantly, we 
compared sleep parameters between chronic BZD/Z users and nonusers.
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METHODS
In this baseline assessment of a longitudinal cohort study in the Belgian nursing home setting, 
we investigated the sleep quality in a group of mentally competent chronic BZD/Z users and 
a group of mentally competent nonusers (control group). 
Setting: 
The Belgian long-term residential care structure consists of residential and/or nursing homes 
for older people, which offer a home replacement with or without nursing care. Governance 
of nursing homes for older people is either public (community health services) or private 
(predominantly non-profit) with little difference in quality. The point prevalence of dementia 
among residents is around 50% with considerable variation among nursing homes[24].
Design: 
From a convenience sample of 10 nursing homes, all mentally competent residents were 
identified, screened for inclusion and exclusion criteria, and separated in an exposure group 
of BZD/Z users and a control group based on analysis of the medication chart. No matching 
procedure was applied. Both groups were evaluated at baseline (and will be re-evaluated at 
1 year). 
Inclusion and exclusion criteria: 
We only included mentally competent residents defined as having a Mini Mental State Ex-
amination (MMSE)[25] score of at least 18. We excluded residents that only used the sedative 
antidepressants trazodone or mirtazapine or phytotherapy as a sleep medication. We also 
excluded residents that used BZDs for the indication anxiety. Residents with BZDs or Z-drugs 
administered at bedtime for at least 3 months were allocated to the exposure group. Resi-
dents who were free of any hypnotic medication and did not use a BZD during daytime for 
anxiety were allocated to the control group.
Data collection: 
Demographic data were obtained from the resident’s record and medication data from the 
medication chart in the period December 2011- January 2012. Cognitive function was scored 
by the MMSE test. The scores of this crude screening tool range from 0 to 30, with higher 
scores indicating a better global cognition. Functional characteristics were scored by the KATZ 
Activities of Daily Living (ADL) scale[26]. This instrument is mandatory in the Belgian nursing 
homes. The first part of this instrument scores six ADLs from 1 (independent) to 4 (total de-
pendent). The second part scores disorientation in time and place ranging from 1 (no disori-
entation) to 4 (severe) and was used to confirm mental competence.
Based on the Anatomical Therapeutic and Chemical classification (ATC)[27], we selected the 
classes N05BA (anxiolytics), N05CD (hypnotics) and N05CF (Z-drugs) to define the BZD/Z 
group. The BZDs, tetrazepam and clonazepam, both taken by one person were in this study 
classified as sleep medication, though they have a different ATC nomenclature. We divided the 
BZDs and Z-drugs according to half-life based on a reference source[28]: triazolam, lormetaze-
pam, loprazolam, oxazepam, lorazepam, bromazepam, alprazolam, zopliclone and zolpidem 
were grouped into short-acting drugs (T
1/2
<24h) and tetrazepam, clonazepam, flurazepam, 
flunitrazepam, diazepam, prazepam and chorazepate into long-acting drugs (T
1/2
>=24h). We 
recorded the total number of chronically used medications as well as possible interfering 
medication such as antidepressants (ATC N06A), antipsychotics (ATC N05A), anti-dementia 
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drugs (ATC N06D), anti-Parkinson (ATC N04) drugs and narcotic pain medication (ATC N02A). 
Sleep evaluation: 
The PSQI[20], a self-rated questionnaire that investigates global sleep quality and sleep dis-
turbances was used (Dutch translation[29]). Because our sample was a geriatric population, 
the researchers assisted the resident with the recording and rating of the questionnaire. The 
seven components of the PSQI are scored from 0 to 3, yielding a total score ranging from 0 
to 21, with a higher score indicating worse sleep quality. The component ‘sleep difficulties’ 
included nocturia and pain, both defined as waking up in the night more than once a week.
A total PSQI score of more than 5 is a widely used cut-off that indicates poor sleep quality. 
Because, we wanted to compare sleep quality in a group of BZD/Z users and nonusers in this 
study, we generated a new PSQI score (adjusted PSQI) without the component ‘sleep med-
ication’. The adjusted PSQI can range from 0 to 19 and was the variable of choice when we 
investigated and compared sleep quality in BZD/Z users and nonusers. 
Sample size calculation: 
We calculated a required sample size of at least 99 individuals per group to detect a differ-
ence of 2 points on the PSQI from 4.5 to 6.5 (SD 5) with a power of 0.80 and P<0.05 as the 
level of significance.
Statistics: 
In the primary analysis, demographic, functional and medication characteristics were de-
scribed for the total nursing home population and compared between the BZD/Z users and 
the nonusers, using Chi² for categorical variables and independent t-tests for continuous var-
iables. 
The internal consistency of the total PSQI was 0.66 (Cronbachs α), which was comparable 
with previous studies[30]. We analysed the sleep parameters in the total population and in 
the two parallel groups. All component scores were compared with non-parametric statistics 
(Mann Whitney U) and the frequencies in each component score were analysed with Chi². 
Within the BZD/Z group, the different PSQI components were compared between users of 
long-acting and short-acting BZD/Z with non-parametric statistics (Mann Whitney U).
To find which components of the PSQI were related to the subjective PSQI component 
‘self-perceived sleep quality’, we used multiple linear regression with the score on self-per-
ceived sleep quality as the dependent variable. 
Variability of different parameters among the nursing homes was analysed with non-para-
metric statistics (Kruskal Wallis).
Furthermore, we analysed which demographic, functional and medical characteristics were 
associated with global sleep quality in a multiple linear regression model with the total ad-
justed PSQI as dependent variable. All statistical analyses were performed using the statistical 
package SPSS version 20 with p<0.05 as the level of significance. 
Ethical considerations: 
This observational cohort study was approved by the Ethics Committee of the University Hos-
pital of Antwerp (registration number B300201112211). Each nursing home received infor-
mation and gave approval to screen the nursing home population. Each included resident 
received oral and written information and gave consent.
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RESULTS
Recruitment: 
Ten nursing homes with a total of 1152 beds (located in two Flemish regions of Belgium, 
Antwerp and Ghent) agreed to participate. Inclusion criteria were met by 410 residents. Sixty 
three residents were excluded based on analysis of the medication chart. We asked 347 eli-
gible residents to participate and 47 refused. Of the 300 enrolled residents, 178 (59%) used 
a BZD/z-drug and were included in the BZD/Z group and 122 nonusers in the control group 
(Fig 1). 
Fig 1: Flowchart of prospective cohort study
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Demographic and functional characteristics of the total population: 
The mean age of the total population was 85.5 years (range 57-100) and the average time of 
institutionalisation was 40 months. Three quarters were female. Schooling age was not high-
er than 14 years in 59% of the residents. The mean MMSE score was 25.6 (range 18-30), and 
the mean ADL score was 12.1 (range 6-24), with mainly difficulties with washing and clothing. 
The average number of chronic medications was 8.1 (range 0-18) (Table 1).
Table 1. Description of demographic, functional and medication characteristics in total population and compared between 
chronic benzodiazepine users and nonusers.
total population BZD/Z group CONTOL group p value**
N=300 N=178 N=122
Demographic characteristics
age (mean-range) 85.5  (57-100) 85.4 (57-100) 85.7 (65-99) 0.767
gender (%female) 74.7 75.3 73.8 0.768
length of stay in months (mean-range) 39.7 (0-223) 39.7(1-191) 39.6 (0-223) 0.985
education level
elementary (%) 14.7 17.4 10.7 0.342
high school till 14y (%) 44.7 42.1 48.4
high school till18y (%) 33.0 32.0 34.4
higher (%) 7.7 8.4 6.5
Functional characteristics (mean-range)
self-dependency score (ADL) (6-24) 12.1 (6-24) 12.3 (6-24) 11.8 (6-22) 0.382
disorientation score  (2-6) 2.6 (2-6) 2.5 (2-6) 2.7 (2-6) 0.073
MMSE score (0-30) 25.6 (18-30) 25.4 (18-30) 25.7 (18-30) 0.407
Medication
chronic medications (mean-range) 8.1 (0-18) 9.2 (1-18) 6.6 (0-17) <0.001
use of Sleepmedication (%) 59.3 100.0
ATC class 
hypnotic* (%) 43.8*
anxiolytic* (%) 39.9*
Z-drug*  (%) 25.3*
duration of action
long-acting (%) 12.4*
short-acting (%) 90.4*
use of Psychotropics (%) 53.3 62.4 40.2 <0.001
antidepressant (%) 36.3 44.9 23.8 <0.001
antipsychotic (%) 13.0 15.7 9.0 0.089
anti-dementia  (%) 4.7 3.4 6.6 0.199
anti-Parkinson (%) 6.0 5.6 6.6 0.736
use of narcotic analgesic (%) 16.7 23.0 7.4 <0.001
* sum of percentages >100% due to duplicate use
** p value: continuous variables with independent t-test and dichotomous variables with Chi²
ADL: Activities of Daily Living
MMSE: Mini Mental State Examination
ATC: Anatomical Therapeutic Chemical Classification/ (hypnotic= N05CD, Z-drug= N05CF; anxiolytic= N05BA)
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In the BZD/Z group, 44% used a hypnotic (ATC N05CD), 40% used an anxiolytic (ATC N05BA) 
and 25% a z-drug (ATC N05CF). Dual BZD use was seen in 13% (n=23). Most often (34%) 
lormetazepam was used. Zolpidem and lorazepam were each used by 25% of the users. 
Based on the half-life, 90% used a short-acting and 12% a long-acting benzodiazepine (2% 
overlap due to dual use).
Sleep characteristics of the total population: 
The mean adjusted PSQI score (without the medication component) of the 300 residents 
was 4.9 (SD 2.4). This score was mainly influenced by the component sleep latency (r=0.705, 
p<0.001) and the self-perceived sleep quality (r=0.703, p<0.001). Additionally, the compo-
nents daytime dysfunction, sleep disturbance, efficiency and duration had a significant corre-
lation with the total PSQI of 0.566, 0.450, 0.286, and 0.231, respectively. 
The number of bad sleepers (adjusted PSQI more than 5) was 36%. The mean hours of night-
time sleep was 8h57min (3h25 to 13h15). The mean number of minutes before a resident fell 
asleep was 27 minutes (1min. to 210min.). Mean scores of the different PSQI components 
are shown in table 2. Nocturia occurred in more than 70% of the nursing home residents and 
was the most frequent night-time disturbance. Awakenings due to pain were present in 24%, 
of which 46% had a prescription for a narcotic analgesic.
Table 2. Sleep characteristics compared between benzodiazepine users and nonusers.
COMPONENTS of PSQI* BZD/Z group CONTROL group
N=178 N=122 p value**
SLEEP duration (0-3) 0.17 0.10 0.334
hours of sleep (mean-range) 8h56 (3h25-13h15) 8h58 (5h10-11h55) 0.818
SLEEP latency (0-3) 1.40 1.19 0.072
minutes before falling asleep (mean-range) 28 min (1-210) 25 min (1-150) 0.414
SLEEP disturbance (0-3) 1.21 1.02 0.002
midnight awakenings (0-3) 2.12 1.68 0.001
difficulties falling asleep (0-3) 1.47 1.20 0.050
midnight toilet awakenings (0-3) 2.08 2.07 0.804
awakenings pain (0-3) 0.82 0.50 0.013
Daytime dysfunction (0-3) 1.44 1.16 0.015
daytime sleepiness (0-3) 1.60 1.48 0.388
well rested (0-3) 0.82 0.48 0.002
SLEEP efficiency (0-3) 0.07 0.03 0.335
SLEEP self-perceived sleep quality(0-3) 1.12 0.78 0.001
total adjusted PSQI  (0-19) 5.4 (1-12) 4.3 (0-11) <0.001
% bad sleepers (adjusted PSQI >5) 42.1 27.0 0.007
total PSQI (0-21) 8.2 (1-17) 4.6 (0-11) <0.001
* six components of the adjusted PSQI ; expressed as mean score,  with higher scores indicating worse outcome
‘Sleep duration’ is categorised into more than 7 hours of sleep (score 0), between 6 and 7 hours (score 1), between 5 and 6 hours (score 2) and less than 
5 hours (score 3). ‘Sleep latency’ consists out of 2 items; ‘difficulties falling asleep’ and ‘minutes before falling asleep’ categorised as less than 15min-
utes (score 0), between 16 and 30minutes (score 1), between 31 and 60minutes (score 2), and more than 60minutes (score 3). The components ‘sleep 
disturbances’, ‘daytime dysfunction’ and ‘sleep medication’ are scored from 0 to 3 (coded as not during the past month to three or more times a week. ‘Sleep 
efficiency’, composed as the ratio hours slept/ hours spent in bed is divided into 85% or more (score 0) , between 75% and 84% (score 1), between 65% and 
74% (score 2), and less than 65% (score 3). The subjective component ‘self-perceived sleep quality’ is also scored from 0 to 3, meaning very good, fairly 
good, fairly bad and very bad respectively.
** scores with Mann Whitney U test,continuous variables with independent t test and percentage with Chi²
PSQI= Pittsburgh Sleep Quality Index / adjusted PSQI= PSQI without the medication component
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The mean score of the component ‘self-perceived sleep quality’ was 0.98 (SD 0.84). We inves-
tigated which components of the PSQI were associated with self-perceived bad sleep quality 
(table 3) and in univariate analysis; we found that all sleep parameters were associated. In 
multivariate analysis, sleep latency had the highest correlation (r=0.349), followed by pain 
(r= 0.161), the feeling of not being rested in the morning (r=0.146) and midnight awakenings 
(r=0.134). 
Table 3. Sleep parameters (derived from the Pittsburgh Sleep Quality Index) associated with the component self-perceived sleep 
quality: Univariate and multivariate analysis.
self-perceived sleep quality (range 0-3)
COMPONENTS of PSQI UNIVARIATE MULTIVARIATE**
r p value* B ß p-value
SLEEP duration (0-3) 0.152 0.009 0.258 0.141 0.004
hours of sleep (mean-range) -0.137 0.018
SLEEP latency (0-3) 0.411 <0.001 0.264 0.349 <0.001
minutes before falling asleep 0.528 <0.001
SLEEP disturbance (0-3) 0.240 <0.001
midnight awakenings (0-3) 0.233 0.001 0.089 0.134 0.008
difficulties falling asleep (0-3) 0.439 0.001
midnight toilet awakenings (0-3) 0.149 0.010
awakenings pain (0-3) 0.259 <0.001 0.120 0.161 0.002
Daytime dysfunction (0-3) 0.196 0.001
daytime sleepiness (0-3) 0.125 0.031
well rested (0-3) 0.240 <0.001 0.133 0.146 0.004
SLEEP efficiency (0-3) 0.198 0.001
SLEEP medication (0-3) 0.223 <0.001 0.066 0.115 0.023
*non parametric statistics (spearman rank)
** multivariate linear regression (r²=0.32) 
Factors associated with bad sleep: 
With this analysis, we wanted to investigate several demographic, functional and medication 
characteristics associated with sleep quality (Table 4). Univariate analysis showed there was 
no correlation between adjusted PSQI and the use of psychotropic drugs other than BZD/
Zs. Gender, MMSE score, functional status, education level, and length of stay also were not 
associated. Multivariate analysis showed that the adjusted PSQI had the highest association 
with BZD/Z use (r= 0.173). Age and the number of chronic medications also were associated 
(Table 4). Although the variance explained in our model remained small, it did increase from 
8% to 13% when we included study centre in the model.
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Table 4. Demographic, functional and medication characteristics associated with bad sleep (according to the total adjusted 
Pittsburgh Sleep Quality Index score).
 total adjusted PSQI(range 0-19)
UNIVARIATE* MULTIVARIATE**
Factors/Characteristics r p-value B ß p-value R²
BZD/Z use 0.230 <0.001 0.850 0.173 0.003 0.053
number of chronic medications 0.185 0.001 0.077 0.126 0.030 0.067
age 0.130 0.025 0.048 0.144 0.008 0.083
disorientation -0.107 0.066
narcotic use 0.097 0.094
antipsychotic use 0.073 0.210
MMSE score 0.073 0.208
education -0.065 0.262
antidepressant use -0.021 0.719
gender (female) 0.012 0.839
length of stay -0.012 0.838
ADL -0.011 0.846
anti-Parkinson drugs -0.030 0.601
anti-dementia drugs -0.061 0.289
study centre effect (nursing home) 0.234 <0.001 0.205 0.229 <0.001 0.134
* Pearson correlation
**multivariate linear regression: cumulative R² shown
MMSE: Mini Mental State Examination
ADL: Activities of Daily Living
Variability among nursing homes: 
We saw considerable variation in the adjusted PSQI score in the ten nursing homes ranging 
between 3.1 and 5.2 (p=0.018). The percentage of BZD/Z users per nursing home ranged 
from 41% to 69% while the prevalence of bad sleepers (adjusted PSQI >5) ranged from 19% 
to 50%. There was a negative correlation between these two parameters, but it was not sig-
nificant (r=-0.231, p=0.522) (Fig 2).
Fig 2: Percentages of chronic benzodiazepine use and bad sleepers per nursing home.
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Comparison between benzodiazepine users and nonusers: 
The BZD/Z users and the nonusers did not differ in demographic and functional characteris-
tics. The average number of chronic medications differed in the two groups; 9.2 chronic med-
ications in the BZD/Z group, and 6.6 in the control group. The use of other psychotropic drugs 
differed between users and nonusers, more specifically the use of antidepressants (45% vs. 
24%) and narcotic analgesics (23% vs. 7%) (Table 1).
We looked at the differences in the mean scores of PSQI components (Table 2) and also at the 
frequency distribution of the scores in percentages (Fig 3). The total adjusted PSQI score dif-
fered between the two groups; 5.4 in the BZD/Z group and 4.3 in the control group (p<0.001). 
Fig 3: Frequency distribution of the scores of the Pittsburgh Sleep Quality Index for chronic benzodiazepine users 
and non-users per component (score range: 0-3).
In the BZD/Z group, 8% perceived their sleep quality very bad and 20% rather bad. This per-
centage was at least two times higher than in the control group (2% and 11% respectively, 
p<0.001). Approximately 30% of the BZD/Z users had frequent difficulties with falling asleep 
compared to 22% in the control group. Midnight or early morning awakenings were frequent 
in 60% of the users compared to 40%. Sleep disturbance due to pain was frequent in 19% of 
the users compared to 7%. The feeling of not being well rested in the morning was present 
in 8% of the users compared to 2% of the nonusers. All of these differences were statistically 
significant (Table 2). Nocturia, the mean hours of nighttime sleep, the minutes before falling 
asleep and the feeling of sleepiness during the day did not significantly differ between users 
and nonusers.
Within the BZD/Z group, a separate analysis comparing users of long-acting (n=17) versus 
short-acting BZDs (n=156) showed a worse adjusted PSQI score (6.5 vs. 5.3, p=0.012), though 
there were no differences in sleep duration and time to fall asleep. Users of long-acting BZDs 
had more difficulties with falling asleep than users of short-acting (mean score 2.2 vs. 1.4 
p=0.013) and perceived a poorer subjective sleep quality (1.6 vs. 1.1 p=0.02). Other sleep 
parameters, such as midnight awakenings, not feeling rested in the morning, and daytime 
sleepiness did not significantly differ.
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DISCUSSION
Our study was the first study especially designed to investigate sleep quality among chronic 
BZD/Z users in the nursing home setting and to compare this to a well-defined control group 
using an adequate tool that reports several aspects of sleep quality. 
The main finding of our study was that chronic users of BZD/Zs had a poorer sleep quality 
than nonusers, though they did not differ in terms of demographic and functional character-
istics. More specifically, chronic users reported more difficulties with falling asleep, a higher 
frequency of midnight awakenings, and a higher frequency of not being well rested in the 
morning. Additionally, we found that the sleep quality considerably differed between the 
participating nursing homes. 
Sleep characteristics of the total population: 
Nursing home residents in our study needed approximately half an hour (27min) to fall asleep 
and had a long but disturbed night-time sleep (9 hours). Midnight toilet awakenings occurred 
in 70% and were the most common sleep disturbance in our study, as well as in other stud-
ies[31, 32]. Surprisingly, the self-perceived sleep quality of nursing home residents was not de-
termined by nocturia, but was predominantly determined by difficulties falling asleep and by 
pain. Because pain can provoke sleep problems[33], underlying causes should be addressed 
and could reduce the prescribing of sleep medication. In future research, the concomitant 
use of a pain assessment scale could help in clarifying sleep problems. 
Characteristics associated with bad sleep: 
We investigated which demographic, functional and medical characteristics were associated 
with poorer sleep quality. Except for a weak association with age, we found no specific as-
sociations with demographic and functional characteristics such as gender, education, and 
ADL score. Similar to other studies[34], we found that the more intense the polypharmacy 
was (even when the use of psychotropic drugs was excluded), the poorer the sleep quality. 
Multiple pathologies and the associated medication use can influence the sleep quality[35]. 
The variance of our model was small, though it increased from 8% to 13% when we intro-
duced the study centre effect. A large part remains unexplained; therefore institutional char-
acteristics such as the type of ward and nighttime policy[31, 36] should be included in future 
research of sleep quality. Additionaly more psychometric properties of the older adults such 
as depressive symptoms should be investigated. 
Sleep characteristics compared between benzodiazepine users and nonusers:
Although the main reason to initiate BZD/Zs is to shorten the time before falling asleep[7, 
8], chronic users reported more difficulties with falling asleep in our study. Surprisingly, the 
self-reported more objective sleep parameters such as time before falling asleep and hours 
of sleep did not differ between the two groups. Pseudoinsomnia, a misperception of sleep 
in which sleep latency is overestimated, has been described in the literature[37] and could be 
the reason why residents using sleep medication perceive subjective sleep complaints more 
intensely. 
The feeling of being tired in the morning was more present among chronic BZD/Z users. This 
confirms the risk of the hangover effect[38]. Long-acting BZDs are said to have more daytime 
residual effects[39]. In our study, when a long-acting BZD was used, the overall differences 
were accentuated, but not in daytime dysfunction.
It is known that BZD/Zs change sleep architecture at the expense of the deep restorative 
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stages of sleep; therefore our finding that chronic users reported more midnight awakenings 
is logical. Another explanation could be that the BZD/Z user had a less restorative and more 
fractionated sleep as a consequence of aging, and had no persistent improvement with the 
drug.
Furthermore, awakenings due to pain were more frequent among chronic BZD/Z users in our 
study, which additionally could  influence the overall rate of awakenings. 
Strengths and limitations: 
The strength of our study compared to other studies examining the differences in sleep qual-
ity between sleep medication users[15-17], was our focus on BZD/Zs, considered the use of 
co-medication, used a validated questionnaire, and reported the different aspects of sleep 
quality. Furthermore, we enhanced data accuracy by only including mentally competent res-
idents, and we had a participation rate of 87%. This strenght allowed us to confirm results 
from other studies, but in a more specific setting.
There are several limitations related to our study design. We used a convenience sample of 
nursing homes. However, the respondents’ characteristics were comparable to the Belgian 
nursing home population (age-gender-chronic drug intake)[24]. 
Our finding that sleep quality was poorer in chronic BDZ/Z users does not support the hy-
pothesis of the long-term effectiveness of BZD/Zs but cannot disprove it either. To make con-
clusions with regard to long-term effectiveness, and development of tolerance, longitudinal 
studies with incident users and baseline sleep parameters are necessary. Unfortunately, we 
do not have this information, given the cross-sectional character of our study. Further fol-
low-up for our study (1 year) will provide evidence regarding differences in temporal evolu-
tion of sleep quality between BZD/Z users and nonusers. 
Another limitation was that we used proxies for clinical data. Unfortunately, we had no in-
formation on specific sleep disorders and on specific medication other than psychotropics or 
narcotics that could influence sleep quality (i.e. beta blocker, thyroid medication)[3]. Further-
more, we did not collect information on fall incidents or fractures. We did not gather infor-
mation regarding the length of BZD/Z use beyond the minimum requirement of 3 months and 
we did not record dosages.
The use of a subjective tool to evaluate the effectiveness of hypnotics, such as the PSQI, is 
both a limitation and strength. Self-reported time in and out of bed can be inaccurate, though 
there is a good correlation between self-reported sleep measurements and objective meas-
urements such as actigraphy[41] and polysomnography[23]. Another limitation of the PSQI in 
our study was the presence of the medication component. Similar to other studies[15, 42], we 
excluded this component in analysis, leading to a lower total score and an underestimation 
of the percentage bad sleepers. 
CONCLUSION
Our findings do not support long-term effectiveness of BZD/Zs; chronic users slept worse 
than nonusers (even more pronounced in users of long-acting BZDs). In future longitudinal 
comparative studies of sleep quality, unexplained variability needs further assessment with 
medical, psychological, and institutional parameters. 
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ABSTRACT
Objectives: Chronic use of benzodiazepines and Z-drugs (BZD/Zs), the most commonly used 
symptomatic treatment for sleep problems is discouraged because of the unproven long-
term effectiveness and potential side-effects. 
In this study, we evaluated one-year evolution of subjective sleep quality of chronic BZD/Z 
users compared to nonusers.
Methods: All cognitively competent residents from 10 Belgian nursing homes were screened 
and compiled in a group of chronic BZD/Z users or nonusers, based on the medication chart. 
We collected demographic, functional and psychometric characteristics (depressive symp-
toms with the 8-item Geriatric Depression Scale), sleep parameters (with the Pittsburgh 
Sleep Quality Index-PSQI) and medication use. We analysed evolution of sleep quality with 
nonparametric statistics. Associations with worsening of sleep quality were analysed with 
linear regression.
Results: We collected data of 131 BZD/Z users and 95 nonusers. The mean age in both groups 
was 85 years and 77% was female. 
Over a period of one year, the PSQI score evolved from 5.2 to 5.8 (p=0.035) in the BZD/Z 
users, and from 4.3 to 4.7 (p=0.078) in the nonusers. Though the mean deterioration in one 
year did not differ significantly between both groups, the BZD/Z users had a significantly 
worse sleep quality compared to nonusers at both time points.
Depressive symptoms were significantly associated with worsening sleep quality (ß=-0.243, 
p<0.001).
Conclusion: Sleep quality in chronic BZD/Z users significantly decreased over one year and 
was significantly worse than nonusers at the end of this period. This study suggests that using 
BZD/Zs chronically does not maintain or improve sleep quality. Depressive symptoms are an 
important factor in the deterioration of sleep quality.
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INTRODUCTION
Benzodiazepines and related z-drugs (BZD/Z) are the most frequently used symptomatic 
treatment for sleep problems in the older population and particularly in the nursing home 
setting[1, 2]. Although BZD/Zs alter the sleep architecture by suppressing deep sleep stag-
es, they are initiated because they shorten the time to fall asleep and increase total sleep 
duration[3]. Due to their sedating action, the (short-term) adverse effects of BZD/Zs include 
decreased alertness with risk of falls[4] and anterograde amnesia. Although most patients 
engage in chronic use, the hypnotic effect decreases due to tolerance [5]. Due to the risk of 
adverse drug events and drug dependence, guidelines advise short-term use of BZD/Zs In-
terruption of treatment can lead to withdrawal symptoms[6], and this is often the reason for 
continued use. 
Long-term effectiveness is difficult to assess and requires long-term follow-up data. Until 
now, there have been no randomised controlled studies published that have investigated the 
long-term effectiveness of chronic BZD/Z use (max. follow-up time is 6 months[7]). Epidemio-
logical studies of the effects of chronic BZD/Z use on sleep quality [8-11] indicate a worse sleep 
quality in chronic BZD/Z users. But longitudinal studies which investigate the temporal evo-
lution of sleep quality are scarce[12], especially in older people residing in the nursing homes 
[13]. Moreover, most studies on benzodiazepines do not differentiate between the indication 
insomnia or anxiety.
Our aim was to investigate the one-year evolution of sleep quality in a well-defined group 
of chronic BZD and z-drug users (indicated for insomnia) and compare this to a well-defined 
group of nonusers. Furthermore, we investigated which demographic, functional and clinical 
characteristics and medications were associated with worsening sleep quality over time.
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METHODS
In this longitudinal cohort study in the Belgian nursing home setting, we compared the one-
year evolution of sleep quality in a group of cognitively competent chronic BZD/Z users to 
a group of cognitively competent nonusers. The methodology and baseline findings were 
previously published[11].
Design: 
From a convenience sample of 10 nursing homes, all cognitively competent to respond to 
questionnaires (defined as having a Mini Mental State Examination (MMSE)[14] score of at 
least 18 out of 30[15]) residents were identified. We excluded residents which only used the 
antidepressants trazodone or mirtazapine or phytotherapy as a sleep medication, and resi-
dents that used BZDs for the indication anxiety (defined as daytime use of BZDs). Residents 
with BZDs or Z-drugs administered at bedtime for at least 3 months were allocated to the 
BZD/Z group. Residents free of any hypnotic medication were allocated to the nonuser group. 
Both groups were evaluated at baseline (December 2011-January 2012) and after one year 
(January 2013).
Data collection:
 
Demographic data were obtained from the resident’s record and medication data from the 
medication chart. Clinical data included cognitive competence (assessed with MMSE), hear-
ing, visual problems, and functionality (Activities of Daily Living, ADL).
Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI)[16], a self-rated 
questionnaire for global sleep quality and specific aspects of sleep disturbance. The 7 com-
ponents of the PSQI are scored from 0 to 3, with higher scores indicating worse sleep quality. 
Similar to other studies[10, 17], we used an adjusted PSQI score that can range from 0 to 19 
(with higher scores indicating a worse sleep quality). This adjusted score excludes the PSQI 
component ‘sleep medication’ because of its full correlation with BZD/Z use. The widely used 
cut-off of 5 was used to indicate poor sleep quality.
At one-year follow-up, additional items were investigated. Depressive symptoms were scored 
with the 8-item Geriatric Depression Scale (GDS-8)[18]. This abbreviated version of the GDS-30 
was especially designed and validated for nursing home residents. A score of three or more 
on the GDS-8 is indicative for depression[19]. Additionally, we recorded falls by checking the 
medical file. We also recorded the presence of restless legs, frequent pain, the frequency 
of social activities, social contacts (visitors in and out the nursing home) and mental stimuli 
(watching TV, reading, memory games) by using a yes or no question. 
Ethical considerations: 
This observational cohort study was approved by the ethics committee of the University Hos-
pital of Antwerp (registration number B300201112211). Each nursing home received infor-
mation and approved the screening of residents. Each resident included in our study received 
oral and written information, and gave their consent.
Statistics: 
The analysis and presentation of our results focused on the residents still included at one-
year follow-up and was based on initial group assignment.
Demographic, functional, psychometric and medication characteristics were described and 
compared between the BZD/Z group and the control group, using percentages and Chi² for 
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categorical variables and means and independent t-tests for continuous variables except for 
scaling results where we used nonparametric statistics. 
Sleep evolution was presented with mean adjusted PSQI scores and standard deviations (SD) 
and analysed with Wilcoxon Signed Rank test. Differences in adjusted PSQI scores between 
both groups were analysed with Mann Whitney U test. 
Multiple linear regression was used to analyse the associations between demographical, 
functional, and clinical characteristics, and medication and the worsening sleep quality (dif-
ference in adjusted PSQI score between the baseline and the 12 month assessment). 
RESULTS
At baseline, 300 residents met the inclusion criteria: 178 BZD/Z users and 122 nonusers 
(sleep characteristics are previously published [11]). After one year, we had follow-up data of 
226 residents; 131 BZD/Z users and 95 nonusers.
There were no differences in characteristics between residents lost-to-follow (n=74) and res-
idents still in the study (n=226) at one year, except for the baseline MMSE score, which was 
1 point lower in the residents lost-to-follow (25.8 vs. 24.9, p=0.015). Mortality was an impor-
tant cause of lost-to-follow-up in both groups (16.3% in the BZD/Z group and 11.5% in the 
control group, p=0.253).
Comparison of BZD/Z users’ characteristics to nonusers: 
The comparisons of BZD/Z users’ clinical, psychometric characteristics and medication infor-
mation to nonusers are presented in Table 1. 
The demographic and clinical profile of the BZD/Z users and the nonusers was similar, except 
for depressive symptoms, which were more present among the BZD/Z users (43% vs. 27%). 
The BZD/Z users played less memory games compared to the control group (31% vs. 45%). 
The BZD/Z group took significantly more chronic medications compared to the control group 
(mean of 9.1 vs. mean of 7.5), with a larger intake of pain medication (41% vs. 17%). 
The most frequently used BZD/Zs at baseline (n=131) were lormetazepam (34%), zolpidem 
(26%) and lorazepam (23%). Short/intermediate-acting BZD/Z were used in 90% (n=118) and 
long-acting in 14% (n=18), with 4% overlap.
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Table 1. Comparison of characteristics between BZD/Z users and nonusers.
BZD/Z users nonusers p valued
N=131 N=95
Demographic characteristica
age (mean-range) 85.3 (57-99) 85.0 (65-99) 0.763
gender (%female) 75.6 78.9 0.552
length of stay in months (mean-range) 40.4 (3-191) 41.1 (3-223) 0.901
education level- higher education(%) 36.6 43.2 0.322
Clinical characteristicsb
self-dependency score (ADL) (6-24) 12.82 12.38 0.418
disorientation score  (2-6) 2.81 2.86 0.935
MMSE score (0-30) 23.9 24.2 0.301
visual problems (%) 9.2 9.5 0.936
hearing problems (%) 9.9 13.7 0.382
falls during 1 year (%) 41.2 33.7 0.249
Psychometric characteristicsb
frequent pain (%) 47.3 42.1 0.436
depression (GDS≥ 3) (%) 43.3 27.2 0.014
adjusted PSQI score (0-19) 5.79 4.74 0.004
bad sleeper (adjusted PSQI>5) (%) 45.8 27.7 0.006
frequent social activities (%) 48.6 43.6 0.440
frequent social contactc (%) 86.3 87.4 0.880
mental stimuli: reading (%) 61.8 66.3 0.489
mental stimuli: memory games (%) 31.3 45.3 0.032
mental stimuli: watching TV (%) 92.4 88.4 0.313
Medication Informationb
chronic medications (mean-range) 9.08 7.48 0.002
benzodiazepine/Zdrug (%) 93.1 10.5 <0.001
antidepressant (%) 42.7 30.5 0.061
antipsychotic (%) 18.3 9.5 0.063
anti-Alzheimer  (%) 2.3 5.3 0.232
anti-Parkinson (%) 6.1 7.4 0.707
pain medication (%) 41.2 16.8 <0.001
narcotic analgesic (%) 22.1 6.3 0.001
non-narcotic analgesic(%) 22.9 8.4 0.004
NSAIDs(%) 4.6 4.2 0.894
a baseline , b  we report the 1 year results of these parameters
c frequent social contacts defined as frequent visitors
d pvalue: continuous variables with independent t test, percentages with Chi² and Mann Whitney U for scales
MMSE= Mini Mental State Examination, GDS= Geriatric Depression Scale, ADL= Activities of Daily Living, 
PSQI= Pittsburgh Sleep Quality Index, NSAID= non-steroidal anti-inflammatory drugs
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Sleep evolution in the BZD/Z users compared to nonusers: 
Over a period of one year, in the BZD/Z group, the adjusted PSQI score evolved from 5.2 (SD 
2.4) to 5.8 (SD 3.1) (p=0.035) and in the nonusers from 4.3 (SD 2.3) to 4.7 (SD2.9) (p=0.078). 
This mean deterioration in both groups did not differ significantly (Fig. 1). 
Fig 1: One-year evolution of sleep quality (adjusted PSQI score) in BZD/Z users and nonusers.
   
The percentage of bad sleepers (adjusted PSQI >5) was larger in the BZD/Z group compared 
to the nonusers at baseline (39.7% vs. 28.4% p=0.079) and increased in one year (45.8% vs. 
27.7% p=0.006). In the BZD/Z group 19.5% became a new bad sleeper compared to 11.7% 
nonusers (NS). 
Associations with sleep quality worsening: 
In the univariate analysis, we did not find correlations between worsening sleep quality and 
any demographic (age, gender, educational level), any (number of) medication or any func-
tional or any clinical characteristic except for depressive symptoms (ß=-0.235, p<0.001) (Table 
2). In multivariate analysis controlled for age, gender and BZD/Z use, depressive symptoms 
were significantly associated with worsening sleep quality (ß=-0.243, p<0.001) (Table 2).
Legend:
PSQI: Pittsburgh Sleep Quality Index, MWU: Mann Whitney U test, BZD/Z 
user: benzodiazepine or Z-drug user
Horizontal lines indicate the median, and the small circles indicate outliers
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Table 2. Factors related to the observed difference in sleep quality between the baseline and the 12-month assessment using the 
adjusted PSQI: Univariate and multivariate linear regression model.
worsening sleep quality (delta PSQI adjusted) a
factors UNIVARIATE MULTIVARIATE b
B beta p-value B beta p-value
Age -0.012 -0.032 0.631 0.007 0.020 0.779
Gender -0.307 -0.046 0.495 -0.394 -0.058 0.396
BZD/Z use -0.124 -0.022 0.745 0.044 0.008 0.908
Education -0.310 -0.091 0.173
Number of medications 0.011 0.015 0.825
Antidepressant use 0.375 0.065 0.333
Pain medication 0.447 0.074 0.270
Antipsychotic 0.642 0.080 0.232
ADLscore 0.038 0.066 0.326
MMSEscore -0.050 -0.084 0.209
Pain 0.004 0.001 0.992
GDSscore -0.277 -0.235 <0.001 -0.286 -0.243 <0.001
Social activities 0.409 0.072 0.284
a dependant variable is delta PSQI = PSQIadjusted baseline minus PSQIadjusted  12 months, worsening sleep quality is indicated by a negative score
b  R² of the model was 0.041
MMSE= Mini Mental State Examination, GDS= Geriatric Depression Scale, ADL= Activities of Daily Living,
DISCUSSION
During the one-year follow-up, the sleep quality of the BZD/Z users deteriorated significantly, 
while in nonusers there was also a deterioration of the sleep quality, but not significant. The 
rate at which this deterioration occurred did not differ significantly between BZD/Z users and 
nonusers, which could indicate a questionable clinical impact.  However, the sleep quality in 
chronic BZD/Z users was significantly worse compared to nonusers both at baseline and at 
one-year follow-up. 
In both groups the sleep quality deteriorated, which can be partly explained due to aging[20] 
or comorbidities[21]. The comorbidity ‘depression’ was in this study a significant factor in wors-
ening sleep quality. Depression and sleep problems are often linked together[22, 23] (e.g. sleep 
problems are often included in depressive symptoms). In this study, depressive symptoms 
were also more prevalent in chronic BZD/Z users compared to nonusers. There is a complex 
relationship between sleep and depression that needs further investigation. Moreover, resi-
dents with BZD/Zs take more chronic medication, especially psychotropic medication. Polyp-
harmacy and psychotropic drugs could influence sleep quality and its evolution. Although we 
did not find explicit factors besides depressive symptoms related to worsening sleep quality, 
other influences such as pain and other comorbidities cannot be ruled out. 
Our study shows that chronic use of BZD/Z does not maintain or improve sleep quality. We 
now know that the sleep quality of chronic BZD/Z users is worse than nonusers and it does 
not improve (over 1 year). A study in community dwelling older adults also found a worse 
sleep quality in long-term BZD/Z users[10] and reported a negative impact on evolution com-
pared to nonusers[12].
This was the first study especially designed to investigate sleep quality and its temporal evo-
lution among a well-defined group of chronic BZD/Z users in the nursing home setting and 
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compare it to a well-defined control group (free of any hypnotic) using an adequate tool 
that reports several aspects of sleep quality. In order to reduce indication bias, we included 
residents who used BZD/Zs only at bedtime as a proxy for the indication insomnia. Never-
theless indication bias cannot be completely ruled out because we did not ask the GP for 
confirmation of this indication. Another strength was the inclusion of several risk factors such 
as functionality, social status, depressive symptoms and medication use. Several limitations 
are inherent to the study design. We used a convenience rather than a representative sam-
ple of nursing homes. However, the respondents’ characteristics were comparable to the 
Belgian nursing home population (age-gender-chronic drug intake)[24]. Although there were 
no noticeable differences between residents lost-to follow up and residents in the study, se-
lection bias cannot be excluded. Unfortunately, we had no information about specific sleep 
disorders, specific medications other than psychotropics or narcotics that could influence 
sleep quality, or ‘past BZD/Z use’ and duration of use. However, in most residents the BZD/Z 
is already present at nursing home admission and remains on the medication list for a long 
period of time [25-27]. Although the study adds to the knowledge that chronic continuation is 
not recommended in terms of sleep quality, we did not investigate incident users and base-
line sleep parameters. Longitudinal studies with incident BZD/Z users followed over a longer 
period of time (i.e. more than 6 months) are lacking. In future research, it is recommended to 
monitor the evolution of sleep quality in incident users and to investigate the consequences 
of BZD/Z discontinuation on sleep.
CONCLUSION
Sleep quality in chronic BZD/Z users significantly decreased over one year and was signifi-
cantly worse than nonusers at the end of this period. This study suggests that using BZD/Zs 
chronically does not maintain or improve sleep quality. Depressive symptoms are an impor-
tant factor in the deterioration of sleep quality.
ACKNOWLEDGMENTS
We thank Anne Balis, Kim Elst, Jacqueline De Pooter and Ambre Hamelink, all Master of Sci-
ence in Nursing, for their contribution in the data collection at the University of Antwerp. We 
also tank the management and staff of the participating nursing homes.
98
2.4
RESU
LTS:     O
ne-year evolution of sleep quality in older benzodiazepine users: A
 longitudinal cohort study in Belgian nursing hom
e residents.
REFERENCES
1. Conn DK, Madan R. Use of sleep-promoting medications in nursing home residents : risks versus benefits. 
Drugs & Aging.2006;23(4):271-87.
2. Bourgeois J, Elseviers MM, Azermai M, et al. Benzodiazepine use in Belgian nursing homes: a closer look 
into indications and dosages. European Journal of Clinical Pharmacology. 2012 May;68(5):833-44.
3. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insom-
nia. Cmaj.2000 Jan 25;162(2):225-33.
4. Mets MA, Volkerts ER, Olivier B, et al. Effect of hypnotic drugs on body balance and standing steadiness. 
Sleep Med Rev. 2010 Aug;14(4):259-67.
5. Vinkers CH, Olivier B. Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future 
for Subtype-Selective GABA(A) Receptor Modulators? Adv Pharmacol Sci. 2012;2012:416864.
6. Poyares D, Guilleminault C, Ohayon MM, et al. Chronic benzodiazepine usage and withdrawal in insomnia 
patients. J Psychiatr Res. 2004 May-Jun;38(3):327-34.
7. Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 
mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, rand-
omized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep.2008 Jan;31(1):79-90.
8. Ohayon MM, Caulet M, Arbus L, et al. Are prescribed medications effective in the treatment of insomnia 
complaints? J Psychosom Res. 1999 Oct;47(4):359-68.
9. Englert S, Linden M. Differences in self-reported sleep complaints in elderly persons living in the commu-
nity who do or do not take sleep medication. J Clin Psychiatry. 1998 Mar;59(3):137-44; quiz 45.
10. Beland SG, Preville M, Dubois MF, et al. Benzodiazepine use and quality of sleep in the community-dwell-
ing elderly population. Aging & Mental Health. 2010;14(7):843-50.
11. Bourgeois J, Elseviers MM, Van Bortel L, et al. Sleep quality of benzodiazepine users in nursing homes: a 
comparative study with nonusers. Sleep Med. 2013 Jul;14(7):614-21.
12. Beland SG, Preville M, Dubois MF, et al. The association between length of benzodiazepine use and sleep 
quality in older population. International Journal of Geriatric Psychiatry. 2011 Sep;26(9):908-15.
13. Monane M, Glynn RJ, Avorn J. The impact of sedative-hypnotic use on sleep symptoms in elderly nursing 
home residents. Clin Pharmacol Ther.1996 Jan;59(1):83-92.
14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.
15. Alencar MA, Dias JM, Figueiredo LC, et al. Frailty and cognitive impairment among community-dwelling 
elderly. Arq Neuropsiquiatr. 2013 Jun;71(6):362-7.
16. Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for 
psychiatric practice and research. Psychiatry Res. [Research Support, U.S. Gov’t, P.H.S.]. 1989 May;28(2):193-213.
17. Sasai T, Inoue Y, Komada Y, et al. Effects of insomnia and sleep medication on health-related quality of life. 
Sleep Med. 2010 May;11(5):452-7.
18. Jongenelis K, Gerritsen DL, Pot AM, et al. Construction and validation of a patient- and user-friendly nurs-
ing home version of the Geriatric Depression Scale. International Journal of Geriatric Psychiatry.2007 Sep;22(9):837-
42.
19. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: 
a preliminary report. J Psychiatr Res. [Research Support, U.S. Gov’t, Non-P.H.S.]. 1982;17(1):37-49.
20. Dijk DJ, Groeger JA, Stanley N, et al. Age-related reduction in daytime sleep propensity and nocturnal 
slow wave sleep. Sleep. 2010 Feb;33(2):211-23.
21. Hayashino Y, Yamazaki S, Takegami M, et al. Association between number of comorbid conditions, depres-
sion, and sleep quality using the Pittsburgh Sleep Quality Index: results from a population-based survey. Sleep Med. 
2010 Apr;11(4):366-71.
22. Komada Y, Nomura T, Kusumi M, et al. Correlations among insomnia symptoms, sleep medication use and 
depressive symptoms. Psychiatry and Clinical Neurosciences. 2011 Feb;65(1):20-9.
99
2.4
RESU
LTS:     O
ne-year evolution of sleep quality in older benzodiazepine users: A
 longitudinal cohort study in Belgian nursing hom
e residents.
23. Benca RM, Peterson MJ. Insomnia and depression. Sleep Med. [Review]. 2008 Sep;9 Suppl 1:S3-9.
24. Elseviers MM, Vander Stichele RR, Van Bortel L. Drug utilization in Belgian nursing homes: impact of res-
idents’ and institutional characteristics. Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1041-8.
25. Curran HV, Collins R, Fletcher S, et al. Withdrawal of older adults from benzodiazepine hypnotics in Gen-
eral Practice: effects on cognitive function, sleep, mood and quality of life. Journal of Psychopharmacology. 2003 
Sep;17(3):A26-A.
26. Morin CM, Belanger L, Bastien C, et al. Long-term outcome after discontinuation of benzodiazepines for 
insomnia: a survival analysis of relapse. Behav Res Ther. 2005 Jan;43(1):1-14.
27. Bourgeois J, Elseviers MM, Azermai M, et al. Barriers to discontinuation of chronic benzodiazepine use 
in nursing home residents: Perceptions of general practitioners and nurses. European Geriatric Medicine. 2014 
Jun;5(3):181-7.
100
2.4
RESU
LTS:     O
ne-year evolution of sleep quality in older benzodiazepine users: A
 longitudinal cohort study in Belgian nursing hom
e residents.
101
102
2.5CHAPTER
The impact of chronic benzodiazepine 
use on cognitive evolution in nursing 
home residents.
Jolyce Bourgeois PharmD, Monique M. Elseviers 
MSc PhD, Luc Van Bortel MD PhD, Mirko Petrovic 
MD PhD, Robert H. Vander Stichele MD PhD
 Under Review in the journal Human Psychopharmacology 
(Nov 2014)
103
104
2.5
RESU
LTS:     The im
pact of chronic benzodiazepine use on cognitive evolution in nursing hom
e residents.
ABSTRACT
Background & objectives: Chronic use of benzodiazepines and Z drugs (BZD/Zs) has been 
linked to cognitive decline. In this one year prospective cohort study, we aim to investigate 
the association between users of chronic BZD/Zs for insomnia, and cognitive evolution in 
comparison to nonusers.
Methods: Cognitively capable residents of 10 Belgian nursing homes were divided in BZD/Z 
users and nonusers, based on medication charts. We assessed cognition with the Mini Men-
tal State Examination test (MMSE) at baseline and 12 months later. A decrease of ≥4 points 
on the MMSE (clinically relevant decrease) was used in multiple logistic regression. We col-
lected baseline demographics, functional, psychometric and social characteristics potentially 
influencing cognition. 
Results: We collected data of 131 BZD/Z users and 95 nonusers (in both groups: mean age 
85 year, 77% female). In both groups the cognition decreased significantly over time, but 
without significant difference between the groups. Clinically relevant decrease was present 
in 34% BZD/Z users and 27% nonusers (NS). Controlled for age, gender, education and BZD/Z 
use, the strong, significant risk factors for clinically relevant cognitive decline were depression 
(OR 2.77, 95%CI 1.39-5.52), hearing (OR 3.83, 95%CI 1.45-10.13) and functional impairment 
(OR 1.18, 95%CI 1.10-1.27). Frequent reading was associated with less MMSE decrease (OR 
0.46, 95%CI 0.23-0.91).  
Conclusions: Our findings could not demonstrate with statistical significance that BZD/Z use 
was associated with fast cognitive decline. The strong risk factors for fast decline were de-
pression, hearing and functional impairment, and the absence of a reading attitude. In addi-
tion, BZD/Z users had a higher prevalence of depression and depression influenced cognitive 
decline, which indicates a complex relationship between cognitive impairment, depression 
and BZD/Z use.
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INTRODUCTION
Benzodiazepines and related Z-drugs (BZD/Zs) are indicated for the short-term treatment of 
sleep disorders (and benzodiazepines also for anxiety). However, these medications are often 
prescribed for longer periods, particularly in older adults. Because of the unproven long-term 
effectiveness [1], possibly caused by tolerance [2] and because of both physical and psycho-
logical dependence [3], international guidelines warn against chronic use [4, 5]. Nevertheless, 
the consumption of BZD/Zs among community dwelling older adults is high and even higher 
(range 20%-55%) among European nursing home residents [6-8]. It has been hypothesized that 
chronic use might have a detrimental effect on cognition and might cause acceleration of 
cognitive impairment [9, 10]. Still, the literature is inconclusive whether or not there is a nega-
tive impact of chronic BZD/Z use on cognitive decline [11-13]. Due to the abundant chronic use 
of BZD/Zs and the major impact of cognitive decline on society, this research domain remains 
important.
In a review of six large-scale (varying between n=242 and n=3309) epidemiological observa-
tional studies, conflicting results were found with regard to the association of chronic BZD/Z 
use and cognitive decline/onset of dementia [11]. A later nested-case control study suggested 
increased risk for dementia among long-term users of BZD/Zs [14]. The Caerphilly Prospective 
Study in Wales [15] provided long-term prospective evidence of an adverse effect of BZD/Zs 
on the development of dementia, but included only males. A recent prospective study [16] in 
community dwelling older adults found a significant increased risk of dementia in incident 
BZD/Zs users compared to nonusers. Mura et al. [17] found a poorer cognitive performance 
in chronic BZD/Z users, but no association with accelerated cognitive decline. Most of these 
studies had no differentiation between BZD/Z use for sleep problems or anxiety and most of 
the observational cohort studies were not specifically set up to investigate the use of chronic 
BZD/Z use on cognition. 
Our study focuses on the evolution of cognition and on the benzodiazepines (BZDs) and Z 
drugs used for sleep problems in the nursing home setting.
The objectives of our study were to describe the one year evolution of cognition in a group 
of chronic BZD/Z users compared to a control group of nonusers, both cognitive capable at 
baseline, and to investigate whether chronic BZD/Z use was associated with a differential 
decrease in cognition. Furthermore, in addition to other possible risk factors, we aimed to 
explore the impact of BZD/Zs on a clinically relevant decrease in cognition. 
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METHODS
In this prospective cohort study in the Belgian nursing home setting, we assessed cognition in 
a group of chronic BZD/Z users (BZD/Z group) and compared this to a group of nonusers (con-
trol group) at baseline (December 2011 and January 2012) and at 12 months (January 2013).
Setting: 
The Belgian long-term residential care structure consists of residential or nursing homes for 
older people, which offers a home replacement with or without nursing care. Governance 
of nursing homes for older people is either public (community health services) or private 
(predominantly non-profit) with little difference in quality of care. The point prevalence of 
dementia among residents is approximately 50% with considerable variation among nursing 
homes [18].
Design: 
In a convenience sample of 10 Belgian nursing homes, all cognitively capable residents were 
screened for inclusion and divided in an exposure group of BZD/Z users and a control group 
based on the medication chart. No matching procedure was applied. Study design and base-
line findings were published elsewhere[1].  Only residents with baseline and 12 month fol-
low-up data were included in the analysis.
Inclusion and exclusion criteria: 
At baseline, we only included cognitively capable residents defined as having a Mini Mental 
State Examination (MMSE)[19] score of at least 18 out of 30. We excluded residents who only 
used sedative antidepressants trazodone or mirtazapine or phytotherapy as a sleep medica-
tion. We also excluded residents who used BZDs for the indication of anxiety (daytime use of 
BZD). Residents with BZDs or Z drugs daily administered at bedtime for at least 3 months were 
allocated to the chronic BZD/Z group. Residents who were free of any hypnotic medication 
were allocated to the control group. This analysis was based on the initial group assignment.
Data collection: 
Demographic data were obtained from the resident’s record and medication data were ob-
tained from the medication chart. Functional characteristics, as a proxy for functional inde-
pendence, were scored by the nurse with the Katz scale [20]. The first part of this instrument 
scores six Activities of Daily Living scale (ADL) from 1 (independent) to 4 (totally dependent). 
The second part scores disorientation in time and place ranging from 1 (no disorientation) to 
4 (severe) and was used to confirm cognitive competence. 
Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) [21, 22], a self-rated 
questionnaire for global sleep quality and specific aspects of sleep disturbance. The 7 com-
ponents of the PSQI yield a total score ranging from 0 to 21, with higher scores indicating 
poorer sleep quality. A total PSQI score of more than 5 is a widely used cut-off that indicates 
poor sleep quality. 
Medication data were obtained from the medication chart. We recorded the total number 
of chronic medications (used for more than 3 months). Medication was coded with the Ana-
tomical Therapeutic and Chemical (ATC) classification [23]. We considered the classes N05BA 
(anxiolytic), N05CD (hypnotic) and N05CF (Z drugs) as benzodiazepines. The BZD ‘clonaze-
pam’ and ‘tetrazepam’ were classified as sleep medication in this study, though they have a 
different ATC nomenclature. Based on half-life, we categorised the BZD/Zs into short-acting 
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(T1/2 < 24h) and long-acting (T1/2 ≥24h) [24].
Depressive feelings were scored with the 8-item Geriatric Depression Scale (GDS) [25]. The 30 
item GDS [26] was designed for older adults. An abbreviated version of the GDS (8 item) was 
especially designed and validated for nursing home residents. A score of three or more on 
the GDS-8 is indicative for depression [25, 27]. Additionally, we recorded falls by checking the 
medical file. We also recorded other possible risk factors of cognitive decline such as hearing 
and visual impairment, frequent pain, and the frequency of social activities, social contacts 
(visitors in and out the nursing home) and mental stimuli (watching TV, reading, memory 
games) by using a yes or no question. 
Cognitive evaluation: 
The cognitive screening as well as the evolution was investigated with the MMSE test [19]. This 
widely used and validated instrument has a maximum score of 30. Five different domains of 
cognition are investigated: (1) Orientation, contributing a maximum of 10 points, (2) Memory, 
contributing a maximum of 6 points, (3) Attention and calculation, as a measure of working 
memory, contributing a maximum of 5 points, (4) Language, contributing a maximum of 8 
points, and (5) Design copying, contributing a maximum of 1 point. Internal consistency of 
the MMSE was evaluated with Cronbach’s alpha (and was in our study 0.70).
Ethical considerations: 
This observational cohort study was approved by the ethics committee of the University Hos-
pital of Antwerp (registration number B300201112211). Each nursing home received infor-
mation and gave approval to screen the nursing home population. Each resident, included in 
our study, received oral and written information and gave consent.
Statistics: 
The analysis and presentation of our results was focused on the residents still included at 12 
months follow-up (n=226). 
In a primary analysis, demographic, functional, psychometric and medication characteristics 
were described and compared between the BZD/Z group and the control group, using per-
centages and Chi² for categorical variables and means and independent t-tests for continuous 
variables except for scaling results where we used nonparametric statistics. 
Cognitive evolution was presented with mean MMSE scores and standard deviations (SD) and 
analysed with Wilcoxon Signed Rank test. Differences in MMSE scores between both groups 
were analysed with Mann Whitney U test. 
Clinically relevant decrease in cognition was defined as a MMSE decrease of 4 or more points 
[28-31]. We analysed which factors were associated with this MMSE decrease and particularly 
whether chronic BZD/Z use, controlled for other variables, had an influence on it. Multiple 
logistic regression was used to indicate the determinants of this decrease. 
RESULTS
Study flow: 
At baseline, 300 residents met the inclusion criteria; 178 in the BZD/Z group and 122 in the 
control group. As illustrated by the flowchart (Fig. 1), we had 12 month follow-up data of 
226 residents; 131 in the BZD/Z group and 95 in the control group. We observed no dif-
ference in characteristics between residents lost-to-follow (n=74) and residents still in the 
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study (n=226), only the baseline MMSE score was 1 point lower in the residents lost-to-follow 
(25.8 vs. 24.9, p=0.015). Mortality was an important cause of lost-to-follow-up in both groups 
(16.3% in the BZD/Z group and 11.5% in the control group, p=0.253). 
At 12 months follow-up, we observed retrospectively that 10 residents in the control group 
initiated a BZD/Z and 9 BZD/Z users had stopped. We analysed the 226 residents based on 
the initial group assignment.
Fig 1: Flowchart
	  
12month	  follow-­‐up	  
131	  chronic	  
Benzodiazepine/Zdrug	  
users	  
	  
BASELINE	  (December	  2011-­‐January	  2012)	  
300	  residents	  
178	  chronic	  
Benzodiazepine/Zdrug	  
users	  
122	  nonusers	  
12month	  follow-­‐up	  
95	  nonusers	  
	  
Lost-­‐to	  follow	  up	  
Death:	  29	  
Refusal:	  11	  
Too	  ill:	  7	  
	  
Lost	  to	  follow-­‐up	  
Death:	  14	  
Refusal:	  6	  
Too	  ill:	  7	  
Comparison of demographic and clinical characteristics in the BZD/Z and control group: 
As shown in Table 1, the baseline demographic profile of the BZD/Z users and the nonusers 
was similar: the mean age was 85 year, 77% was female and 60% attended school till the age 
of 14. 
Clinical characteristics such as the ADL score, disorientation score, the prevalence of hear-
ing and sight impairment were similar in both the BZD/Z group and the control group. Falls 
during the last year (41% vs. 34%) and the prevalence of reported pain (47% vs. 42%) did not 
differ significantly (Table 1). 
The amount of bad sleepers was 46% in the BZD/Z group and significantly larger than the 28% 
in the control group (p=0.006). The presence of depressive symptoms differed significantly 
between the BZD/Z group and control group (43% vs. 27% p=0.014). The combined presence 
of depression and sleep problems was predominantly present in the BZD/Z group (29% vs. 
8% p<0.001). 
Regularly attending social activities, as well as frequent reading, watching TV and social con-
tacts was similar in both groups. The BZD/Z group did less memory games compared to the 
control group (31% vs.45% p=0.032).
The BZD/Z group took significantly more chronic medications compared to the control group 
(mean of 9.1 vs. mean of 7.5) in particular pain medication (41% vs. 17%) including narcotic 
(22% vs. 6%) as well as non-narcotic analgesics (23% vs. 9%). In the BZD/Z group, 52% of 
the residents with pain medication reported pain. In the control group, this was 56% of the 
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residents. 
In the BZD/Z group (n=131), lormetazepam (34%), zolpidem (26%) and lorazepam (23%) were 
the most frequently used. Short-acting BZD/Z were used in 90% (n=118) and long-acting in 
14% (n=18), with some overlap due to duplicate use.
The residents that switched medication during the one-year follow-up (n=19) were similar on 
al demographical and clinical characteristics. They did not differ in MMSE score at baseline 
(25.8 vs. 25.6, p=0.825).  
Table 1. Demographic, Clinical, Psychometric characteristics and Medication information of the benzodiaze-
pine group (BZD/Z) and the control group.
BZD/Z group CONTROL group p valued
N=131 N=95
Demographic characteristica
age (mean-range) 85.3 (57-99) 85.0 (65-99) 0.763
gender (%female) 75.6 78.9 0.552
length of stay in months (mean-range) 40.4 (3-191) 41.1 (3-223) 0.901
education level- higher education(%) 36.6 43.2 0.322
Clinical characteristicsb
self-dependency score (ADL) (6-24) 12.82 12.38 0.418
disorientation score  (2-6) 2.81 2.86 0.935
MMSE score (0-30) 23.9 24.2 0.301
visual problems (%) 9.2 9.5 0.936
hearing problems (%) 9.9 13.7 0.382
falls during 1 year (%) 41.2 33.7 0.249
Psychometric characteristicsb
frequent pain (%) 47.3 42.1 0.436
depressive symptoms (GDS≥ 3) (%) 43.3 27.2 0.014
adjusted PSQI score (0-19) 5.79 4.74 0.004
bad sleeper (adjusted PSQI>5) (%) 45.8 27.7 0.006
frequent social activities (%) 48.6 43.6 0.440
frequent social contactc (%) 86.3 87.4 0.880
mental stimuli: reading (%) 61.8 66.3 0.489
mental stimuli: memory games (%) 31.3 45.3 0.032
mental stimuli: watching TV (%) 92.4 88.4 0.313
Medication Informationb
chronic medications (mean-range) 9.08 7.48 0.002
benzodiazepine/Zdrug (%) 93.1 10.5 <0.001
antidepressant (%) 42.7 30.5 0.061
antipsychotic (%) 18.3 9.5 0.063
anti-Alzheimer  (%) 2.3 5.3 0.232
anti-Parkinson (%) 6.1 7.4 0.707
pain medication (%) 41.2 16.8 <0.001
       narcotic analgesic (%) 22.1 6.3 0.001
       non-narcotic analgesic(%) 22.9 8.4 0.004
       NSAIDs(%) 4.6 4.2 0.894
a baseline , b  we report the 1 year results of these parameters
c frequent social contacts defined as frequent visitors
d pvalue: continuous variables with independent t test, percentages with Chi² and Mann Whitney U for scales
MMSE= Mini Mental State Examination, GDS= Geriatric Depression Scale, ADL= Activities of Daily Living, 
PSQI= Pittsburgh Sleep Quality Index, NSAID= non-steroidal anti-inflammatory drugs
110
2.5
RESU
LTS:     The im
pact of chronic benzodiazepine use on cognitive evolution in nursing hom
e residents.
Comparison of evolution of cognition over 12 months: 
In the BZD/Z group the total MMSE decreased from 25.7 (SD 3.0) to 23.9 (SD 4.5), and in the 
control group the total MMSE decreased from 25.9 (SD 2.9) to 24.2 (SD 5.2). The baseline 
scores did not differ in both groups as well as the mean differences (Fig. 2), respectively 1.76 
(SD 3.9) in the BZD/Z group and 1.71 (SD 3.9) in the control (p=0.640). 
Fig 2: EVOLUTION OF COGNITION (as measured by the MMSE)
       
A closer analysis of the different elements of the MMSE showed that in both groups ‘orien-
tation (spatial and temporal)’, ‘memory’, ‘attention’ and ‘language’ significantly decreased, 
while ‘constructional praxis’ increased over 12 months. In the BZD group, we observed a 
trend showing that MMSE scores on ‘orientation’, ‘memory’, and ‘language’ decreased more 
in 12 months compared to the control group (NS).
In the BZD/Z group, 33.6% of the residents decreased 4 or more points (clinically relevant) on 
the MMSE test compared to 27.4% in the control group (p=0.318). 
Risk factors of a clinically relevant MMSE decrease: 
With this analysis on the total 226 residents, we wanted to investigate the risk factors for 
clinically relevant MMSE decrease and whether chronic BZD/Z use was a risk factor controlled 
for other related factors. 
Univariate analysis (Table 2) of variables influencing a MMSE decrease of 4 or more points 
showed that age, functionality (ADL score), depression (GDS score), hearing problems, and 
antidepressant use were associated with a decrease in the MMSE score. A higher educational 
level, social activities, memory games and frequent reading were associated with a reduced 
risk of MMSE decrease. 
p-value of mean MMSE score after 12 months 
were based on Wilcoxon Signed Rank test 
p-value of mean difference between the 
BZD/Z group and the CONTROL group were 
based on Mann Whitney U test.
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Multivariate analysis (Table 2) controlled for age, gender and educational level failed to show 
an impact of chronic BZD/Z use (OR 1.29, 95% CI 0.64-2.58) on MMSE decrease. Hearing im-
pairment (OR 3.83, 95%CI 1.45-10.13), depression (OR 2.77, 95%CI 1.39-5.52) and a higher 
functional dependency (ADL score) (OR 1.18, 95%CI 1.10-1.27) were significantly associat-
ed with MMSE decrease. There was a reduced risk of MMSE decrease when the resident 
read frequently (OR 0.46, 95%CI 0.23-0.91). The variance explained by the model was 31% 
(Nagelkerke R²=0.312).
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DISCUSSION
Main findings:
In this prospective observational controlled study we found that the general cognition of 
nursing home residents (as measured by the MMSE) decreased significantly in 12 months, 
both in the group of BZD/Z users and in the nonusers, but there was no significant difference 
in mean MMSE decrease between those two groups. When focusing on clinically relevant 
cognitive decrease, there were more residents in the BZD group with severe deterioration 
(MMSE decrease of 4 or more points), but this difference was not significant (34% vs. 27%). 
We found the following risk factors of accelerated cognitive decline: depressive feelings, 
hearing impairment and functional impairment.  Additionally, we found that frequent reading 
was significantly associated with less cognitive decline. 
Strenghts and limitations: 
Discovering risk factors of cognitive decline is an important research topic. In this regard, 
the use of BZDs has been subject of numerous studies [11-13], but not always in a prospective 
research design and with inconsistent findings. 
The first strength of this study lies in its sampling; a well-defined group of chronic (more than 
3 months) BZD and Z-drug users as sleep medication and a group of nonusers, free of any 
hypnotic, followed prospectively for one year. In order to reduce indication bias, our results 
focus on BZD/Z use for sleep problems. 
The second strength was the inclusion of a wide range of possible risk factors (associated in 
the literature with cognitive decline) such as depressive symptoms [32, 33], sleep problems [34], 
functionality [35], social status [36], pain [37] and medication [38]. 
The third strength was our stringent definition of cognitive decline. Small changes in MMSE 
should be interpreted with care due to measurement error, learning effects and regression 
to the mean. We did not focus on mean change, but enhanced clinical relevance by using a 
cut-off.  Comparable to other studies, we defined clinically relevant decrease as a 12 month 
decrease of 4 points or more on the MMSE[28, 31, 39]. 
However, an important limitation, not only in our study but in many other studies trying to 
investigate cognition in older adults, was the use of the MMSE. The MMSE has been criticised 
for being insufficiently sensitive for cognitively capable older adults and for not taking enough 
into account patients’ characteristics such as visual and hearing impairment and level of edu-
cation. We tackled this by including all these covariates in our multivariate analysis and using 
a cut-off. Unfortunately, we did not have sufficient medical information to analyse the impact 
of comorbidity. We focused on psychotropic medication and the total number of medication, 
as a proxy for co-morbidity. We acknowledge the existence of other medication classes (for 
example anticholinergic drugs [40, 41]) as a possible risk factor for cognitive decline. In order to 
reduce indication bias, we included residents who used BZD/Zs only at bedtime as a proxy 
for the indication insomnia. Nevertheless indication bias cannot be completely ruled out be-
cause we did not ask the GP for confirmation of this indication. We had no information on 
‘past BZD/Z use’ and length of use. But in most residents the BZD/Z is fixed on the medication 
list for a long period of time [42, 43]. We did not omit the residents that stopped or started a 
BZD/Z and we performed an intention-to-treat analysis on this cohort. We acknowledge the 
possible bias. However, there were no differences on baseline characteristics between those 
19 residents and the cohort. Since the effects on cognition are subtle, larger studies with 
more than 226 residents are necessary. In this study, the residents for whom we had no 12 
month follow-up data (due to refusal, illness or death), had a one point lower baseline MMSE 
score (survivorship bias). In addition, the BZD/Z users had a non-significantly higher mortality. 
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Comparison of demographic and clinical characteristics in the BZD/Z and control group: 
The BZD/Z group and control group were similar in all demographic and most clinical charac-
teristics. The risk of falling is a major concern in older adults, and in several studies associated 
with psychotropic medication use, in particular with BZD/Z use [44]. However, in our study we 
did not find a significant impact of BZD/Z use on fall risk.. 
We observed differences in medication use and psychometric properties. The BZD/Z group 
used more chronic medications, especially more analgesics, though they did not indicate to 
have pain more frequently.
Similarly to our baseline findings in a former article on sleep quality in this cohort [45], we also 
found at 12 months a worse sleep quality in chronic BZD/Z users compared to nonusers. This 
finding does not support effectiveness of chronic hypnotic use [46].
Depression was more prevalent in the group of chronic BZD/Z users compared to the non-
users [12]. A possible hypothesis might be that the high prevalence of depressive symptoms, 
sleep problems and the higher intake of medication among BZD/Z users are related to a 
greater tendency of these users to feel and to express complaints and to a prompt pharma-
co-therapeutic response from the prescriber. Furthermore, depression and sleep problems 
are often linked together[47]: diagnostic instruments for depression (Hamilton depression rat-
ing scale [48], “DSM IV criteria”) include sleep difficulties, which makes it difficult to differen-
tiate between pure insomnia symptoms and depressive symptoms. Initiating a BZD/Z which 
often evolves into chronic use does not resolve the depressive symptoms. Instead, non-phar-
macological treatment and appropriate antidepressants for major depression are advised [49]. 
Comparison of evolution of cognition over 12 months: 
When focusing on the evolution of cognition, we found that in cognitively capable nursing 
home residents, the cognition declined significantly in 12 months’ time as well in the BZD/Z 
group as in the control group. When looking at clinically relevant cognitive deterioration 
(MMSE decrease of 4 or more points), one third of our sample had a fast decline. After 12 
months the mean decline did not differ between BZD/Z group and control group. 
A closer analysis of the MMSE components revealed that all components decreased, except 
the ‘constructional praxis’. In this component the resident was asked to copy a complex fig-
ure. It is possible that recognition occurs for this aspect [31, 50].
Risk factors of a clinically relevant MMSE decrease: 
Due to methodological limitations in the research on cognitive deterioration, it is not possible 
to determine causality. Is it because of the risk factors that older adults develop cognitive im-
pairment or is it because of the cognitive impairment that they behave and feel differently? 
This analysis only reveals associations.
Residents with social activities, residents who read frequently and play memory games had a 
lower risk of a fast cognitive deterioration. In multivariate analysis these factors were lost, ex-
cept for frequent reading. This suggests the importance of stimulating and training the mind 
[36, 51]. A low ADL score was associated with cognitive decline [35]. An important finding, similar 
to another observational study in older adults [52], was the impact of hearing impairment on 
cognitive decline. Possible hypotheses are: the social deprivation associated with hearing 
loss, or a shared neuropathological origin of hearing loss and cognitive decline [52]. 
In some studies [34, 53] insomnia and sleep problems were associated with cognitive impair-
ment. Our study was especially designed to measure cognitive evolution and sleep quality. 
We used the validated PSQI to measure sleep parameters and difficulties, but we found no 
association with cognitive decline. 
Furthermore, we found that residents with depression had 2.8 higher risk of a rapid MMSE 
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decline. This association was also observed in other studies [12, 54, 55], but the mechanisms be-
hind the association have not been elucidated [55, 56]. Is depression an early-phase symptom of 
cognitive impairment, is it a risk factor, or is it a reaction on cognitive decline. As mentioned 
above, depression was in our study more common in BZD/Z users and was also linked with 
bad sleep among the BZD/Z users. The complex relationships between cognitive impairment 
and depression and BZD/Z use need to be further investigated. Meanwhile, current guide-
lines advocating prudent use of BZD/Zs in older adults prevail.
Implications for research: 
Our findings could not demonstrate with statistical significance that BZD/Z use was associ-
ated with fast cognitive decline. In concordance with other research on the association of 
BZD/Z and cognition, we conclude that the expected effects of chronic BZD/Z use on cognitive 
decline were subtle. Therefore large observational studies and more sensitive instruments 
are necessary.  Moreover, there is a complex relationship between BZD use and depression, 
and depression and cognitive decline, which needs to be further investigated. In future re-
search, we need adequately funded larger prospective cohort studies, together with a full 
collection of data on medication use and (psychometric) comorbidities.  
Implication for practice: 
Because of the extensive BZD/Z use in the older nursing home population, and the possible 
detrimental effect on cognitive evolution, the current advice to limit chronic BZD/Z use pre-
vails.
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ABSTRACT
Background & objectives: Prescription guidelines caution against chronic benzodiazepine 
and Z-drug (BZD/Z) use. Nevertheless, chronic use among older adults, especially in nursing 
homes is widespread. We wanted to explore why it is difficult to implement discontinua-
tion. We focused on individual residents that used BZD/Zs and explored benefit and harm 
of chronic BZD/Z use, willingness to try and barriers against the discontinuation of chronic 
BZD/Z use. 
Methods: In this cross-sectional study, we selected nursing home residents with at least 3 
months of BZD/Z use. A resident-specific questionnaire was addressed to the GP and to the 
responsible nurse and questioned effectiveness, side effects, initiation and willingness to 
stop. For every resident, the GP and nurse had to score 8 barrier statements on a 10 point 
Likert scale. Additionally, we collected 10 general attitudes scored by GPs and nurses.
Results: We received data for 109 chronic BZD/Z users. GPs and nurses indicated that the 
BZD/Z still had the desired effect in respectively 87% and 83% of the 109 residents and in 75% 
and 70% they observed no side-effect. Dependence was seen in respectively 41% and 28%. 
Overall, the GPs had higher barriers than the nurses but indicated a higher willingness to stop 
(33% vs. 21%). Both caregivers were willing to stop in 13% of the residents. 
Conclusion: The perceived effectiveness, the absence of side-effects and the presence of 
dependence in most residents on chronic BZD/Z use resulted in a low willingness to stop. 
Future discontinuation guidelines should consider all caregivers’ perceptions and promote a 
multidisciplinary approach.
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INTRODUCTION
Benzodiazepines (BZDs) are indicated for the short-term treatment of insomnia and anxiety. 
They are the most commonly prescribed psychotropic drugs, especially among the nursing 
home population [1, 2]. In most patients, their use becomes chronic. In Belgium, half of the 
nursing home population takes BZD/Zs (including Z-drugs) chronically [3]. Prescribing guide-
lines caution prescribers and patients against this chronic use [4-8]. Several research units 
launched a protocol to tackle chronic BZD/Z prescribing and to investigate discontinuation 
[9-12]. Two studies reported success rates of 57% and 59%, respectively 2 and 10 years after 
discontinuation [13, 14]. Nevertheless, chronic BZD/Z use outside the research context remains 
high. Possible reasons for this discrepancy are the perceived dependence of BZD/Zs [15] and 
the risk of withdrawal effects with temporary worsening of insomnia and anxiety [16, 17]. More-
over, the perception among prescribers and patients of BZD/Zs as harmless drugs [18] hinder 
discontinuation efforts.
Long-term BZD/Z use is of particular concern because of the lack of proven continuous effec-
tiveness [19] because of adverse effects such as sedation and hang-over effects [20], because 
of the risk of dependence, and because of potential acceleration of cognitive impairment [21]. 
Withdrawal attempts are recommended for long-term users. In the nursing home setting, 
both prescribers and nurses are important in the initiation and the discontinuation of BZD/
Zs. Therefore, it is crucial to understand the perceptions of prescribing general practitioners 
and nurses towards BZD/Zs before engaging in efforts to obtain sustained change in chronic 
BZD/Z use. 
Qualitative studies have investigated the general perceptions of BZD/Z use among patients 
[22], among physicians [23-25] and among nurses [26]. There are some quantitative studies [27-29], 
but these did not focus on possible discontinuation in an individual resident. The objective 
of this study was to investigate initiation, indications, previous stop attempts and perceived 
benefit and harm of BZD/Zs as well as the willingness to stop chronic BZD/Z use in individual 
nursing home residents. By focussing on perceptions pertaining to an individual resident, we 
hope to obtain a more realistic view on the feasibility to discontinue chronic BZD/Z use. We 
wanted to capture resident-specific barriers and also general attitudes towards discontinu-
ation of chronic BZD/Z use among the two key care givers in the nursing home setting (the 
general practitioner and the nurse). 
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METHODS
This was a cross-sectional study based on a resident-specific questionnaire addressed to the 
general practitioner (GP) and to the nurse.
Development of the questionnaire: 
As we did not find examples in literature specific to the nursing home setting, we developed 
a questionnaire based on an expert meeting. The expert meeting included different repre-
sentatives of geriatric care (GPs, nurses, nurse assistants, pharmacists and clinical pharma-
cologists) and focussed on the discontinuation of BZD/Z use. Based on what was discussed in 
the expert meeting, we developed a questionnaire intended for GPs and nurses and designed 
to be filled in for each individual resident in order to avoid global impressions. The question-
naire was developed with the expertise of an epidemiological researcher, GP, pharmacist and 
nurse. The preliminary version of the questionnaire was pretested among GPs and nurses for 
5 residents. 
As shown in Table 2, the resident-specific questionnaire examined indications (insomnia, 
anxiety, depression, agitation), where and when the BZD/Z was initiated (before entering 
the nursing home, in the nursing home, during hospital admission, unknown), whether the 
BZD/Z still showed benefit, whether there were any side-effects (listed by the Belgian farma-
cotherapeutic information centre[30]: sedation during the day, confusion, muscle weakness, 
concentration problems, apathy, memory problems, dizziness, physical and psychological de-
pendence) or previous stop-attempts and the willingness to stop chronic BZD/Z use in each 
individual resident. Furthermore, we wanted to identify possible barriers against discontinu-
ation. We formulated eight resident-specific barriers to be scored on a 10 point Likert scale, 
with a higher score indicating agreement with the barrier statement.
Additionally, we collected ten general attitudes (not resident specific) towards BZD/Z discon-
tinuation of the GPs and nurses. These were also scored on a 10 point Likert scale.
Inclusion of nursing home residents: 
In a convenience sample of five nursing homes in the region of Antwerp, Belgium, we 
screened medication charts and included those residents that used BZD/Zs daily for at least 
three months (chronic). The Anatomical Therapeutic and Chemical Classification (WHO 2012) 
was used to define BZD/Z use including the classes N05BA (anxiolytics), N05CD (hypnotics), 
N05CF (Z-drugs) and clonazepam (N03AE01). Tetrazepam (M03BX07) was included in our 
analysis but is withdrawn from the Belgian market since September 2013.
Data collection: 
After selecting the residents with chronic BZD/Z use, the questionnaires were delivered to 
the medical coordinator of the nursing home, who handed them over to the head nurse and 
to the GP responsible for the specific resident. In Belgian nursing homes, residents are su-
pervised by their own GP, with an average of 32 GPs per nursing home (Elseviers et al 2010). 
Data collection was performed between November 2011 and March 2012. Data collection 
included demographic and functional information of the resident. Functional characteristics 
were scored by the KATZ scale [31]. This instrument is mandatory in the Belgian nursing homes. 
The first part of this instrument scores six activities of daily living (ADL) from 1 (independent) 
to 4 (total dependent) and the sum score can range from min. 6 to max. 24. The second part 
scores disorientation in time and place, each ranging from 1 (no disorientation) to 4 (severe 
disorientation) and was used as a proxy to estimate the cognitive competence. A disorienta-
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tion sum score of more than 4 was considered as impaired cognitive competence.
Statistical analysis: 
All statistical analyses were performed using the statistical package IBM SPSS statistics version 
20 with p<0.05 as the level of significance. Level of agreement between GP and nurse was as-
sessed using kappa coefficients and descriptive percentages of positive agreement. The bar-
rier statements as well as the general attitudes, both scored on a 10 point Likert scale, were 
described using medians and ranges. Differences between GP and nurse were assessed using 
non-parametric statistics: the barrier statements with Wilcoxon Signed Rank test for paired 
observations and the general attitudes with Mann Whitney U test. The internal consistency 
(cronbach’s alfa) of the general barriers was 0.80 for the GPs and 0.76 for the nurses, and of 
the resident-specific barriers, this was 0.76 and 0.83, respectively.
Ethical consideration: 
This study was approved by the Ethics committee of the University Hospital Antwerp (approv-
al number B300201112279). The participating nursing home management, nurses and GPs 
all gave approval. All information of the resident was coded. We communicated with the GPs 
and nurses through the coordinating physician of the nursing home.
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RESULTS
Study population: 
In the five participating nursing homes (total of 570 beds), 170 (30%) residents took BZD/Zs 
chronically. In this study, we only included those residents for whom we received completed 
questionnaires from both the GP and the nurse. We received completed questionnaires for 
109 residents (response rate of 64%); 25 GPs and 16 nurses filled in the questionnaires (Fig. 
1). 
Fig 1: FLOWCHART
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response	  rate) 
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  GPs	  responded	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  (64%	  response	  
rate) 
Of the 109 residents, the mean age was 86 years (range 60-100) and 81% was female. The 
mean time spent in the nursing home was 40 months. The mean activities of daily living score 
was 15, with mainly problems with washing and clothing. Around one third (30%) of this pop-
ulation was considered to have dementia (Table 1). 
The most prescribed BZD/Z was zolpidem (28%), followed by lorazepam (27%) and lormetaz-
epam (20%). Concomitant BZD/Z use was seen in 8% of the residents (Table 1).
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Table 1. Characteristics of chronic benzodiazepine users in Belgian nursing homes
CHARACTERISTICS of Chronic BZD/Z users n= 109
Demographic
Age (years-range) 85.9 (60-100)
Gender (% female) 80.7%
ADL score (mean-SD) 15.4 (5.5)
Dementia (% disorientation) 30.3%
Institutional
Stay in months (median-range) 40.3 (1-186)
Medication Information
duplicate  BZD/Z use 8.3%
substance name (ATC code)*
zolpidem (N05CF02) 28.4%
lorazepam (N05BA06) 26.6%
lormetazepam (N05CD06) 20.2%
tetrazepam (N03BX07) 7.3%
prazepam (N05BA11) 6.4%
bromazepam (N05BA08) 6.4%
alprazolam (N05BA12) 5.5%
clonazepam (N03AE01) 1.8%
zopiclone (N05CF01) 1.8%
BZD/Z= benzodiazepine or Z-drug use
ATC= Anatomical  Therapeutic Chemical classification
*percentages exceed 100% due to double use; Additionally to this list: clorazepate, cloxazolam, flurazepam, 
flunitrazepam, brotizolam were all used by 1 resident
Initiation, indication and previous attempts to stop chronic benzodiazepine use:
GPs and nurses did not know where the BZD/Z was initiated in respectively 15% and 26% of 
the residents. According to the GPs, 62% of the chronic BZD/Z users started before entering 
the nursing home, 22% in the nursing home itself and less than 1% in the hospital. According 
to the nurses, 46% of the residents started BZD/Z use before entering the nursing home, 27% 
in the nursing home itself and only 2% in the hospital (Table2).
GPs and nurses could not estimate the duration of BZD/Z use in respectively 65% and 62% of 
the residents. In the other residents, the GPs estimated an average duration of 66 months (SD 
82, n=38) and the nurses estimated 29 months (SD40, n=42).
The most common indication for chronic BZD/Z use was insomnia (69% and 68%). Other indi-
cations are shown in table 2. The GPs and the nurses indicated that they already attempted a 
withdrawal in the past in respectively 26% and 12% of the residents (Table 2). 
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Benefit and harm of benzodiazepine use: 
GPs and nurses indicated that the BZD/Z still had the desired effect in respectively 87% and 
83% of the chronic BZD/Z users (Table 2).
GPs and nurses noted dependence (psychological or physical) in respectively 41% and 28% of 
the residents. Apart from dependence problems, no other side-effects were observed by the 
GPs and the nurses in respectively 75% and in 70% of the residents. Daytime sleepiness was 
noted by the GP and nurse in respectively 17% and in 22% of the residents.
Willingness to stop chronic benzodiazepine use: 
GPs indicated that in 33% of the residents they were willing to stop chronic BZD/Z use. We did 
not find a difference in willingness to stop when there was a previous stop attempt. Nurses 
considered a stop possible in 21% of the chronic BZD/Z users. Only in 13% of the residents, 
the GP and the nurse were both willing to stop (Table 2). 
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Table 2. Initiation, indications, previous stop attempts, side effects, perceived effectiveness and willing-
ness to stop in 109 chronic BZD/Z users as indicated by the GPs and nurses.
INITIATION of BZD/Z in 109 residents as indicated by
GPs Nurses
WHERE?
before entering nursing home 62.4% 45.7%
in nursing home 22.0% 26.7%
during hospital admission 0.9% 1.9%
unknown 14.7% 25.7%
HOW LONG?
median number of months (range) 66.4 (3-240) 28.7 (3-240)
unknown 65.1% 61.5%
INDICATIONSa  of BZD/Zs in 109 residents as indicated by
GPs Nurses agreementb kappac
insomnia 69.4% 67.6% 56.5% 0.442
anxiety 28.4% 15.7% 9.3% 0.268
acute agitation 11.0% 21.3% 8.3% 0.431
muscle relaxation 5.5% 6.5% 4.6% 0.775
depression 7.3% 9.3% 4.6% 0.516
unknown 4.6% 13.0% 2.8% 0.266
other 8.3% 2.8% 0.9% 0.130
STOP ATTEMPTS in 109 residents  as indicated by 
GPs Nurses agreementb kappac
previous stop attempts 25.8% 11.8% 6.5% 0.216
PERCEPTION of BENEFIT of BZD/Zs  in 109 residents as observed by
GPs Nurses agreementb kappac
BZD still has desired effect 87.0% 82.7% 74.8% 0.262
PERCEPTION of HARMa of BZD/Zs in 109 residents as observed by
GPs Nurses agreementb kappac
no side effects 40.4% 44.9% 28.3% 0.386
psychological dependence 38.9% 23.4% 18.9% 0.462
physical dependence 21.3% 16.8% 11.3% 0.510
daytime sleepiness 17.0% 22.6% 7.5% 0.232
memory problems 8.5% 0.9% 0.9% 0.186
muscle weakness 4.6% 4.6% 1.9% 0.370
dizziness 2.8% 1.9% 0.9% 0.386
WILLINGNESS to STOP BZD/Z use in 109 residents as indicated by
GPs Nurses agreementb kappac
willingness to stop 33.3% 21.2% 13.1% 0.300
asum of percentages exceeds 100% due to multiple indications or side effects 
b percentage of positive agreement between the GP and the nurse
C kappa=  (observed  agreement-the probability of random agreement) / (1-the probability of random agreement)
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Resident-specific barriers against discontinuation: 
Of all eight resident-specific barriers (Fig. 2), most common among the GPs were the fear of 
resistance from the resident (median 9 on 10 point Likert scale), the preference of a pharma-
cological treatment above a non-pharmacological treatment (median 9), the fear that in this 
resident initial problems will come back (median 9), the fear of an increase of the care burden 
for the staff (median 8), the perception that change is not necessary as long as the resident 
functions well (median 8) and the fear of withdrawal effects (median 7).
Among the nurses, the most common barrier was the fear that in this resident initial prob-
lems will come back (median 8), the preference of a pharmacological treatment (median 8) 
and the conviction that change is not necessary as long as the resident functions well (me-
dian 7).
Among both caregivers, resistance of family or care staff was presumed to be low (Fig. 2).
The GPs perceived the resident’s motivation as a larger barrier than the nurses (median 9 vs. 
7, p = 0.001). The GPs, more than the nurses, indicated that discontinuation of BZD/Zs can 
lead to an increase in care burden (median 8 vs. 6, p = 0.028).
Fig 2: boxplots of barrier statements of 109 residents compared between GP and nurse. 
General attitudes of GPs and nurses towards stopping chronic benzodiazepine use:
Of all ten general statements (Fig. 3), the most common attitude among both GPs and nurses 
was that the longer the resident takes the medication, the more difficult it is to stop (median 
8). GPs and nurses agreed on the statement that old age of a resident makes it difficult and 
unnecessary to stop (median 6 vs.5, NS). According to both GPs and nurses, the help of other 
care professions such as a psychologist (median 3) and a pharmacist (median 1 vs. 2, NS) was 
not really perceived to be necessary. Electronic prescribing was not perceived to be a barrier 
(median 3 vs. 2, NS).
The GPs and nurses perceived that alternative strategies are more time consuming (median 5 
vs.3, NS) and that the rhythm of a nursing home with strict bedtimes also limits possibilities 
for discontinuation (median 5 vs. 3, NS). Nurses agreed and GPs disagreed on the statements 
that there is little knowledge on alternative strategies to cope with problems when stopping 
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BZDs (median 7 vs. 2, p< 0.001) and that there is little scientific information available for 
stopping (medians 6 vs. 2, p =0.004). 
Fig. 3: Boxplot of general attitudes of GP and nurses towards stopping chronic BZD use
DISCUSSION
This study on perceptions of benefit and harm, the willingness to stop and perceptions to-
wards barriers against discontinuation of BZD/Zs in the nursing home setting elucidates rea-
sons why the discontinuation of chronic BZD/Z use is difficult.
We found that both GPs and nurses perceived that the BZD/Z still had the desired effect in 
respectively 87% and 83%; and that except for dependence, there were no observed side-ef-
fects in 75% and 70% of the residents. The GPs were willing to stop this chronic use in one out 
of three residents and the nurses in one out of five. Surprisingly, in only 13% of the residents 
they were both willing to stop. Overall, there was a low agreement between GP and nurse.
Strenghts and limitations: 
The major strength of our study design is that we focused on perceptions pertaining to an 
individual resident. Therefore, we had a more realistic representation of the possibility to 
discontinue chronic BZD/Z use. Other studies on the perceptions of GPs and nurses towards 
BZD use [24-26] were often qualitative and did not focus on discontinuation. Our response rate 
of 64% was quite high. All nurses participated and non-response was exclusively caused by 26 
GPs who did not return their questionnaires. This discrepancy can be explained  because the 
medical coordinator gave questionnaires directly to the responsible nurse, whereas the GPs 
received it through mail. Although this was a convenience sample, demographics and func-
tionality (ADL) were comparable with a representative sample of Belgian nursing homes res-
idents in 2006[32]. Content validity was assured (expert meeting). Because this questionnaire 
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was not developed to be used as a scoring instrument, we did no further construct validation.
As to limitations, we collected information of 109 residents through only 16 different nurses 
and 25 GPs, so our observations could be biased by the consecutive completion of the ques-
tionnaire by nurse and GP for several residents. Although we focused on the perceptions of 
GPs and nurses, the patient’s perspective on BZD/Z use is important and his motivation is 
necessary in order to discontinue BZD/Zs successfully. We collected data for several demo-
graphic parameters, but we did not collect data on co-medication and co-morbidities. Recall 
bias is possible, because time between the BZD/Z initiation and the questionnaire completion 
could be lengthy. Although there is an important link between BZD/Z use and risk of falls in 
literature[33, 34], we did not collect specific data on falls.
Discussion of the main findings: 
For this study, the main selection criterion was chronic use for at least 3 months. But when 
we asked the GPs about the duration of use, they indicated that more than 50% started be-
fore entering the nursing home and very often the GPs could not indicate for how long the 
BZD/Z was used. Hence, chronic use of at least 3 months was in most cases permanent use.
Similar to another study of our research group [3], ‘insomnia’ was the main indication for the 
chronic BZD/Z use. Therefore, the results and conclusions of this study are predominantly 
relevant for sleep problems.
GPs as well as nurses considered the chronic use of BZDs to be still effective. This can be 
a socially desirable response, because GPs are still responsible for prescribing these drugs. 
Nevertheless, long-term BZD effectiveness is doubtful[35, 36]. Longitudinal studies of incident 
users with validated instruments are necessary to evaluate long-term effectiveness. 
The most commonly reported side-effect was psychological and physical dependence. As re-
ported in other studies[8, 37], GPs and nurses also pointed out that the expected resistance 
from the resident is a high barrier to try discontinuation. Prescribers are often confronted 
with patients’ demands to continue these drugs [25]. Nevertheless, some patients are  suscep-
tible to change, therefore routinely raising the issue, negotiating dose reduction schedules 
should be advised [25, 29]. Together with the perception of the effectiveness of chronic BZD/Z 
use and the lack of other side-effects, these notable addiction problems [8] lead to the chronic 
continuation of these drugs. There should be a shift in the caregivers general acceptance of 
chronic BZD/Z use to an holistic addiction management approach that aims to discontinue 
BZD/Z use in the best interest of the patient.
The scores for the resident-specific barriers were higher (more agreement with the barrier) 
than for the general statements. This finding confirms that this study with resident-specific 
information provides realistic views towards discontinuation compared to general opinions 
of the caregivers.
A common barrier for both the GPs and the nurses was the preference for pharmacological 
instead of non-pharmacological approaches. Nurses indicated that they had too little scientif-
ic information and knowledge on that matter. Training programs should focus on medication 
reassessment and on implementation of non-pharmacological approaches. GPs, more than 
nurses, indicated that the non-pharmacological treatment options take more time and effort. 
However, in a nursing home there is more care support (occupational therapist, physical ther-
apist,… ) available to try non-pharmacological approaches than in primary care. Nevertheless, 
in our study, the help of a psychologist or pharmacist to assist with the discontinuation was 
not perceived to be important. 
The fear that the initial problems will come back is also a barrier that was scored high among 
GPs and nurses. During withdrawal it is known that rebound insomnia or anxiety is possible 
[16]. But patients as well as prescribers should focus on the long-term outcome. For the indica-
tion ‘insomnia’, there is evidence that sleep quality improves after the BZD/Z is withdrawn [19]. 
Informing the patient on possible, but temporarily withdrawal symptoms and on sleep quality 
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improvement can help the patient’s motivation on discontinuing sleep medication.
The prolonged use of the BZD/Zs and the old age of nursing home residents affect the will-
ingness to discontinue BZD/Zs [25]. Most people enter a nursing home as a final step in life, 
and for the sake of convenience, care staff as well as patients can be more resistant towards 
prescribing guidelines urging them to stop. In this older, more vulnerable population with 
co-morbidities and polypharmacy  (including other psychotropic drugs), caregivers should be 
stimulated to discontinue chronic BZD/Z use, because of side-effects such as sedation, the 
risk of falling, the deterioration of cognitive functions, and poor sleep quality.
Although the GPs indicated higher resident-specific barriers, they were more willing to try 
discontinuation compared to the nurses. Maybe the prescribers are aware that discontinu-
ation is advised and although they report higher barriers, they feel more obliged to follow 
guidelines. The level of agreement between the GP and the nurse was low, showing that both 
caregivers, with different responsibilities towards patients, do not share the same opinion on 
the same individual patient. Consequently, this finding illustrates the need for more struc-
tured interdisciplinary contacts between caregivers in order to optimise medication use. 
In conclusion, the caregivers in our study reported a low willingness to discontinue chronic 
BZD/Z use in individual patients due to the caregivers’ perceptions about the chronic effec-
tiveness of, the residents’ dependence on and the absence of side-effects of BZD/Zs. Barriers 
towards discontinuation were higher among GPs than nurses. On the other hand, GPs were 
willing to try discontinuation in one out of three residents while nurses only wanted to try in 
one out of five.  Overall, there was a low level of agreement between GP and nurse indicating 
the need for interdisciplinary contacts.
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ABSTRACT
Background & objectives: Although guidelines discourage the chronic use of benzodiaze-
pines and related Z-drugs (BZD/Zs) for sleep problems, the prevalence among older adults 
residing in nursing homes remains high. Discontinuing these drugs is widely recommended, 
but seems difficult to implement.
The aim of our study was to evaluate the overall feasibility in the nursing home, in terms of 
willingness towards discontinuation and success rate at 8 months in willing patients, together 
with the impact on withdrawal symptoms, change in sleep quality, quality of life and medi-
cation use.
Methods: In a convenience sample of 5 Belgian nursing homes (823 residents), we includ-
ed cognitively competent residents with chronic BZD/Z use for insomnia. Sleep quality was 
investigated with the Pittsburgh Sleep Quality Index (PSQI), quality of life with the EQ-5D, 
and withdrawal symptoms with the Benzodiazepine Withdrawal Symptom Questionnaire 
(BWSQ). The (not) willingness to initiate a discontinuation was analysed with descriptive sta-
tistics, and the success rate with survival analysis. 
Results: Of the 135 eligible residents, both GP and resident were willing to initiate discon-
tinuation in 38 residents. The most indicated reason for refusing to initiate discontinuation 
among GPs was the ‘unmotivated patient’ and among residents the ‘reluctance towards 
change’. At 8 months, 66.0% were successful in completely discontinuing BZD/Z use. In these 
successful discontinuers (n=25) the subjective PSQI component evolved favourably (p=0.013) 
and the number of midnight awakenings decreased (p=0.041). In the relapse group (n=13), 
the quality of life decreased (p=0.012), with mainly an increase of problems with activities 
and pain/discomfort. In both groups, the withdrawal symptoms, functionality and medication 
use did not change.
Conclusion: Discontinuation of chronic BZD/Z use is feasible in the nursing home setting 
without noticeable withdrawal symptoms, without a switch in medication use, without det-
rimental effect on quality of life and with a positive effect on the self-perceived sleep quality.
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INTRODUCTION
Benzodiazepines and related Z-drugs (BZD/Zs) are the most frequently used symptomatic 
treatment for sleep difficulties in older adults [1]. International guidelines discourage the 
chronic use of these BZD/Zs, because of the lack of long-term effectiveness, the risk of de-
pendence, tolerance and withdrawal syndromes [2-4]. Though there were several campaigns 
and guidelines issued (the UK report in 1988 [5], US reconciliation act in 1987[6] and a more 
recent report in Belgium [7]), the prevalence of chronic BZD/Z use remains high, particularly in 
the nursing home setting (prevalence ranges in European nursing homes from 28% to more 
than 50%[8-11]). 
Due to the BZD/Z’s sedating action, the acute adverse effects include decreased alertness 
with risk of falling[12] and anterograde amnesia[13]. It has been suggested that chronic BZD/Z 
use has also been associated with increased risk on cognitive decline [14] and mortality [15]. 
With increasing age, pharmacokinetics change and central nervous system sensitivity in-
creases [16, 17]. Together with comorbidities and associated (in particular psychotropic) polyp-
harmacy, older people are more at risk for the adverse effects. A meta-analysis of risks and 
benefits in older people [1] showed an increased risk and marginal benefit of acute hypnotic 
use. However, this meta-analysis did not take into account the dependency problems associ-
ated with chronic use.  Most of the nursing home residents have established chronic use, long 
before entering the nursing home [18, 19].
Discontinuing BZD/Zs is widely advised, but seems difficult to implement [20, 21]. There is no 
consensus on the optimal tapering strategy [20, 22], with options varying from abrupt discon-
tinuation [23, 24] to tapering schedules of more than a year [25]. Several meta-analysis tried to 
evaluate strategies for BZD/Z discontinuation [22, 26] and concluded that a minimal intervention 
(for example: sending a letter from physician to patient), followed by gradual tapering (led 
by a physician or psychologist, and sometimes augmented with psychotherapy or pharmaco-
therapy), is effective in reducing BZD/Z use. Most studies included in this meta-analysis did 
not focus on older adults, and were performed in primary care or in psychiatric clinics (and 
are not representative for low dose users). Often, the BZD/Z initiation followed by chronic 
continuation is established in primary care. Therefore, this setting is an important research 
domain. However, it can be valuable to guide BZD/Z discontinuation in this older population 
in a more controlled setting such as hospitals and nursing homes.
A recent meta-analyse on reducing BZD/Zs  in older people [27] , included 16 studies, in pri-
mary care [28], in geriatric wards [29, 30] and in nursing homes [31, 32] and pointed at the effect 
of consultations, education of both prescribers and patients, both followed by a supervised 
withdrawal. In general, the studies in this analysis had a limited follow-up (3 studies with fol-
low up of max 12 months, and none in the nursing home) resulting in a lack of knowledge on 
long-term effectiveness (of specific interventions). The discontinuation of BZD/Zs in commu-
nity dwelling older people (aged 85+years), appears to be possible [33]. The question remains 
whether BZD/Z discontinuation is feasible in the nursing home setting.
Some (non-randomised) studies have investigated BZD/Z withdrawal in the nursing home 
setting and reported success rates of 87% after 8 weeks [34], a 50% reduction in BZD/Z use 
after 3 months [35], and 60% after 1 year [36]. In those studies there was a focus on the success 
rate (focus on residents already willing to discontinue). However, health policy makers should 
have an idea of the extent of the target population and the overall feasibility, including the 
willingness towards discontinuation in this setting.  
Therefore, we designed a study in the nursing home setting to analyse both the feasibility in 
terms of willingness towards discontinuation and the success rate at 8 months follow-up. We 
focused on cognitively capable residents with chronic BZD/Z use for sleep problems. Second-
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ary, we investigated possible withdrawal symptoms, the impact on sleep quality and on the 
quality of life. 
METHODS
Design: 
This pilot study with a follow-up of 8 months investigated the overall feasibility of a discontin-
uation process of chronically used BZD/Zs in cognitively competent nursing home residents. 
The analysis of overall feasibility was divided into the willingness to initiate a discontinua-
tion both among general physicians (GPs) and residents, and into the success rate in those 
residents who started discontinuation. We focused on BZD/Z use for sleep problems and 
explored possible withdrawal symptoms and the evolution of sleep quality and quality of life.
Setting: 
The Belgian long-term residential care structure consists of residential or nursing homes for 
older people, which offers a home replacement with or without nursing care. Governance 
of nursing homes for older people is either public (community health services) or private 
(predominantly non-profit) with little difference in quality of care. Often, the resident retains 
his/her own GP, resulting in an average of 32 consulting GPs per nursing home. The point 
prevalence of dementia among residents is approximately 50% with considerable variation 
between nursing homes [37].
Inclusion and exclusion criteria: 
In a convenience sample of 5 Belgian nursing homes, all cognitively competent residents 
were screened for inclusion (September 2012 till July 2013). 
Eligible residents had established chronic use of benzodiazepines or Z-drugs for insomnia 
(daily administered at bedtime for at least 3 months) and were cognitively competent, which 
was confirmed with a KATZ disorientation score of 1 or 2 (disorientation in time and place 
ranging from 1-no disorientation to 4-severe))[38]. 
We excluded residents who were critically ill, or had a fatal diagnosis with short life expec-
tancy; residents who used a benzodiazepine during the day (for the indication anxiety) or 
used a sedative antidepressant (trazodone, amitriptyline, mirtazapine) or phytotherapy as 
co-medication.
Willingness to initiate discontinuation in chronic BZD/Z use (GP and resident): 
One part of the overall feasibility focused on investigating how many GPs and residents were 
willing to initiate discontinuation. 
The general physician (GP) of the eligible resident received a recruitment letter. In this letter, 
the GP saw the name of his patient and the prescribed BZD/Z with the dose. In this recruit-
ment letter we asked the GP for the duration of BZD/Z use and whether he/she was willing 
to initiate a discontinuation in this particular resident. In case the GP did not want to initiate 
discontinuation, he/she could indicate the reason(s) among the following options: ‘psychi-
atric problems or major depression; specific sleep disorders; specific medication inducing 
insomnia (e.g.psychotropic drugs, thyroids); BZD/Z used as anxiolytic or muscle relaxant; not 
feasible because of failed prior attempt(s); not feasible because of the lack of the resident’s 
motivation; and other reasons.’
All residents, whose GP agreed to initiate discontinuation, were informed and asked for their 
willingness to discontinue their BZD/Z (informed consent).
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Success Rate of discontinuation process: 
In cases where both the GP and resident agreed, the discontinuation was initiated. Because 
of our naturalistic study design, we did not implement a strict discontinuation schedule and 
used no substitution or alternatives. The GP was responsible for the discontinuation but we 
proposed a possible discontinuation schedule to the GP in the recruitment letter (25% reduc-
tion per week or per 2 weeks).
The successful discontinuation rate 8 months after inclusion was our main outcome parame-
ter. We documented relapse and its reason (sleep problems during or after withdrawal; loss 
of motivation; and other).
Data collection- outcome: 
We performed data collection at baseline, 2 months and 8 months after baseline, except for 
withdrawal symptoms (at baseline and after discontinuation). As our sample was a geriatric 
population, the researcher (J.B.) assisted residents with the recording and rating of the ques-
tionnaires. 
Demographic data was obtained from the resident’s record and medication data from the 
medication chart. Based on the Anatomical Therapeutic and Chemical classification (ATC) [39], 
we selected the classes N05BA (anxiolytics), N05CD (hypnotics) and N05CF (Z-drugs) as BZD/Z 
use. We divided the BZDs and Z-drugs according to half-life in short/intermediate (T1/2<24h) 
and long-acting (T1/2>=24h) based on a reference source [40]. We also used the Defined Daily 
Dose (DDD) to compare dosages. The total number of chronically used medications as well 
as possible interfering medication such as antidepressants (ATC N06A), antipsychotics (ATC 
N05A), anti-dementia drugs (ATC N06D), anti-Parkinson (ATC N04) drugs and pain medication 
(ATC N02) were recorded. Functional characteristics were scored by the KATZ scale [38]. This 
instrument is mandatory in the Belgian nursing homes. The first part of this instrument scores 
six Activities of Daily Living (ADL) from 1 (independent) to 4 (totally dependent). The second 
part scores disorientation in time and place ranging from 1 (no disorientation) to 4 (severe) 
and was used in the inclusion of eligible residents (residents with score 1 or 2). Depressive 
feelings were scored with the 8-item Geriatric Depression Scale (GDS), which is an abbreviat-
ed version of the GDS 30 [41] and especially designed and validated for nursing home residents 
[42, 43]. A score of three or more on the GDS-8 is indicative for depressive symptoms. Addition-
ally, we recorded hospital admissions and falls by checking the medical file and recorded 
hearing and visual impairment, and frequent pain (by using a yes or no question). 
The validated Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) was used [44] to 
detect withdrawal symptoms. This self-report questionnaire measures 20 symptoms. The 
three answer possibilities (no-moderate-severe) are linked to a rating of 0, 1 or 2, with higher 
scores indicating more withdrawal symptoms (maximum score is 40). 
The sleep quality was analysed with the Pittsburgh sleep quality index (PSQI) [45], a self-rated 
questionnaire which investigates global sleep quality and sleep disturbances (Dutch trans-
lation [46]). The seven components of the PSQI are scored from 0 to 3, yielding a total score 
ranging from 0 to 21, where higher scores indicate worse sleep quality. A total PSQI score of 
more than 5 is a widely used cut-off that indicates poor sleep quality. Because in this study, 
we wanted to compare sleep quality before and after discontinuation, we left out the PSQI 
component ‘sleep medication’ in the total PSQI score (adjusted PSQI, with a score ranging 
between 0 and 19). We also reported the component ‘subjective sleep quality’ as perceived 
by the resident himself (scored from 0 to 3).
Quality of life was assessed with the descriptive part of the EQ-5D-3L, which is a standardised 
measure of health status developed by the EuroQol Group [47] and also validated in nursing 
home residents [48]. The EQ-5D-3L descriptive system comprises the following dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which can be 
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scored from 1 (no problems), 2 (some problems) till 3 (extreme problems). The descriptive 
profile score is converted into the EQ-5D index [49], with higher sores indicating better health.
Ethical considerations: 
This observational study was approved by the ethics committee of the University Hospital of 
Ghent (registration number B670201213943). Each nursing home received information and 
gave approval to screen the nursing home population. The GP had to approve the resident’s 
inclusion. Each resident, included in our study, received oral and written information and 
gave consent.
Statistics: 
We used descriptive statistics to analyse the feasibility of discontinuation and survival anal-
ysis to analyse the success rate of discontinuation during an 8 month period. The outcome 
parameters, i.e. withdrawal symptoms, sleep quality, quality of life, functionality and medica-
tion use were described and compared between the discontinuers and the controls, and also 
between the successful discontinuers and the relapse group. Because of the small number of 
residents in each group, we used nonparametric statistics (Mann Whitney U for the compari-
son of categorical variables between groups and Kruskal Wallis for paired analysis).
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RESULTS 
Willingness to stop: 
In the five nursing homes with a total of 823 residents, our exclusion of residents with known 
dementia or disorientation (n= 558) and of residents with BZD use for anxiety or other sleep 
enhancing medication (n=130), resulted in 135 eligible residents (16%) (Fig 1).
Fig 1: Flowchart of the willingness to discontinue chronic benzodiazepine/Z-drug use. 
	  
ELIGIBLE	  
N=	  135	  
Convenience	  sample	  of	  5	  Belgian	  nursing	  homes	  
Total	  residents=	  823	   excluded:	  
• Dementia/disorientation:	  N=558	  
• BZD/Z	  use	  during	  daytime	  
And/or	  
Use	  of	  sedative	  antidepressant	  (trazodone,	  
amitriptyline,	  mirtazapine)	  or	  other	  sleep	  enhancing	  
drug:	  N=130	  
GP	  agreed	  to	  initiate	  discontinuation	  in	  
study	  
(positive	  recruitment	  letter)	  
N=51	  
RESIDENT	  agreed	  to	  START	  discontinuation	  
N=38	  
	  
2	  month	  follow-­‐up	  N=	  38	  
8	  month	  follow-­‐up	  N=37	  (1	  deceased)	  
excluded:	  
• GP	  did	  NOT	  agree	  to	  initiate	  discontinuation	  N=63	  
• GP	  did	  not	  respond	  N=13	  
• GP	  started	  discontinuation	  outside	  study	  N=8	  
	  
excluded:	  
• Resident	  did	  NOT	  agree	  to	  initiate	  discontinuation	  N=13	  
The GPs of those 135 residents indicated that a discontinuation was feasible in 51 residents 
by returning a positive recruitment letter. For 13 residents, the GP did not respond to the re-
cruitment letter. The reasons why GPs (n=71) were not willing to initiate a discontinuation are 
summed in Figure 2. More than half of the GPs indicated that there was a lack of motivation 
of the resident himself (56%). In 18%, the failure of a previous attempt was the reason not to 
initiate a discontinuation. 
Of those 51 residents, where the GP agreed, 13 residents refused to start the discontinuation 
of their BZD/Z. The main reason (12/13) was the reluctance towards change (too old, I sleep 
well). In total, 38 residents gave informed consent and were included in the discontinuation 
study. The most frequently used BZD/Zs in the 38 discontinuers were lormetazepam (36.8%) 
and lorazepam (21.1%), 37 residents used a short acting BZD/Z and the median prescribed 
dose was 1 DDD (range 0.10-2.00). 
146
2.7
RESU
LTS:     Feasibility of discontinuing chronic benzodiazepine use in nursing hom
e residents: A
 pilot study 
Fig 2: General Physicians’ reasons for not initiating discontinuation in a resident in the study (n= 71).
 
Success rate (survival analyse): 
After 2 months, 25/38 residents were BZD/Z free, 7/38 residents reduced their dose and 6/38 
residents relapsed. After 8 months, one resident of the 25 successful discontinuers relapsed, 
one deceased and one additional resident stopped BZD/Z. The median duration of the dis-
continuation process was 21 days (range 7 days to 88 days). The reasons why residents were 
not successful in their discontinuation was because of sleep problems during the discontin-
uation (n=6/13) and overall loss of motivation (n= 5/13). Real increase in withdrawal symp-
toms (as scored by the BWSQ) was not observed. Of the 24 residents who were successfully 
weaned after 8 months, one person took placebo, and one person used an antihistaminic 
(hydroxyzine) as needed.
The survival analysis revealed that 66.0% were successful in completely discontinuing BZD/Z 
use at 8 months. If we also considered the residents who decreased their BZD/Z dose as suc-
cessful, the success rate increased to 82.0% (Fig. 3).
Fig 3: Survival Analysis of the 38 residents who initiated discontinuation (Kaplan Meier).
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Baseline comparison between successful discontinuation group and relapse group:
At baseline, the successful discontinuers (n=25) and relapse group (n=13) were comparable 
on all demographic, clinical, institutional and medication characteristics (Table 1) as well as 
for baseline outcome parameters (sleep quality components, quality of life). 
Table 1. Baseline characteristics of included residents with a comparison between Successful discontinuation (n=25) and 
Relapse (n=13).
BASELINE COMPARISON
TOTAL SUCCESSFUL RELAPSE p-valuea
n= 38 n= 25 n=13
Demographic characteristics
Age in years (mean-range) 84.3 (65-97) 84.3 (65-97) 84.3 (72-93) 0.987 
Gender (% female) 71.1% 79.2% 53.8% 0.108
Length of stay in months (mean-range) 34.1 (3-128) 37.9 (3-128) 26.9 (3-107) 0.426 
Education (%higher education >14y) 36.8% 37.5% 38.5% 0.867
Clinical characteristics
ADL score (mean-range) (0-24) 14.1 (6-23) 15.4 (6-23) 11.6 (6-22) 0.051
Disorientation score (mean-range) (0-8) 2.7 (2-4) 2.8 (2-4) 2.5 (2-4) 0.377 
Sight impairment (not blind) 23.7% 16.7% 38.5% 0.140
Hearing impairment (not deaf) 39.5% 41.7% 30.8% 0.514
Fall<12months 31.6% 29.2% 38.5% 0.564
Chronic pain 15.8% 12.5% 23.1% 0.405
Depressive symptoms (%GDS≥3) 27.0% 20.8% 38.5% 0.249
Medication Information
Total number of chronic medication (mean-range) 8.2 (1-18) 8.6 (4-13) 7.5 (1-18) 0.168 
Benzodiazepine/Zdrugb DDD 0.9 (0.1-2.0) 1.0 (0.1-2.0) 0.8 (0.1-2.0) 0.437 
       long-actingc 2.6% 0.0% 7.7% 0.160
Antidepressant medication 26.3% 29.2% 23.1% 0.690
Antipsychotic medication 13.2% 8.3% 15.4% 0.510
Anti-Epileptic medication 7.9% 8.3% 7.7% 0.946
Pain medication 26.3% 37.5% 7.7% 0.051
       narcotic 18.4% 25.0% 7.7% 0.199
       nonnarcotic 13.2% 20.8% 0.0% 0.077
a  p-value of difference between successful and relapse with nonparametric statistics (Chi² for categorical variables and Mann Whitney U for continuous)
b BZD/Zs: lormetazepam was used by 14, lorazepam by 8, zolpidem by 7, bromazepam by 4 and alprazolam by 3 residents;flurazepam and triazolam by 1 resident. 
c  long acting was defined as a BZD/Z with a half-life of ≥24h; in our study only flurazepam was recorded 
ADL= Activities of Daily Living, GDS=Geriatric Depression Scale, DDD= defined daily dose
Impact of discontinuation on withdrawal symptoms: 
The mean BWSQ score among the 38 discontinuers evolved from 3.9 (SD 2.8, range 0-11) 
at baseline to 4.1 (SD 2.6, range 0-12) after discontinuation (p=0.865), indicating that there 
were no excess symptoms noticeable during withdrawal. Both in the successful (n=25) and 
the relapse group (n=13), the withdrawal symptoms did not differ at baseline and did not 
change over time (p=0.175).
Among the 38 discontinuers, the most commonly reported symptoms incorporated in the 
BWSQ were muscle pain (baseline 49% and 63% afterwards), muscle twitching (41% and 
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37%), loss of memory (41% and 32%), pins and needles (35% and 39%) and feeling depressed 
(32% and 37%). 
Impact of discontinuation on sleep quality: 
The total adjusted PSQI score in the successful discontinuers (n=24) was the same over the 
three time points 5.3 (SD 2.9), 5.1 (SD 2.6) and 5.3 (SD 3.3) at baseline, 2 months and after 
8 months, respectively (difference between baseline and 8 months p= 0.880). In the relapse 
group, this adjusted PSQI score evolved from 5.8 (SD 2.8) at baseline to 5.5 (SD 2.3) at 2 
months and increased to 7.9 (SD 4.8) at 8 months (difference between baseline and 8 months 
p=0.075) (Table 2). 
The subjective component in the PSQI questionnaire showed an overall improvement of 
the sleep quality in the successful discontinuers (from 1.25 at baseline to 0.88 at 8 months, 
p=0.013). In the relapse group the subjective sleep quality evolved from 1.23 at baseline to 
1.15 at 8 months, p=0.739). 
The total “hours of sleep” decreased over 8 months, in the successful discontinuers from 
8h44min at baseline to 8h01min at 8 months (p=0.031); in the relapse group from 8h24min 
to 7h01min (p=0.019). The “sleep latency” increased over 8 months; from 27min to 42min 
(p=0.304) in the successful group, and from 26min to 41min (p=0.107) in the relapse group.
The number of midnight awakenings decreased significantly among the successful discontin-
uers (1.56 at baseline to 0.83 at 8 months, p=0.041). All other components of the PSQI did 
not change significantly. 
Impact of discontinuation on other outcome parameters: 
The functionality (ADL score) or the number of chronic medications (BZD/Z not included) did 
not change in both groups over 8 months (p value= 0.280) (Table 2).
The EQ-5D-3L index score did not evolve significantly in the successful discontinuers (from 
0.439 to 0.456, p=0.879) (Table 2). In the relapse group, quality of life decreased from 0.676 
to 0.556 (p=0.012), with mainly an increase of problems with activities and pain/discomfort.
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DISCUSSION
This discontinuation study in the nursing home setting showed that discontinuation of chron-
ic BZD/Z use is feasible without noticeable withdrawal symptoms, without a switch in med-
ication use, without a detrimental effect on quality of life and with a positive effect on the 
sleep quality. Our analysis at 8 month follow-up showed that 66% succeeded in stopping 
their BZD/Z use. The success rate was enhanced to 82% when we included everyone who 
decreased their dose. Nevertheless, the proportion of eligible residents was low and the 
recruitment was difficult. Our inclusion criteria provided a small sample of eligible residents 
(135/823). Recruiting residents of which both GP and resident agreed to initiate discontinua-
tion reduced our sample further to 38/135. The most frequently indicated reason for refusing 
discontinuation among GPs was an ‘unmotivated patient’ and among residents the ‘reluc-
tance towards change’.
Strenghts and limitations: 
Rational medication use also includes the discontinuation of drugs which are not really nec-
essary or can cause harm [21, 50]. This concept is in accordance with the concept of quaternary 
prevention, which is the avoidance of unnecessary medical activity [51]. Because discontinuing 
medication in older adults is not yet a routine procedure and is especially difficult when it 
concerns chronic BZD/Zs for insomnia problems [20], our study on the feasibility of discontinu-
ing chronic BZD/Z use in the nursing home setting appears to be very relevant. 
The major strength is our focus on the overall feasibility. Some studies investigated the gen-
eral perceptions of chronic BZD/Z use among physicians [52-54] and among patients [55-57]. Other 
studies focused on the discontinuation process [34, 58]. Our study combines those two impor-
tant research topics in order to represent the overall feasibility; the willingness to initiate a 
discontinuation and whether this discontinuation can be successful for a longer period (8 
months). This study was not intended to find the optimal tapering strategy; the GP was free 
to tailor the withdrawal to the needs of his/her patient as suggested in the literature [20].
Another strength of this study lies in its pragmatic approach and easy translation to the re-
al-life setting. However, several exclusion criteria limit the total generalizability. We excluded 
residents with dementia/disorientation because of the controversy towards medication with-
drawal and because of the difficulty of monitoring study outcomes (withdrawal symptoms, 
sleep quality…) in this patient group. This ethical hindrance has led to a paucity of valuable 
information, with no specific studies on BZD/Z withdrawal in this patient group [59]. From a 
previous study in the Belgian nursing homes [19], we knew that 59% of the chronic BZD/Z use 
is intended to treat the sole indication ‘insomnia’. All guidelines agree on the time-limited use 
for this indication. Because there is uncertainty on the appropriateness of long-term use of 
BZD/Z for anxiety disorder [60] and other indications (such as epilepsy, muscle spasm,…) and 
because we were not able to offer alternative (non-)pharmacological therapy, we excluded 
residents that used the BZD/Z for anxiety. Because our focus on BZD/Z use, we excluded res-
idents that used other hypnotic medication, such as trazodone or other antidepressants and 
phytotherapy. 
Though inherent to a pilot study, our small sample size is an important limitation. Moreover, 
we had no control group which limits the interpretations towards differences in outcome pa-
rameters. Although it would be of great value to have a comparable group of residents who 
do not stop their BZD/Z and serve as controls, no study has been able to include this because 
of recruitment difficulties. Our large cascade limits the possibilities of comparison and forces 
us to use nonparametric statistics. However, we had a very small number of lost-to-follow-up. 
We did collect the number of chronic medication and focused on psychotropic medication, 
but we had no information on comorbidities. Recall bias could not be avoided, as we ques-
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tioned the withdrawal symptoms after the completion of the discontinuation process.
Main discussion: 
Overall feasibility: willingness and success rate
Of the total sample of 135 eligible residents, only 28% were willing to initiate a discontinua-
tion. This finding confirmed the results of a previous survey among GPs and nurses investi-
gating willingness to stop [19]. This older population with years (even decades) of daily BZD/Z 
use [18] and with limited prospects for clinical improvement, expresses a lack of motivation 
and even reluctance towards discontinuation [53, 61]. Because we were ethically obliged to first 
ask the GP for agreement to initiate withdrawal, we could not know whether the GP had 
discussed discontinuation with his/her patient or he just assumed a lack of motivation. Nev-
ertheless, some patients are susceptible to change. Therefore it is advised to routinely raising 
the issue and negotiating dose reduction [62, 63]. 
Of the residents who initiated withdrawal, 66% succeeded in withdrawing their BZD/Z fully at 
8 months, and an additional 16% decreased their dose. This percentage is similar to another 
study in this setting [36] (60% still BZD/Z free at 1 year). 
Outcome parameters 
In our study, the residents with chronic BZD/Z for sleep problems used low dosages and there 
was no increase in withdrawal symptoms noticeable. The BWSQ is intended to detect change 
in different symptoms. We found an already high frequency of several symptoms at baseline 
(muscle pain, muscle twitching,…), but we did not find a change during withdrawal. However, 
there were some residents who relapsed due to sleep problems during or after withdrawal 
(n=6/13), indicating possible rebound insomnia [64].
We saw that residents with successful discontinuation reported a better sleep quality than 
before the discontinuation and the number of midnight awakenings was significantly re-
duced. We found a significant reduction of the total ‘hours of sleep’. Whether this is a posi-
tive or a negative effect depends on the amount of restorative sleep and impact on daytime 
functioning. It is known that BZD/Zs shorten the sleep latency and change sleep architecture 
at the expense of the deep restorative stages of sleep [65]. Stopping the chronic BZD/Z use 
could imply that the sleep rehabilitates, becomes less fractionated and less vulnerable to 
pain, noise, and other potential distractions.
There was no change in quality of life and functionality among the successful discontinuers. 
The quality of life index (EQ-5D-3L) did decrease significantly in the relapse group, but was 
still higher than in the success group.
Medication substitution is a common concern [66-68], but in our study, there was no increase 
in medication use or switch towards other (psychotropic/sedative) medication (except for 
intermittent use of a placebo or antihistaminic in 2 residents).
Implications for research:  
More research is needed to decide whether a discontinuation campaign in this subpopula-
tion is cost-effective, and which interventions can lift barriers and increase the willingness to 
engage in discontinuation, both in patients and in physicians. 
In order to confirm with sufficient power that discontinuation of BZD/Z leads to better sleep 
quality, prospective studies with sufficient sample size and a random or matched control 
group should be set up.
Finally, the feasibility, success rate and outcome should also be investigated in residents with 
dementia/disorientation and in people with BZD/Zs used for the indication anxiety, not only 
in the nursing home setting, but also in ambulatory care.
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Implications for practice: 
The approach to discontinuation in our study can be implemented on a larger scale. Nursing 
homes may be a protected environment where GPs (and other care personnel) can familiar-
ize with discontinuation efforts, gain confidence and even extend these efforts to the large 
community of home dwelling older adults. Informing all prescribers, caregivers and patients 
of the negative effects of chronic BZD/Z use and the positive prospects of discontinuation 
together with educating prescribers in motivational techniques could impact the overall will-
ingness. 
When taking care of the oldest old, especially in the nursing home, multiple actors are re-
sponsible for the medication use so it is important to include nurses, physicians, pharmacists 
and management, taking into account powerful barriers towards willingness to change. 
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DISCUSSION
A discrepancy exists between current guidelines cautioning against chronic benzodiazepine 
and Z-drug (BZD/Z) use and its high prevalence among older nursing home residents in Bel-
gium. Major gaps in BZD/Z research are the lack of data on long-term efficacy, and inconsist-
ent findings on long-term risk, such as cognitive deterioration. 
With this thesis we wanted to contribute to the knowledge on the benefits and risks of chron-
ic BZD/Z use and focus on the largest consumer group of these drugs, the older nursing home 
residents. Furthermore, we investigated whether discontinuation was feasible in this setting. 
A clear cut differentiation between BZD/Z use for insomnia and use for anxiety or other in-
dications has not been made in many studies. This thesis focused on the main indication, 
insomnia. 
1. ANSWERS TO THE RESEARCH QUESTIONS
What are the indications of the benzodiazepines and Z-drugs used in the nursing home 
and at which dosages (chapter 2.1)?
We found that half (50%) of the nursing home residents in Belgium used BZD/Z drugs on a 
daily base and for at least 3 months. This indicates chronic use, generally considered to be 
inappropriate. The main indication of chronic BZD/Z use was insomnia (59%), followed by 
anxiety (17%). For anxiety, multiple dosing per day resulted in a higher daily BZD dosage com-
pared to insomnia. For insomnia, BZD/Zs were taken once in the evening, in dosages equal to 
the DDD but higher than recommended for the geriatric population.
What is the proportion of antidepressants used for insomnia and anxiety in the nursing 
home and what are the dosages (chapter 2.2)?
In our exploration of antidepressant use for the overlapping indications with BZD/Zs, we 
found that sedative antidepressants (mainly trazodone) were prescribed at dosages below 
the DDD for the off-label indication insomnia without concomitant depressive symptoms. For 
the indication anxiety, guidelines recommend antidepressants as first-line treatment. Howev-
er, in our study, we found that the Belgian physicians preferred to prescribe BZDs above the 
recommended SSRIs for long-term treatment of anxiety.
What is the sleep quality of chronic BZD/Z use in nursing home residents and does it differ 
from nonusers (chapters 2.3 and 2.4)?
In our cohort of cognitively competent nursing home residents, we found at baseline that 
chronic BZD/Z users had a worse sleep quality than nonusers. More specifically, chronic us-
ers reported more difficulties with falling asleep, reported a higher frequency of midnight 
awakenings, and a higher frequency of not being well rested in the morning. The one-year 
follow-up results of this observational cohort study revealed that the sleep quality of the 
BZD/Z users deteriorated significantly, while in nonusers, there was also a deterioration of the 
sleep quality, but not significantly. 
The comorbidity ‘depression’ was in this study a significant factor in worsening sleep quality, 
and also in this study, depressive symptoms were more prevalent in chronic BZD/Z users. 
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What is the relationship between chronic BZD/Z use and cognitive deterioration in nursing 
home residents? (chapter 2.5).
We explored the risk of chronic BZD/Z use on cognitive deterioration in the same cohort. The 
general cognition of nursing home residents (as measured by the MMSE) decreased signif-
icantly in one year, both in the group of BZD/Z users and in the nonusers, but there was no 
significant difference in mean MMSE decrease between those two groups. When focusing 
on clinically relevant cognitive decrease, there were 34% BZD/Z users with severe deterio-
ration (decrease of 4 or more points in one year) compared to 27% nonusers, but this small 
difference was not significant. A strong risk factor for clinically relevant cognitive decline was 
depression. Social activities and cognitive stimuli (such as reading, memory games) were as-
sociated with less cognitive decline.
Is it feasible to implement discontinuation in the nursing home (chapter 2.6 and 2.7)?
First, we explored perceptions of benefit and harm, the willingness to stop BZD/Z and barriers 
against discontinuation by performing a survey addressed to the two main caregivers in the 
nursing home, the GP and nurse. In more than 60% of the residents, the GP could not indicate 
the duration of BZD/Z use. In those who had a defined duration, it was 66 months, which 
illustrates chronic use. GPs as well as nurses considered the chronic use of BZD/Zs to be still 
effective and did not report many noticeable side-effects, except for dependence. Together 
with the expected resistance from the resident, all these factors contribute to the low will-
ingness to discontinue BZD/Zs; GPs were willing in one third, while nurses were willing in one 
fifth of the residents with chronic BZD/Z use. Overall, there was a low agreement between 
GP and nurse.
Finally, we investigated overall feasibility, incorporating both the willingness towards discon-
tinuation and also the success rate of discontinuing chronic BZD/Z use. 
Our focus on cognitively competent residents, using BZD/Z only for insomnia led to a small 
sample of 135 on a total of 823 residents. Only for 38 residents both GP and resident were 
willing to discontinue. Lack of motivation was the main barrier to refuse discontinuation. Nev-
ertheless, we learned that in this pilot group of 5 nursing homes, discontinuation of chronic 
BZD/Z use is feasible without noticeable withdrawal symptoms, without a switch to other 
medication, without a detrimental effect on quality of life, and with a positive effect on the 
sleep quality. Our analysis at 8 month follow-up showed that 66% succeeded in stopping 
their BZD/Z use. The success rate was enhanced to 82% when we included everyone that 
decreased their dose. 
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2.     STRENGTHS AND LIMITATIONS
This thesis has contributed to the understanding of the high prevalence of chronic BZD/Z use 
in the Belgian nursing home setting, with an exploration of its indications and optimal dos-
ages (chapter 2.1). This thesis has contributed to the much needed information on chronic 
effectiveness of BZD/Zs in term of sleep quality (chapter 2.3 and 2.4), and also explored the 
worrisome link with cognitive decline (chapter 2.5). In this thesis, we did not limit ourselves 
to observational studies, but we also set up a pilot discontinuation study to enhance the clin-
ical relevance of our work (chapter 2.7).
 
An overall strength of this thesis was our focus on BZD/Z use for sleep problems, whereas 
most studies do not differentiate between BZD/Z use for insomnia, for anxiety, or for other 
indications. The strength of the descriptive studies with data from the PHEBE database (chap-
ter 2.1 and 2.2) was the large representative sample of residents and the data collection from 
primary sources (GP and medication chart). Although the indications were gathered retro-
spectively, this clinical information was essential to differentiate between insomnia, anxiety 
and other indications, thus limiting indication bias. Strength of the first chapter was our ex-
ploration of “optimal geriatric dosing” and the confrontation with actual prescribed dosages 
in clinical practice, which can guide clinicians in installing a dosing regimen.
The strength of our observational cohort study (chapter 2.3, 2.4 and 2.5) was that it was 
the first study especially designed to investigate sleep quality, cognition and its temporal 
evolution among cognitively competent long-term users of BZD/Z for insomnia in the nursing 
home setting, and with a comparison to a well-defined control group using an adequate tool 
for sleep quality (PSQI) and global cognition (MMSE). Although evidence to determine the 
benefit/risk ratio should come from randomised controlled trials (RCTs) with incident users, 
we were not able to perform such a study because most of the time the chronic BZD/Z use 
is already established before admission to the nursing home. Moreover, continuing a long-
term BZD/Z therapy is not concordant with the guidelines. By implementing several exclusion 
criteria, we assembled a well-defined cohort of users, and a comparator group with similar 
demographical and clinical characteristics. In our attempt to minimise indication bias and 
focus on BZD/Z for insomnia, we excluded residents with BZD/Z use for anxiety, and exclud-
ed residents with sedative antidepressants or phytotherapy. Nevertheless, we managed to 
select a relatively large sample of nursing home residents (n=300 at baseline, n=226 at one-
year follow-up). The power was sufficient to detect differences in sleep quality. However, for 
the detection of subtle changes in cognition, a larger sample and a more sensitive cognitive 
measurement tool were required. 
Strength of our discontinuation study (chapter 2.7) lies in its pragmatic approach, which en-
courages an easy translation from research into real-life. However, the sample in our pilot 
study was small and we did not include a control group, thus limiting the interpretations 
towards differences in outcome measurements. A limitation in our cohort study and discon-
tinuation study was our lack of information on comorbidities. We focused on interfering (psy-
chotropic) medication and the impact of depressive symptoms.  Both in our observational 
cohort study and pilot study, we excluded residents with known dementia and disorientation, 
which diminished our sample of eligible residents and consequently limited generalizability. 
On the other hand, this strong focus leads clear interpretation of results in a specific popu-
lation.
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3.     SPECIFIC POINTS OF DISCUSSION
As put forward in many guidelines [1, 2] and explicit criteria for inappropriate prescribing [3-5], 
long-term use of BZD/Z is discouraged. However, in our two cross-sectional studies on BZD/Z 
use in the nursing home setting (PHEBE and barriers study), we saw that chronic use was very 
prevalent. This finding is in accordance with previous studies in this setting [6, 7].
Focus on the indication insomnia
A general characteristic of BZDs is its broad range of physiological effects which results in var-
ious treatment possibilities. This is also the main obstacle for comparing BZD studies. When 
investigating (inappropriate and) off-label prescribing, information on the reasons to initiate 
BZD/Zs together with dosing information is necessary [8]. In most research [9, 10], indication 
analysis is done by linking possible clinical diagnoses, classified with the International Classifi-
cation of Diseases (ICD) or Diagnostic and Statistical Manual of Mental Disorders (DSM), with 
the individual medications. However, this does not automatically provide information on the 
reason or the indication for which each medication was prescribed. To register this informa-
tion automatically in a database, improved software tools are needed to allow the prescriber 
to easily record the indication [11]. 
Optimal geriatric dosing
In our attempt to make an easy guidance for optimal geriatric dosing, we reviewed several 
international pharmaceutical sources with dose recommendations for older adults (interna-
tional formulary[12-14] and explicit criteria for inappropriate prescribing[3, 15, 16]). Overall, there is 
an under-representation of older adults in pharmacokinetic and -dynamic studies leading to 
a lack on dosing information [17]. Most sources stay vague and issue a general dose reduction 
of 50%. Therefore, it is not surprising that most prescribed dosages in older nursing home 
residents exceed recommendations. This finding pinpoints that the prescribing physicians are 
not aware of geriatric dosing regimens, and that the criteria for optimal geriatric dosing for 
BZD/Z use are not well investigated and communicated.
Insomnia and sleep problems in older adults
As mentioned in the introduction, insomnia and sleep problems are, strictly speaking, not the 
same. Daytime impairment is a required item in several insomnia classifications (DSM-V[18], 
ICSD-2[19]). Moreover, subjective exaggeration of sleep difficulties is common and may be 
related to a general tendency to overestimate severity of symptoms [20]. Because it is difficult 
to differentiate between sleep complaints and insomnia, and also because of the elaborate 
aetiological possibilities of insomnia (such as pain, medication use, environmental factors, 
specific sleep disorders-sleep apnoea, somatic and psychiatric comorbidities) a thorough di-
agnostic assessment is necessary before installing a treatment (National guideline Domus 
Medica[21])[22, 23]. This diagnostic assessment should include detailed medical, medication, and 
psychiatric history. The sleep history should cover pre-sleep conditions, sleep-wake patterns, 
other sleep-related symptoms, and daytime consequences, which can help to establish the 
type and evolution of insomnia, perpetuating factors, and identification of comorbid med-
ical, substance, and/or psychiatric conditions [24]. Knowing possible precipitating factors for 
the sleep problems could result in a different treatment strategy, such as an adequate pain 
management, alleviation of depression or a referral to specialist care/sleep clinic for sleep 
apnoea. While a sleep evaluation scale such as a sleep diary is an ideal tool to evaluate sleep 
problems, a more research oriented instrument such as the PSQI could also be useful. In view 
of a good therapeutic adherence it is important to know the expectations of the patient [25, 26].
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An extra impeding factor in aging adults is the physiological change of the sleep architecture. 
The fragmentation with less slow wave sleep (deep sleep) makes the sleep of these older 
adults more vulnerable for interfering comorbidities (such as pain, restless legs,…)[27] and dis-
rupting factors (noise, care routines, nocturia). Moreover, the age-related circadian changes 
are noticeable by the tendency of older adults to go to bed earlier, which also results in earlier 
awakenings [28, 29]. The habit of napping (in the afternoon, or in the early evening-when watch-
ing television) is also prevalent among older adults, and can disrupt the night-time sleep pat-
tern. Discussing sleep patterns and informing patients on sleep hygiene are the initial steps in 
a stepped care approach to treat insomnia. Evaluation of this non-pharmacological approach 
is necessary in order to decide whether there is need for further steps, such as cognitive 
behavioural therapy. As these non-pharmacological treatment strategies imply a well-trained 
GP or psychologist, more time and resources are required for implementation[21, 30].
Alternative pharmacological agents for sleep problems in older adults
Both the BZDs and the Z-drugs have received criticism during the last 30 years, which en-
couraged the search for alternative drugs. Melatonin (licensed in both the US and Europe 
for primary insomnia)[31], a hormone which regulates the circadian rhythm, and a melatonin 
receptor agonist (ramelteon, approved in the US and Japan) [32] have entered the market. 
Though they appear to have a good tolerability, their effect sizes are small [33, 34]. Antihista-
minic drugs (diphenhydramine and doxylamine) are an over-the-counter sedative alternative. 
They bind non-selectively to other neurotransmitter sites which results in their undesira-
ble anticholinergic side-effects [35]. Antidepressants, antipsychotics and anticonvulsants with 
sedative properties are often prescribed for patients with insomnia despite having no FDA/
EMA approved indication to treat insomnia. Although these drug classes might be useful for 
patients with comorbid insomnia, evidence on efficacy and tolerability is lacking and they are 
definitely not recommended as first-line treatment [35]. Nowadays, the sedative antidepres-
sants, mainly trazodone, are increasingly prescribed for insomnia problems [36, 37]. Till now, 
there is little research available on trazodone’s effects and side-effects, which results in the 
absence of official labelling for primary insomnia [38]. Clearly, the poor evidence base for these 
products does not justify their widespread use.
BDZ/Z use and its relationship with depression
Another finding, which surfaced in almost all chapters, was the clear association between 
BZD/Z use and depressive symptoms.  Not only in our studies focusing on BZD/Z use for sleep 
problems, but also in our study analysing antidepressant use for the overlapping indications, 
we saw an association between antidepressant use and BZD/Z use [39, 40]. 
For the indication anxiety, we observed that Belgian physicians preferred BZDs above the 
recommended SSRIs. In recent guidelines, BZDs are relegated for anxiety treatment only as a 
short-term measure during crises or can be co-administered for a short period to overcome 
the delayed pharmacological effect of the antidepressant. But in order to avoid dual therapy, 
the BZD should be tapered (after a maximum of 4 weeks) [1, 41].
We also observed an association between BZD/Z use, bad sleep and depressive symptoms. 
Insomnia and depression can be considered as separate disorders and co-exist, but insomnia 
can also be seen as a risk factor for depression [42], or even perpetuate the development of 
depression [43]. Moreover, sleep problems can be seen as a symptom of depression and are 
often integrated in the diagnostic criteria of screening for depression (Hamilton depression 
rating scale[44]), which makes it difficult to differentiate between pure insomnia symptoms 
and depressive symptoms. Moreover, depression often has an atypical presentation in older 
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adults, which makes a correct diagnosis difficult [45, 46]. The bidirectional relationship between 
insomnia and depression is complex. BZD/Zs which should in fact lessen sleep problems were 
linked to bad sleep and depressive symptoms, in our study as well as in other studies[39, 40]. 
Not treating sleep problems could provoke and worsen the depressive symptoms, although it 
is not well researched whether treating insomnia or depression will automatically impact the 
other[47]. Studies showed that non pharmacological treatments (such as patient-education 
and CBT) reduce sleep problems and positively affect depressive symptoms[48, 49]. 
Next to the BZD/Z’s relationship with depression, our studies showed an association between 
BZD/Z use and pain and psychotropic co-mediation. Another study showed that BZD/Z use is 
linked to a poorer life satisfaction and more somatic and psychological symptoms [50, 51] . Are 
BZD/Z users more psycho-socially vulnerable? Or do they have a greater tendency to express 
complaints? Or both? 
BZD/Z use and the risk on cognitive impairment
The link between chronic BZD/Z use and cognitive impairment has shown up in several stud-
ies [52-55]. The acute effects of BZD/Z use on memory, attention [56] and postural sway [57] have 
been demonstrated. The impaired attentional processes together with the sedative effects 
which impair reaction time and problems with balance/equilibrium lead to impaired driving 
and (car)accidents[58]. The effects of chronic BZD/Z use on the long-term evolution of cogni-
tion are less conclusive [59, 60]. Chronic BZD/Z users perform worse on neurocognitive testing, 
despite the assumed development of tolerance to the acute sedation and impaired atten-
tion[56]. However, most clinical data do not support the existence of tolerance to the BZDs’ 
induced cognitive impairments (memory impairment) [59-61]. Studies investigating cognition 
upon BZD/Z withdrawal showed subtle improvements in cognitive areas [62-64], indicating a 
reversible cognitive impairment. However, a history of long-term daily BZD/Z use shows a 
persistent worse cognition compared to nonusers, even after withdrawal, indicating a persis-
tent influence and incomplete restitution of cognitive function[65].  
In our study, we measured global cognition with the MMSE, which is a much used and vali-
dated instrument to screen cognitive dysfunction in nursing home residents. However, small 
changes in MMSE should be interpreted with care due to measurement error, learning ef-
fects, diurnal fluctuation in alertness and regression to the mean [66, 67]. Therefore we did 
not focus on mean change but enhanced clinical relevance by using a cut-off (a 12 month 
decrease of 4 points or more on the MMSE [68, 69]. Nevertheless, this tool was too crude to 
detect subtle changes in cognition. The importance of cognitive testing with a sensitive cog-
nitive testing battery at baseline and at several follow-up times should give a better idea 
of the impact on cognitive evolution [52]. Another strategy is to concentrate on a relevant 
distant outcome such as severe cognitive decline/dementia. Indeed, dementia has also been 
linked to BZD/Z use [70-73]. However, not controlling for the BZD/Z’s indication (the reason of 
the initiation), and not taking into account co-morbidities, co-medications and psychological 
background have forced critics to question possible causality [74]. Anxiety and sleep problems 
(indications for BZD/Z use), but also depression are possible prodromal effects of early de-
mentia [75]. Moreover, depression, anxiety and sleep problems can influence motivation and 
result in suboptimal performance (effort) on neurocognitive tests [76, 77].
In addition to our observed association between BZD/Z use, sleep problems and depression, 
we found a strong relationship between depression and cognitive impairment. Other studies 
found similar links [78, 79], indicating the existence of a complex psychopathological relation-
ship. Moreover, depression can mimic a dementia state with cognitive deficits leading to the 
functional impairment of depression (pseudo-dementia). This also indicates that the overlap 
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between symptoms of depression and of dementia imposes a diagnostic intricacy. The influ-
ence of depression on cognitive decline is an important topic with a clinical impact, but which 
is difficult to research. Is depression an early-phase symptom of cognitive impairment, is it a 
risk factor, or is it a reaction to cognitive decline? 
BZD/Z’s benefit: effectiveness 
Tolerance and the consequential loss of efficacy undermine the benefit of chronic BZD/Z 
use. There are several hypotheses on the neuro-adaptive mechanism that underlie tolerance, 
although there is no consensus [59]. Tolerance implies that a dose escalation is necessary in 
order to maintain the effects. However, we did not see dosages exceeding the DDD, suggest-
ing that patients do not ask for a dose escalation, maybe due to the presence of a strong 
placebo effect. 
Several meta-analysis showed that placebo treatment also improves the sleep significantly 
[80, 81]. Together with the publication bias[82] and the limited effect sizes[83], one may argue the 
additional benefit of BZD/Zs.
An ideal way to investigate effectiveness of BZD/Zs in clinical studies is to combine objective 
sleep recordings with a subjective sleep scale (sleep diary, sleep questionnaire). Objectifying 
sleep with polysomnography (PSG), which is an in-laboratory (sleep clinics) recording tool, is 
not feasible for long-term follow-up data. Wrist actigraphy is currently the most appropriate 
measure available to objectively record general sleep patterns in the non-laboratory setting, 
although the interpretation should be combined with sleep diaries [84]. The development and 
further validation of other non-invasive, inexpensive and user-friendly objective sleep meas-
ures (e.g. bed sensors and the non-contact biomotion sensor) could provide additional alter-
natives for the evaluation of disordered sleep [85]. Because, the patient’s perception of sleep 
quality remains the determinant of most requests for prescribing hypnotics and is a common 
criterion by which the GP and patient judge efficacy, assessing subjective sleep quality is 
important. In 2005, Devine et al. [86] published a review on subjective measures in sleep med-
icine and concluded that the PSQI, a self-administered questionnaire, which we used in our 
studies, was an ideal patient-reported outcome instrument investigating all relevant sleep 
domains. 
Several studies that assessed short-term effectiveness of BZD/Zs have shown significant im-
provements in both subjective and objective parameters in placebo arms in placebo con-
trolled trials [81], concluding that there is a strong, clinically effective placebo response [87]. 
BZD and Z-drugs were always assumed to be effective on the short-term, but the existence of 
clinical effective placebo response, together with the existence of publication bias and spon-
sorship bias, indicated that the hypnotic drug effects might be overestimated [82].
Long-term effectiveness (is even more difficult to assess and) requires long-term follow-up 
data [88], which is not concordant with the guidelines. Till now, there is one RCT evaluating esz-
opicone for 6 months [89] and one study of a 1-year open-label extension phase of two RCTs of 
zaleplon [90], though in general, the mean duration of BZD/Z use extends the duration of these 
follow-up. A more feasible approach could be to follow new BZD/Z users, evaluate their sleep, 
both objectively and subjectively, at baseline and at fixed time points. However, in the nursing 
home setting, the initiation of BZD/Z is limited. In our study, the sleep quality of chronic BZD/Z 
users was worse compared to nonusers and more importantly, it decreased further in the 
one-year follow-up. This finding highlights the uncertainty regarding long-term effectiveness.
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The nursing home and its impact on sleep quality: organisational influences and policy
Another finding of our observational cohort was the variation in BZD/Z use and sleep qual-
ity among the participating nursing homes. We did not collect institutional characteristics 
that could explain the variation among nursing homes[91]. Structure-related aspects such as 
ownership (private non-profit, private for profit, public), number of beds, number of GPs, 
and organisational-related aspects such as a pharmacist inside the nursing home, electronic 
prescribing (database), regular re-assessment of prescriptions could influence BZD/Z use [92]. 
It would be helpful to detect possible organisation-related indicators of BZD/Z use, as these 
are probably more easily modifiable than subject-related indicators [92]. In general, the quality 
of care improves when a nursing home gives appropriate attention to the different aspects 
of care including medication management[93, 94]. Some nursing homes and staff are aware of 
the abundant psychotropic medication use which could explain the difference in knowledge 
on and attitude towards psychotropic medication. A general knowledge of the pathophysi-
ology of sleep by the care personnel could result in the understanding of altered sleep pat-
terns of older adults, and deliberation of possible solutions. Shortage of staff is a barrier for 
promoting training and implementation of nonpharmacologic interventions to reduce BZD 
consumption [95]. Organisation-related aspects that can also impact sleep quality are envi-
ronmental factors, such as noise and light in the homes’ care routines [96, 97].  Commonly per-
ceived subject-related causes of nocturnal wakefulness in a nursing home are nocturia and 
pain. Although nocturia is difficult to treat [98], some care routines could influence the sleep 
of the residents. Pain was in our study a defining factor of worse sleep quality.  A good pain 
detection and management could result in better sleep [99, 100]. 
Approaches to discontinuation
While there is an abundance of literature about starting medications, there is a scarcity of 
data about discontinuation [101, 102]. In most cases, initiating a BZD/Z consequently leads to 
long-term continuation, and is the reason why BZD/Z use is highly prevalent among nursing 
home residents. Perceived effectiveness, unrecognized side-effects, and psychological and 
physical dependence make it more difficult for a physician to persuade their patient to try 
discontinuation. Moreover, physicians are not familiar with withdrawal and it has not been 
sufficiently implemented in daily practice. 
Most older BZD/Z users for the indication insomnia are low-dose users. Gradual tapering is 
recommended (25% dose reduction every week or bi-weekly)[103], though abrupt discontin-
uation of long-term low-dose treatment seems feasible [104]. The best strategy is to remain 
flexible without prolonging the process [103]. Although there is not much research done on 
which BZD/Z is more resistant to weaning, generally, short-acting BZD/Zs are more likely to 
cause withdrawal symptoms upon discontinuation than long-acting BZDs. Therefore, substi-
tution with a long-acting BZD (diazepam) can lessen (and delay) withdrawal symptoms[103]. 
However, it is not appropriate to use long-acting BZD/Zs in older adults (cfr. all explicit crite-
ria). The long half-life can result in accumulation. Therefore, substitution with an intermedi-
ate working BZD/Z (lorazepam/lormetazepam) or simply stay with the same product when 
discontinuing is advised. Substitution with other medications is not firmly established (Lader 
et al 2009). Psychological interventions which aid withdrawal, such as Cognitive Behavioural 
Therapy (CBT), have shown to be effective [105, 106], also in older adults [107]. These psycho-
logical techniques are intended to facilitate withdrawal and motivate patients to maintain 
abstinent over time (relapse prevention). More importantly, they may treat any underlying 
psychological disorder [103, 107]. CBT includes psycho-education (advantages and disadvantages 
of chronic BZD/Z use), cognitive restructuring techniques (tackling unrealistic expectations, 
apprehension and misattribution of withdrawal symptoms) and behavioural techniques (such 
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as relaxation, sleep deprivation, stimulus control).
Discontinuation in the nursing home setting
In our thesis, we wanted to focus on discontinuation which is feasible in the nursing home. A 
meta-analysis focusing on older adults showed that the best strategy for discontinuing BZD/Z 
in older adults was the combination of supervised withdrawal with psychotherapy [107]. Super-
vising the withdrawal in a setting with supporting care personnel is possible, but delivering 
psychotherapy seems more difficult to implement. A promising strategy for reducing BZD/
Zs in the nursing home, next to other inappropriate prescriptions, was the implementation 
of a (clinical) pharmacist medication review [108, 109]. Often, the pharmacists gave recommen-
dations or feedback to the nursing staff and delivered  “an educational message”. Also a 
programme led by a psychologist which educated prescribers and caregivers, offered health 
education and relaxation training to the residents, reduced the overall prevalence of BZD/Z 
use (from 70% to 35%) in this setting [110]. The educational tools used in long-term care facil-
ities varied from prescribing algorithms and bulletins to staff meetings and lectures [111]. But 
educational interventions alone cannot be expected to change behaviour when health care 
providers do not perceive it to be important, or when the change is complex and dependent 
on the interaction of many stakeholders. The nursing home is an environment where several 
disciplines are involved in the treatment decisions (patient, GP, specialist, geriatrician, nurse, 
family, pharmacists), and influence prescribing [112]. Moreover, there are several visiting GPs 
per nursing home and there is a large equip of nursing staff (day and night team), which makes 
clear straightforward communication difficult. However, a good communication is necessary 
to avoid contradiction and to ensure seamless care. Therefore, the educational interventions 
should be multi-faceted and targeting this variety of people, rather than just targeting GPs. 
The nursing home should invest in a well-structured medication management. There should 
be a  periodic reassessment of the medication chart, taking into account the perception of 
the GP, nurse and patient. The pharmacist with his specific medication expertise could also be 
involved in the multidisciplinary communication between nurses and prescribers. They can 
monitor (chronic) consumption and advise withdrawal schemes.
Several studies have investigated BZD/Z withdrawal in the nursing home setting and focused 
on the success rate (focus on residents already willing to discontinue) [63, 64, 110, 113]. However, 
health policy makers should have an idea of the extent of the target population and the over-
all feasibility, including the willingness towards discontinuation in this setting. Therefore, GP, 
nurse, but more importantly, the patient has to be susceptible towards change. In our studies 
(barrier study and feasibility study), the lack of motivation seemed a strong barrier which 
impacts willingness. Moreover, a lack of knowledge on non-pharmacological treatments and 
a lack of time to administer, make it difficult for health providers to offer alternatives when 
withdrawal or rebound symptoms emerge. Some studies show that patients are susceptible 
towards change. Therefore it is advised to routinely raise the issue of discontinuation and 
negotiate dose reduction [26, 114]. Nevertheless, ‘reluctance towards change’ in this older pop-
ulation is expected because their sleeping pill has become a daily routine and because this 
frail population has limited prospects for clinical improvement. 
However, discontinuing BZD/Zs has been linked to positive effects on sleep quality, cognition 
and quality of life [62-64]. Also in our pilot study, we saw that the residents with successful 
discontinuation had less midnight awakenings and perceived a better sleep quality than be-
fore the discontinuation. This can be persuasive to try discontinuation but should be further 
explored. An overall conclusion of our pilot study was that the willingness towards discontin-
uation was low, but in case the GP and resident approved, the success rate was satisfactory 
(66%). Moreover, if we included the residents with a dose reduction, which is an acceptable 
second option in older adults, the success rate was 82%. This finding indicates that for several 
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people the last step in a discontinuation i.e. stopping the BZD/Z is the most difficult in terms 
of psychological dependence. 
Because of the controversy towards medication withdrawal (ethical) and because of the diffi-
culty of monitoring study outcomes (withdrawal symptoms, sleep quality…) in residents with 
disorientation/dementia, we only included cognitively capable residents in our studies (ob-
servational cohort study and discontinuation study). However, there are many residents in 
nursing homes with dementia. The question remains whether these residents would benefit 
from discontinuing BZD/Zs. 
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CONCLUSION
Based on the results in this thesis and the experiences gained during the practical realisation 
of this work, we present our ideas and vision for future research and possible improvement 
of the practice.
1.     IMPLICATIONS FOR RESEARCH
Although many studies have investigated BZD/Z use, several items remain unexplored territo-
ry or should be researched more into detail.
Basic-Clinical-Pharmacological research
- The evidence base for dosing recommendations for specific indications, and for the geriatric 
population needs to be strengthened by including older adults in pharmacological research.
- In order to strengthen the evidence that BZDs and the newer, chemical different, Z-drugs 
are similar in benefits and risks, there is a need for more research which directly compares 
those 2 groups.
- Discontinuation schedules should be explored with specific reports for each of the BZD or 
Z-drug in their specific indication.
- There is a need for screening and diagnostic tools which could help prescribers to differenti-
ate between sleep problems and several insomnia types (comorbid insomnia).
-The complex psychopathological pathways of insomnia, depression and its influence on cog-
nitive decline need to be further investigated. 
- There is a need for valuable instruments which can measure subtle cognitive evolution in 
nursing home residents.
- In order to investigate the effectiveness of BZD/Z use in the short-term, research which di-
rectly compares placebo groups and untreated groups are necessary to unmask the placebo 
effect. 
- In order to investigate the long-term effectiveness, RCTs with incident users and follow-up 
time that exceeds 6 months are essential.
- Research on effectiveness should combine objective sleep evaluation with subjective pa-
rameters (sleep questionnaires, sleep diaries). The development and further validation of 
non-invasive, inexpensive and user-friendly objective sleep measures are necessary for im-
plementation in the real-life setting. 
- Further research should decide whether BZDs are effective when used chronically for anxi-
ety problems, and whether discontinuation is possible in this indication.
- The effectiveness of trazodone for sleep problems in older adults, together with its discon-
tinuation possibilities should be investigated.
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Implementation research
- Further research should validate the improvements of psychological and behavioural treat-
ments on sleep and should concentrate on the clinical applicability and economic feasibility 
of non-pharmacological approaches.
- Studies with a long follow-up, with inclusion of comorbidities, and with a sensitive cognitive 
testing battery at baseline and at several follow-up times should give robust findings on the 
impact of BZD/Zs on cognitive evolution.
- In order to corroborate the finding of improving the sleep quality upon BZD/Z discontinua-
tion, future research should perform our pilot study on a larger scale with a matched control 
group, and with objective measurement tools.
- More research is needed to decide whether a discontinuation campaign in the nursing home 
setting is cost-effective in both cognitively competent and impaired residents and whether an 
expansion to the home-dwelling older adults is feasible.
2.     IMPLICATIONS FOR PRACTICE
The studies and findings of this thesis have led to specific recommendations towards BZD/Z 
use and its discontinuation in older nursing home residents.
When we want to reduce chronic BZD/Z prescribing, we should prioritize insomnia, given 
its high prevalence as a primary indication. Guidelines on insomnia treatment promote in-
vestigating the cause of insomnia together with non-pharmacological treatments, such as 
psychotherapy, CBT and psycho-education, because they have better durability as manifest-
ed by stable gains at follow-ups. However, before treating insomnia and its possible cause, 
diagnostic evaluation is important. Screening for depressive symptoms should be performed 
routinely as they are often associated with bad sleep. Sleep diaries could help GPs in evaluat-
ing and objectifying the subjective sleep complaint of their patient. Though insomnia is a dis-
abling disease which needs treatment, establishing a pharmacological treatment too quickly, 
eventually leading to chronic continuation is not favourable for the patient in the long run. 
Therefore, efforts to reduce initiation are fundamental. Sleep quality and possibly cognitive 
function are negatively affected by this medication. Good communication on time-limited 
use and a trade-off between benefits and risks on an individual basis can diminish the pa-
tient’s request for sleeping pills and makes a proposal to discontinue more acceptable. 
In the nursing home setting, where the BZD/Z use is chronic, discontinuation is feasible. How-
ever, there is a lack of willingness and a reluctance towards change which seems difficult but 
not impossible to overcome. Frequently perceived barriers among GPs and nurses towards 
discontinuation are the emerging of dependence and the persistent perception that BZD/Zs 
are effective, even in chronic use. As our study showed, a good sleep quality is not associated 
with the BZD/Z use. Informing and educating all involved actors such as prescribers, caregiv-
ers, patients and also family, on the negative effects of chronic BZD/Z use and the positive 
prospects of discontinuation should help to reach a consensus. Assessing the need to discon-
tinue medication in older adults is not yet a routine procedure and is especially difficult when 
it concerns chronic BZD/Zs for insomnia problems, as there is a general lack of confidence 
in the successful outcome of BZD/Z discontinuation. Although it was not the intention of 
our pilot study to investigate the optimal strategy to implement discontinuation in a nursing 
home, our recruitment letter to the GP was a reminder of the chronic BZD/Z use of their 
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patients and was the trigger to question this chronic use and even try to stop. An extra visit 
to the resident to discuss and verify discontinuation was also supportive. In order to achieve 
a better quality of medication management, a regular reassessment of the medication chart 
is necessary. In the nursing home, both the expertise and information of the nurse and GP 
are necessary in this communication, but the pharmacist could contribute to this multidis-
ciplinary consultation and even guide the medication discontinuation (withdrawal scheme).
It is not sufficient that only the caregivers consider a possible discontinuation, the patient’s 
motivation remains the determinant for success. In order to convince patients in chang-
ing their chronic therapy, GPs should be educated in motivational techniques. Moreover, 
non-pharmacological alternatives, manageable in the nursing homes, could support the dis-
continuation. Therefore GPs, nurses, but also psychologists could be educated for the guid-
ance of the discontinuation. 
In our study, we showed that once there is agreement on initiating discontinuation, the suc-
cess rate is high (66% succeeded in remaining BZD/Z free for at least 8 months). Additionally, 
a small group discontinued to half the dose, as a full stop was not possible due to possible 
rebound insomnia or psychological dependence. Considering a dose reduction (even when 
a full BZD/Z stop does not seem feasible) is a good second option in this frail population 
with psychotropic polypharmacy. Our approach towards discontinuation is scalable and a 
commendable candidate for larger implementation programs. The nursing home may be a 
protected environment where GPs (and other care personnel) can familiarize with discontin-
uation efforts, gain confidence and even gradually extend these efforts to the large commu-
nity of home dwelling older adults.
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1.     SUMMARY
With this thesis we add to the debate on the discrepancy between the existing guidelines 
cautioning against chronic benzodiazepine and Z-drug (BZD/Z) use and its high prevalence, 
especially among older nursing home residents in Belgium. In order to understand and tackle 
this highly prevalent BZD/Z use, we contributed to the research on the benefit/risk ratio, and 
on possible discontinuation in this setting.
Because most studies on BZD/Zs do not differentiate between use for insomnia or for anx-
iety or other indications and because guidelines on optimal geriatric dosing are vague, we 
explored indications and dosages of chronic BZD/Z use in a representative sample of Belgian 
nursing home residents (PHEBE database 2006) (Chapter 2.1). The main indication of chronic 
BZD use was insomnia (59%). In order to guide clinicians, we listed most of the existing dose 
recommendations and retrieved a pragmatic threshold, the “geriatric upper limit”. Overall, 
BZD/Zs were used at low dosages (in terms of defined daily dosages and diazepam equiva-
lents), but were not adapted to the geriatric population, especially in the indication insomnia.
Before further focussing on BZD/Zs for insomnia, we also explored the use of antidepres-
sants for the overlapping indications of insomnia and anxiety in the PHEBE database (Chapter 
2.2). Despite the absence of clear evidence and despite the absence of official labelling, in 
Belgium, Europe, and the US, sedative antidepressants (mainly trazodone) are increasingly 
prescribed for primary insomnia without concomitant depressive symptoms (13% of all anti-
depressant prescribing is for the sole indication of insomnia). Although, antidepressants are 
advised for chronic anxiety, only 14 % of the residents with this indication received an antide-
pressant (mostly a Selective Serotonin Reuptake Inhibitor), and the remaining received a BZD.
In an observational cohort study (convenience sample of 10 nursing homes) of cognitively 
competent residents, we investigated the chronic effectiveness of BZD/Z use in terms of sleep 
quality (Chapter 2.3 and 2.4), and also explored the worrisome link with cognitive decline 
(Chapter 2.5). By implementing several exclusion criteria, we composed a well-defined co-
hort of chronic BZD/Z users for the indication insomnia, and a comparator group of nonusers, 
free of any hypnotic medication (also excluding sedative antidepressants). These two groups 
had similar demographical and clinical characteristics and were followed for one year. We 
used a self-administered questionnaire, the Pittsburgh Sleep Quality Index (PSQI), to eval-
uate sleep quality as perceived by the resident. The sleep quality in chronic BZD/Z users 
was significantly worse compared to nonusers both at baseline and at one-year follow-up. 
More specifically, chronic BZD/Z users reported more difficulties with falling asleep, reported 
a higher frequency of midnight awakenings, and a higher frequency of not being well rested 
in the morning. The one-year follow-up results revealed that the sleep quality of the BZD/Z 
users deteriorated significantly. The comorbidity ‘depression’ was in this study a significant 
factor in worsening sleep quality.
In addition to other possible risk factors, we wanted to explore the impact of BZD/Zs on a 
clinically relevant decrease in cognition (Chapter 2.5). We measured global cognition with 
the Mini Mental State Examination (MMSE). We found that the general cognition of nursing 
home residents decreased significantly in one year, both in the group of BZD/Z users and 
in the nonusers, but there was no significant difference in mean MMSE decrease between 
those two groups. When focusing on clinically relevant cognitive decrease, there were 34% 
BZD/Z users with severe deterioration (decrease of 4 or more points in one year) compared 
to 27% nonusers, but this small difference was not significant. The strong risk factor for fast 
cognitive decline was ‘depression’.
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An interesting finding in our five studies was the appearance of a relationship between BZD/Z 
use, depression, sleep problems and cognitive impairment, indicating the existence of a com-
plex relationship.
In order to tackle the highly prevalent BZD/Z use among nursing homes residents, the focus 
should be on discontinuation, since for most residents the use is already established before 
their admission to the nursing home (Chapters 2.6 and 2.7). The nursing home, which is a 
more controlled setting, can be valuable to guide BZD/Z discontinuation in this older popu-
lation. Moreover, GPs and other care personnel can familiarize with discontinuation efforts, 
and possibly extend these efforts to the large community of home dwelling older adults.
First, we performed a cross-sectional survey on perceptions of benefit and harm, the willing-
ness to stop and perceptions towards barriers against discontinuation of BZD/Zs among the 
two main caregivers in the nursing home setting, the GP and nurse (Chapter 2.6). We approx-
imated the real-life setting by focusing on perceptions pertaining to an individual resident. 
GPs as well as nurses considered the chronic use of BZD/Zs to be still effective and did not 
report many noticeable side-effects, except for dependence. Together with the expected re-
sistance from the resident, all these factors contributed to the low willingness to discontinue 
BZD/Zs; GPs were willing in one third, while nurses were willing in one fifth of their residents. 
Overall, the level of agreement between GP and nurse was low, which illustrates the need for 
more structured interdisciplinary contacts.
Finally, in a pilot study in 5 nursing homes, we assessed the overall feasibility, incorporating 
both the willingness towards discontinuation and also the success rate of discontinuation, 
with a follow-up of 8 months (Chapter 2.7). Our focus on cognitively competent residents, 
using BZD/Z only for insomnia led to a small sample of 135 eligible residents on a total of 
823. Our minimal intervention, sending a recruitment letter to the GP of each BZD/Z user and 
obtaining informed consent in those residents where the GP agreed, showed that in only 38 
residents both GP and resident were willing to discontinue. Lack of motivation was the main 
barrier to refuse discontinuation. Nevertheless, discontinuation of chronic BZD/Z use in those 
38 nursing home residents was feasible without noticeable withdrawal symptoms, without a 
switch to other medication, without a detrimental effect on quality of life, and with a positive 
effect on the sleep quality. Our analysis at 8 month follow-up showed that 66% succeeded in 
stopping their BZD/Z use. Moreover, if we included also the residents with a dose reduction, 
which is an acceptable second option in this frail population with psychotropic polypharmacy, 
the success rate was 82%. Our approach towards discontinuation is scalable and a commend-
able candidate for larger implementation programs. 
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2.     SAMENVATTING
Met deze doctoraatsthesis willen wij een bijdrage leveren aan het onderzoek naar het hoge 
gebruik van benzodiazepines en gerelateerde Z-medicatie (BZD/Z) en de betwistbare risi-
co-baten balans van dit chronisch gebruik. We concentreerden ons op de grootste gebruik-
ersgroep, de oudere rusthuisresidenten, en focusten op het gebruik voor slaapproblemen. 
Met deze thesis onderzochten we naast het hoge gebruik, ook de mogelijke stopzetting van 
chronisch BZD/Z gebruik in deze setting.
Omdat de meeste studies geen onderscheid maken tussen BZD/Z gebruik voor slaapprob-
lemen, voor angst, of voor andere indicaties, en omdat richtlijnen over doseringen bij ou-
deren vaag zijn, hebben wij de indicaties en gerelateerde dosissen van BZD/Z gebruik in een 
representatieve steekproef van Belgische rusthuisresidenten (PHEBE database 2006) onder-
zocht (Hoofdstuk 2.1). De meest voorkomende indicatie voor chronisch BZD/Z gebruik was 
slaapproblemen (59%). Om een leidraad te bieden aan clinici hebben we bestaande doser-
ingsaanbevelingen geanalyseerd en samengevat in een pragmatische “geriatrische maximale 
dosis”. De gerapporteerde dosissen waren voor alle indicaties niet echt hoog, maar waren 
niet aangepast aan de geriatrische populatie.
Alvorens we ons verder hebben toegespitst op BZD/Z gebruik voor slaapproblemen, onder-
zochten we in dezelfde PHEBE databank het antidepressiva gebruik voor de overlappende 
indicaties (slaapproblemen en angst) (Hoofdstuk 2.2). Ondanks het ontbreken van bewijs van 
effectiviteit én het uitblijven van officiële registratie worden sederende antidepressiva (voor-
namelijk trazodon) steeds meer voorgeschreven voor insomnia, zonder dat er depressieve 
symptomen aanwezig zijn. Wij vonden dat voor de indicatie chronische angst, er slechts in 
14% een antidepressivum werd voorgeschreven, en voor het overgrote deel een BZD. No-
chtans stellen richtlijnen bepaalde antidepressiva (selectieve serotonine heropname rem-
mers) voor als eerste keuze.
In een observationele cohort studie van cognitief bekwame rusthuisbewoners onderzochten 
we het langdurig effect van BZD/Z gebruik op de slaapkwaliteit (Hoofdstuk 2.3 en 2.4) en 
het risico van chronisch BZD/Z gebruik op de cognitieve achteruitgang (Hoofdstuk 2.5). In 
een willekeurige steekproef van 10 rusthuizen, groepeerden we chronische gebruikers van 
BZD/Zs voor de indicatie slaapproblemen en een controle groep van niet-gebruikers, vrij van 
allerhande slaapmedicatie. Deze twee gedefinieerde groepen volgden we gedurende 1 jaar. 
Omdat de slaapperceptie van de patiënt de bepalende factor is voor het beoordelen van de 
slaapkwaliteit, gebruikten we een vragenlijst die de patiënt zelf moest invullen, namelijk de 
gevalideerde Pittsburgh Sleep Quality Index (PSQI). Aan de hand van dit instrument konden 
we besluiten dat de slaapkwaliteit van chronische BZD/Z gebruikers slechter was dan deze 
van de niet-gebruikers, zowel bij baseline als na 1 jaar follow-up. Meer in detail, de BZD/Z 
gebruikers hadden meer moeite met inslapen, rapporteerden meer nachtelijke ontwakingen 
en waren niet voldoende uitgerust ’s morgens. Tijdens de 1-jaar follow-up werd de slaapkwal-
iteit significant slechter in de BZD/Z groep, waar dit in de controle groep niet significant was. 
Een grote invloed op de slechter wordende slaap was de co-morbiditeit ‘depressie’.
Naast andere beïnvloedende factoren onderzochten we of chronisch BZD/Z gebruik een im-
pact had op de klinisch relevante cognitieve achteruitgang. We gebruikten het gevalideerde 
Mini Mental State Examination instrument om de globale cognitie te screenen. We vonden 
dat de algemene cognitie significant daalde tijdens de 1-jaar follow-up, zowel in de groep 
van chronische BZD/Z gebruikers als in de controle groep van niet-gebruikers. Wanneer we 
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focusten op klinisch relevante cognitieve achteruitgang, zagen we procentueel meer BZD/Z 
gebruikers met een grotere achteruitgang (MMSE daling van minstens 4 punten op een totaal 
van max 30 punten), hoewel dit kleine verschil niet significant was (34% vs. 27%). De meest 
bepalende risicofactor voor snelle cognitieve achteruitgang was depressie.
Een interessante bevinding in ons onderzoek die zeker verder onderzocht moet worden was 
het opduiken van de relatie tussen BZD/Z gebruik, slechte slaap, depressie, en cognitieve 
achteruitgang.
Indien we het chronisch BZD/Z gebruik in de rusthuissetting willen aanpakken, zullen we ons 
moeten richten op afbouw en stopzetting, omdat deze medicatie gewoonlijk opgestart werd 
voor opname in het rusthuis. De rusthuissetting is een waardevolle gecontroleerde setting 
om BZD/Z afbouw te monitoren in de oudere populatie.
Een eerste exploratie van de percepties over afbouw van BZD/Zs verkregen we in een 
cross-sectionele studie bij huisartsen en verpleegkundigen (Hoofdstuk 2.6). Aan de hand van 
een vragenlijst onderzochten we percepties tegenover de risico-baten verhouding, de bereid-
heid tot stoppen en eventuele barrières tegenover stoppen. We benaderden de real-life sit-
uatie door steeds te focussen op een specifieke resident met chronisch BZD/Z gebruik. De 
huisartsen en verpleegkundigen beschouwden het gebruik van BZD/Zs nog steeds als effec-
tief en ze rapporteerden buiten afhankelijkheidsproblemen, nauwelijks bijwerkingen. Samen 
met de verwachte weerstand bij de patiënt, zorgden deze factoren voor een algemene lage 
bereidheid tot afbouw: huisartsen waren bereid bij 1 op 3, en verpleegkundigen bij 1 op 5 be-
woners. Over het algemeen was de onderlinge overeenstemming tussen huisartsen en ver-
pleegkundigen laag, wat er op wijst dat gestructureerde overlegmomenten noodzakelijk zijn.
In onze pilootstudie in 5 rusthuizen onderzochten we de algehele haalbaarheid van afbouw in 
deze setting. We onderzochten zowel de bereidheid tot afbouw, alsook het slaagpercentage 
van afbouw in een pilootstudie met 8 maand follow-up (Hoofdstuk 2.7). Onze focus op cogni-
tief gave bewoners met chronisch BZD/Z gebruik voor slaapproblemen leidde tot een kleine 
sample van 135 geschikte bewoners (op een totaal bewonersaantal van 823). Onze minimale 
interventie bestond uit het versturen van een rekruteringsbrief naar de huisarts van de chro-
nisch BZD/Z gebruiker en, bij akkoord van de huisarts, het vragen van medewerking aan de 
resident. In slechts 38 bewoners waren zowel huisarts als bewoner bereid tot afbouw. Een 
tekort aan motivering was de voornaamste barrière tegenover afbouw. We konden aantonen 
dat na 8 maand 66% erin slaagde te stoppen, zonder afbouwsymptomen, zonder een switch 
naar andere medicatie, zonder een negatieve invloed op de levenskwaliteit, én met een pos-
itief effect op de slaap. Daarbovenop waren er ook enkele bewoners die hun BZD/Z dosis 
halveerden, wat ook een wenselijk gevolg is bij ouderen. Deze aanpak kan toegepast worden 
op grotere schaal, het maakt de huisarts (en verpleegkundigen) vertrouwd met afbouw, en 
kan eventueel leiden tot een uitbreiding naar de thuiswonende ouderen. 
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2.   MINI MENTAL STATE EXAMINATION -MMSE
reference: Folstein 1975
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3. PITTSBURGH SLEEP QUALITY INDEX-PSQI
reference: Buysse 1989 & Verster 2008 (Dutch translation)
DEEL 1: Vul het gepaste antwoord in de kadertjes in.
Vraag 1: Om hoe laat wou je gewoonlijk gedurende de afgelopen maand ’s avonds gaan slapen?
Ø	Gebruikelijke bedtijd: 
Vraag 2: Hoeveel minuten duurde het de voorbije maand gewoonlijk elke nacht vooraleer je in slaap 
viel?
Ø	Aantal minuten: 
Vraag 3: Hoe laat werd je gedurende de afgelopen maand ’s ochtends gewekt?
Ø	Gebruikelijk tijdstip van opstaan:
Vraag 4: Aan hoeveel uren SLAAP kwam je gemiddeld per nacht tijdens de voorbije maand? (Dit 
aantal kan verschillen van de het aantal uren dat je in bed doorbracht)
Ø	Aantal uren ECHTE SLAAP per nacht:
DEEL 2:   Zet bij de volgende vragen een kruisje in het vakje onder het antwoord dat op u van 
toepassing is. Sla geen vragen over.
Vraag 5: Hoe vaak had je tijdens de voorbije maand moeilijkheden met slapen, omdat je… 
(zie stellingen: a - j) 
Niet tijdens de 
voorbije maand (0)
Minder dan 1x per 
week
(1)
1 of 2x per 
week
(2)
3 of meer keer 
per week (3)
a. niet in slaap kon 
vallen binnen de 30 
minuten
    
b. midden in de 
nacht of in de 
vroege morgen 
wakker werd
    
c. naar het toilet 
moest gaan     
d. niet makkelijk 
kon ademhalen     
e. luid hoestte of 
snurkte     
f. het te koud had?     
g. het te warm had?     
h. nachtmerries 
had?     
i. pijn had?     
j. (een) andere 
reden(en) had?     
Omschrijf je 
probleem: ………………………………………………………………………...........
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DEEL 3 : Zet een kruisje in het vakje bij het antwoord dat voor jou het meeste van toepassing is. 
Sla geen vragen over.
Vraag 6
Wat vind je van je 
slaapkwaliteit de 
afgelopen maand?
  ik slaap 
zeer goed (0)
  ik slaap redelijk 
goed (1)
  ik slaap 
eerder slecht 
(2)
  ik slaap zeer slecht 
(3)
Vraag 7
Neem je ’s avonds 
medicatie om te 
slapen?
  niet 
tijdens de 
voorbije 
maand (0)
  minder dan 1x 
per week (1)
  1 of 2 
maal per 
week (2)
  3 of meer maals per 
week (3)
Vraag 8
Hoe vaak had je het 
de voorbije maand 
moeilijk om wakker 
te blijven tijdens je 
dagelijkse activiteiten 
zoals eten, radio 
luisteren, tv kijken
 niet 
tijdens de 
voorbije 
maand (0)
  minder dan 1x 
per week (1)
  1 of 2 
maal per 
week (2)
  3 of meer maals per 
week (3)
Vraag 9
In welke mate was het 
de voorbije maand een 
probleem voor je om 
uitgerust aan de dag te 
beginnen? Je voelde 
je ’s ochtends bij het 
ontwaken nog te moe 
om je uitgeslapen te 
voelen?
  geen 
enkel 
probleem (0)
  slechts een klein 
probleem (1)
  toch wel 
een probleem 
(2)
  heel groot probleem
(3)
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Ø	Aantal minuten: 
Vraag 3: Hoe laat werd je gedurende de afgelopen maand ’s ochtends gewekt?
Ø	Gebruikelijk tijdstip van opstaan:
Vraag 4: Aan hoeveel uren SLAAP kwam je gemiddeld per nacht tijdens de voorbije maand? (Dit 
aantal kan verschillen van de het aantal uren dat je in bed doorbracht)
Ø	Aantal uren ECHTE SLAAP per nacht:
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toepassing is. Sla geen vragen over.
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Minder dan 1x per 
week
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4. GERIATRIC DEPRESSION SCALE (GDS-8)
reference: Jongenelis et al 2007, Smallbrugge et al 2008
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5. SOCIALE CONTACTEN-PIJN BEVRAGING
developed specifically for our research 
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6. QUESTIONNAIRES CHAPTER 6
developed specifically for our research
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   Masteropleiding Verpleeg- en Vroedkunde                                            
Studienummer wzc       □□□ 
Studienummer resident    □□□ 
 
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST RESIDENT  
Gelieve hieronder de gegevens van de resident aan te kruisen of in te vullen.  
Alvast bedankt voor uw medewerking aan dit onderzoek.   
1. PERSOONSKENMERKEN VAN DE RESIDENT 
1.1. Wat is het geslacht van de resident? 
1 □  man                            2 □  vrouw 
1.2. Wat is de leeftijd van de resident? 
 …… jaar 
2. VERBLIJFSGEGEVENS VAN DE RESIDENT 
2.1. Hoelang verblijft de resident al in dit woon- zorgcentrum? 
            .…… jaar …… maanden 
2.2. Verblijft de resident op een open of gesloten afdeling? 
1 □ open 2 □ gesloten 
3.  BIJKOMENDE GEGEVENS VAN DE RESIDENT 
3.1. Gelieve de Katz- schaal van deze resident in te vullen (zie ommezijde) 
3.2. Wat is het resultaat van de meest recente MMSE- score?              
             Totaalscore: ..…/30 
3.3. Gelieve de merknaam of stofnaam van benzodiazepine of z-drug te noteren,              
totale voorgeschreven dagelijkse dosis en moment van inname (medicatiefiche) 
Merknaam of stofnaam 
 
Totale voorgeschreven 
dagelijkse dosis 
Toedieningsmoment: 
8-12-17-20u 
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                         Masteropleiding Verpleeg- en 
Vroedkunde                                            
                Studienummer wzc       □□□ 
                Studienummer huisarts  A□□ 
 
                                                                            
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST HUISARTS (deel 1) 
Gelieve hieronder uw gegevens aan te kruisen of in te vullen. Indien u als huisarts meerdere residenten 
hebt die aan deze studie deelnemen, dient u dit formulier slechts één keer in te vullen. Alvast bedankt voor 
uw medewerking aan dit onderzoek.  
1. ALGEMENE KENMERKEN 
1.1. Wat is uw geslacht? 
1 □  man                       2 □  vrouw 
1.2. Wat is uw leeftijd? 
…… jaar 
1.3. Hoelang werkt u al als huisarts? 
…… jaar 
1.4. Hoelang komt u al in dit woon- zorgcentrum langs? 
…… jaar 
1.5. Bent u CRA van het woon- zorgcentrum waar het onderzoek door gaat? 
                         0 □  neen   1 □  ja 
1.6. Indien u geen CRA bent: Hoeveel keer hebt u in 2011 met CRA overleg gehad? 
             (overleg= overleg dat wordt gehouden tussen de CRA en de huisarts en waarvan een  
                             verslag terug te vinden is) 
             …… keer 
2. ALGEMENE HOUDING OVER MOGELIJKE BARRIÈRES VOOR HET AFBOUWEN 
OF STOPZETTEN VAN BENZODIAZEPINE (BENZO) OF Z-DRUG 
In dit deel kan u een antwoord geven op de mate waarin u volgende stellingen als een barrière 
(belemmering) ervaart. Duid met een kruisje aan in welke mate dat overeenkomt met uw ervaring; van 
geen barrière (in geen mate) tot een sterke barrière (in sterke mate). 
Barrière Score 
1.Ik heb onvoldoende noodzakelijke wetenschappelijke  
informatie om benzo of z-drug af te bouwen of stop te 
zetten. 
      in geen mate □□□□□□□□□□ in sterke mate 
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                           Masteropleiding Verpleeg- en 
Vroedkunde                                            
               Studienummer wzc       □□□ 
               Studienummer huisarts  A□□ 
               Studienummer resident □□□              
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST HUISARTS (deel 2) 
Gelieve hieronder de gegevens voor elke geselecteerde patiënt aan te kruisen of in te vullen.   
Alvast bedankt voor uw medewerking aan dit onderzoek.  
 
1. INDICATIE EN GEBRUIK VAN BENZODIAZEPINE (BENZO) OF Z-DRUG BIJ DEZE RESIDENT 
1.1. Voor welke indicatie werd de benzo of z-drug bij deze resident voorgeschreven?                             
(meerdere antwoorden zijn mogelijk) 
1 □  slapeloosheid  3 □  depressie      5 □  ik weet het niet  
2 □  angst   4 □  kalmering (acute agitatie)          6 □  andere:…………. 
 
1.2. A. Waar is deze resident met de benzo of z-drug gestart?  
0 □  onbekend (ga naar vraag 1.3) 
1 □  gestart alvorens het verblijf in het wzc  (ga naar vraag B)                  
2 □  gestart tijdens het verblijf in het wzc (ga naar vraag B)                     
3 □  gestart tijdens ziekenhuisopname gedurende het verblijf in het wzc (ga naar vraag B) 
  
B. Hoelang gebruikt de resident de benzo of z-drug?   
             …… jaren   …… maanden 
 
1.3. Werd er het afgelopen jaar…? 
         1   overwogen om de dosis te verminderen?                           0 □ neen         1 □ ja     
        2   een poging ondernomen om de dosis te verminderen?                  0 □ neen         1 □ ja 
       3   overwogen om te stoppen?                                        0 □ neen         1 □ ja    
       4   een poging ondernomen om te stoppen?                                       0 □ neen         1 □ ja    
  
1.4. Zou volgens u de benzo of z-drug bij deze rusthuisresident kunnen gestopt worden? 
                                            0 □ neen    1 □ ja      
                        reden: …………………………………………….. 
 
 
2. Ik heb onvoldoende kennis over mogelijke 
alternatieven om problemen bij afbouwen of stopzetten 
van benzo of z-drug op te vangen. 
in geen mate □□□□□□□□□□ in sterke mate 
Barrière Score 
3. Het uitproberen van alternatieven voor benzo of z-
drug kost teveel tijd en moeite.  in geen mate □□□□□□□□□□ in sterke mate 
4. De afwezigheid van een psycholoog in het wzc vormt 
een barrière om de afbouw of het stopzetten van benzo  
of z-drug te ondersteunen. 
in geen mate □□□□□□□□□□ in sterke mate 
5. Het ritme in het wzc (het vroege slapen gaan) vormt 
een barrière om te kunnen afbouwen of stoppen met 
benzo of z-drug. 
in geen mate □□□□□□□□□□ in sterke mate 
6. Hoe langer de resident de benzo of z-drug neemt, hoe 
moeilijker het is om af te bouwen of te stoppen. in geen mate □□□□□□□□□□ in sterke mate 
7. Het overlegmoment tussen huisarts en 
verpleegkundige is te kort om over afbouwen of 
stopzetten van benzo of z-drug te praten.  
in geen mate □□□□□□□□□□ in sterke mate 
8. Het gebruik van een elektronisch herhalingsmedicatie-
voorschrift zorgt ervoor dat er niet kan overlegd worden 
over eventueel afbouwen of stopzetten van benzo of         
z-drug. 
   in geen mate □□□□□□□□□□ in sterke mate 
9. Het ontbreken van een apotheker verbonden aan het 
wzc vormt een barrière om het afbouwen of stopzetten 
van benzo of z-drug te ondersteunen. 
in geen mate □□□□□□□□□□ in sterke mate 
10. De leeftijd van residenten en het langdurig gebruik 
van benzo of z-drug maken het zinloos om af te bouwen 
of te stoppen.  
in geen mate □□□□□□□□□□ in sterke mate 
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                           Masteropleiding Verpleeg- en 
Vroedkunde                                            
               Studienummer wzc       □□□ 
               Studienummer huisarts  A□□ 
               Studienummer resident □□□              
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST HUISARTS (deel 2) 
Gelieve hieronder de gegevens voor elke geselecteerde patiënt aan te kruisen of in te vullen.   
Alvast bedankt voor uw medewerking aan dit onderzoek.  
 
1. INDICATIE EN GEBRUIK VAN BENZODIAZEPINE (BENZO) OF Z-DRUG BIJ DEZE RESIDENT 
1.1. Voor welke indicatie werd de benzo of z-drug bij deze resident voorgeschreven?                             
(meerdere antwoorden zijn mogelijk) 
1 □  slapeloosheid  3 □  depressie      5 □  ik weet het niet  
2 □  angst   4 □  kalmering (acute agitatie)          6 □  andere:…………. 
 
1.2. A. Waar is deze resident met de benzo of z-drug gestart?  
0 □  onbekend (ga naar vraag 1.3) 
1 □  gestart alvorens het verblijf in het wzc  (ga naar vraag B)                  
2 □  gestart tijdens het verblijf in het wzc (ga naar vraag B)                     
3 □  gestart tijdens ziekenhuisopname gedurende het verblijf in het wzc (ga naar vraag B) 
  
B. Hoelang gebruikt de resident de benzo of z-drug?   
             …… jaren   …… maanden 
 
1.3. Werd er het afgelopen jaar…? 
         1   overwogen om de dosis te verminderen?                           0 □ neen         1 □ ja     
        2   een poging ondernomen om de dosis te verminderen?                  0 □ neen         1 □ ja 
       3   overwogen om te stoppen?                                        0 □ neen         1 □ ja    
       4   een poging ondernomen om te stoppen?                                       0 □ neen         1 □ ja    
  
1.4. Zou volgens u de benzo of z-drug bij deze rusthuisresident kunnen gestopt worden? 
                                            0 □ neen    1 □ ja      
                        reden: …………………………………………….. 
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1.5. Hebt u de indruk dat het gebruik van benzo of z-drug bij deze resident het gewenste effect 
geeft? (het gewenste effect is goede slaapkwaliteit, minder angstig of minder depressief) 
0 □ neen    1 □ ja       
 
1.6. Zijn er volgens u bijwerkingen van benzo of z-drug merkbaar bij deze resident?                         
(meerdere antwoorden zijn mogelijk) 
1 □ slaperigheid overdag  5 □ apathie    9 □ afhankelijkheid (psychisch) 
2 □ verwardheid   6 □ geheugenstoornis  10 □ ik weet het niet 
      3 □ spierzwakte   7 □ duizeligheid   11 □ geen 
4 □ concentratiestoornis            8 □ afhankelijkheid (fysisch) 12 □ andere: ……… 
 
2. MOGELIJKE BARRIÈRES OM EEN AFBOUWPOGING VAN BENZODIAZEPINE (BENZO) 
OF Z-DRUG BIJ DEZE RESIDENT TE ONDERNEMEN 
 In dit deel kan u een antwoord geven op de mate waarin u volgende stellingen als een barrière  (belemmering) 
ervaart. Duid met een kruisje aan in welke mate dat overeenkomt met uw ervaring bij deze resident; van geen 
barrière (in geen mate) tot een sterke barrière (in sterke mate). 
Barrière Score 
1. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de initiële problemen bij deze resident zullen terugkomen. 
in geen mate □□□□□□□□□□ in sterke mate 
2. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de zorglast voor het personeel zal toenemen.  in geen mate □□□□□□□□□□ in sterke mate 
3. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
bij deze resident mogelijke ongewenste symptomen zullen 
optreden. 
in geen mate □□□□□□□□□□ in sterke mate 
4. Het afbouwen of stopzetten van benzo of z-drug is niet 
nodig zolang deze resident goed functioneert. in geen mate □□□□□□□□□□ in sterke mate 
5. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de resident zelf niet gemotiveerd is. in geen mate □□□□□□□□□□ in sterke mate 
6. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de familie zich hier tegen zal verzetten. 
in geen mate □□□□□□□□□□ in sterke mate 
7. Bij afbouw of stopzetten van benzo of z-drug bij deze 
resident vrees ik dat het personeel niet gemotiveerd is. 
in geen mate □□□□□□□□□□ in sterke mate 
8. Bij deze resident gaat mijn voorkeur naar medicatie in 
plaats van een niet-medicamenteuze behandeling. 
in geen mate □□□□□□□□□□ in sterke mate 
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                            Masteropleiding Verpleeg- en 
Vroedkunde                                            
 Studienummer wzc       □□□ 
     Studienummer verpleegkundige V□□ 
 
 
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST VERPLEEGKUNDIGE (deel 1) 
Gelieve hieronder uw gegevens aan te kruisen of in te vullen. Indien meerdere residenten van uw 
afdeling deelnemen aan dit onderzoek, dient u dit formulier slechts één keer in te vullen.  
Alvast bedankt voor uw medewerking aan dit onderzoek.  
1. ALGEMENE KENMERKEN 
1.1. Wat is uw geslacht? 
1 □  man                            2 □  vrouw 
1.2. Wat is uw leeftijd? 
 …… jaar 
1.3. Wat is uw hoogst behaalde diploma? 
                         1 □  master in de verpleeg- en vroedkunde 
                         2 □  bachelor/ gegradueerde verpleegkundige (A1) 
                         3 □  gediplomeerde/ gebrevetteerde verpleegkundige (A2) 
                         4 □ verpleegassistente  
1.4. Heeft u een bijkomende opleiding in de gezondheidszorg gevolgd?  
( vb: beroepstitel/ beroepsbekwaamheid in geriatrie, palliatieve zorg, dementie) 
                         0 □  neen  1 □  ja 
1.5. Hoeveel uren vorming heeft u in 2011 gevolgd? (banaba of vormingsuren waarvoor u 
educatief verlof kreeg niet meegeteld) 
             …… uren 
1.6. Hoeveel jaren werkt u al in de gezondheidszorg? 
             …… jaren 
1.7. Hoeveel jaren werkt u in dit woon- zorgcentrum?  
…… jaren 
1.8. Wat is uw huidige functie?      
1 □ hoofdverpleegkundige        2 □ verpleegkundige 
1.9. Wat is uw huidig arbeidsregime? 
…… % 
1.10. Hoeveel keer per week zet u medicatie klaar? (aantal) 
…… keer 
1.11. Hoeveel keer per week deelt u medicatie uit? (aantal) 
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                 Masteropleiding Verpleeg- en 
Vroedkunde                                            
 Studienummer wzc       □□□ 
       Studienummer verpleegkundige V□□ 
 Studienummer resident    □□□ 
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST VERPLEEGKUNDIGE (deel 2) 
Gelieve hieronder de gegevens voor elke geselecteerde resident aan te kruisen of in te vullen.   
Alvast bedankt voor uw medewerking aan dit onderzoek.  
1. INDICATIE EN GEBRUIK VAN BENZODIAZEPINE (BENZO) OF Z-DRUG BIJ DEZE RESIDENT 
1.1. Voor welke indicatie werd de benzo of z-drug bij deze resident voorgeschreven?                             
(meerdere antwoorden zijn mogelijk) 
1 □  slapeloosheid  3 □  depressie      5 □  ik weet het niet  
2 □  angst   4 □  kalmering (acute agitatie)          6 □  andere:…………. 
 
1.2. A. Waar is deze resident met de benzo of z-drug gestart?  
0 □  onbekend (ga naar vraag 1.3) 
1 □  gestart alvorens het verblijf in het wzc  (ga naar vraag B)                  
2 □  gestart tijdens het verblijf in het wzc (ga naar vraag B)                     
3 □  gestart tijdens ziekenhuisopname gedurende het verblijf in het wzc (ga naar vraag B)  
B. Hoelang gebruikt de resident de benzo of z-drug?   
             …… jaren  …… maanden 
 
1.3. Werd er het afgelopen jaar…? 
         1   overwogen om de dosis te verminderen?                           0 □ neen         1 □ ja     
        2   een poging ondernomen om de dosis te verminderen?                  0 □ neen         1 □ ja 
       3   overwogen om te stoppen?                                        0 □ neen         1 □ ja    
       4   een poging ondernomen om te stoppen?                                       0 □ neen         1 □ ja     
 
1.4. Zou volgens u de benzo of z-drug bij deze rusthuisresident kunnen gestopt worden? 
                                            0 □ neen    1 □ ja      
                        reden: …………………………………………….. 
 
1.5. Hebt u de indruk dat het gebruik van benzo of z-drug bij deze resident het gewenste effect geeft? 
(het gewenste effect is goede slaapkwaliteit, minder angstig of minder depressief) 
0 □ neen    1 □ ja       
 
1.6. Zijn er volgens u bijwerkingen van benzo of z-drug merkbaar bij deze resident?                         
(meerdere antwoorden zijn mogelijk) 
1 □ slaperigheid overdag  5 □ apathie    9 □ afhankelijkheid (psychisch) 
 
 
 
2. ALGEMENE HOUDING OVER MOGELIJKE BARRIÈRES VOOR HET AFBOUWEN OF 
STOPZETTEN VAN BENZODIAZEPINE (BENZO) OF Z-DRUG 
In dit deel kan u een antwoord geven op de mate waarin u volgende stellingen als een barrière (belemmering) 
ervaart. Duid met een kruisje aan in welke mate dat overeenkomt met uw ervaring; van geen barrière (in geen mate) 
tot een sterke barrière (in sterke mate). 
Barrière Score 
1. Ik heb onvoldoende noodzakelijke wetenschappelijke informatie 
om benzo of z-drug af te bouwen of stop te zetten.       in geen mate □□□□□□□□□□ in sterke mate 
2. Ik heb onvoldoende kennis over mogelijke alternatieven om 
problemen bij afbouwen of stopzetten van benzo of z-drug op te 
vangen. 
in geen mate □□□□□□□□□□ in sterke mate 
3. Het uitproberen van alternatieven voor benzo of z-drug kost teveel 
tijd en moeite.  
in geen mate □□□□□□□□□□ in sterke mate 
4. De afwezigheid van een psycholoog in het wzc vormt een barrière 
om de afbouw of het stopzetten van benzo of z-drug te ondersteunen. 
in geen mate □□□□□□□□□□ in sterke mate 
5. Het ritme in het wzc (het vroege slapen gaan) vormt een barrière 
om te kunnen afbouwen of stoppen met benzo of z-drug. in geen mate □□□□□□□□□□ in sterke mate 
6. Hoe langer de resident de benzo of z-drug neemt, hoe moeilijker 
het is om af te bouwen of te stoppen. in geen mate □□□□□□□□□□ in sterke mate 
7. Het overlegmoment tussen huisarts en verpleegkundige is te kort 
om over afbouwen of stopzetten van benzo of z-drug te praten.  in geen mate □□□□□□□□□□ in sterke mate 
8. Het gebruik van een elektronisch herhalingsmedicatie-voorschrift 
zorgt ervoor dat er niet kan overlegd worden over eventueel afbouwen 
of stopzetten van benzo of z-drug. 
in geen mate □□□□□□□□□□ in sterke mate 
9. Het ontbreken van een apotheker verbonden aan het wzc vormt een 
barrière om het afbouwen of stopzetten van benzo of z-drug te 
ondersteunen. 
in geen mate □□□□□□□□□□ in sterke mate 
10. De leeftijd van de resident en het langdurig gebruik van benzo of 
z-drug maken het zinloos om af te bouwen of te stoppen.  in geen mate □□□□□□□□□□ in sterke mate 
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                 Masteropleiding Verpleeg- en 
Vroedkunde                                            
 Studienummer wzc       □□□ 
       Studienummer verpleegkundige V□□ 
 Studienummer resident    □□□ 
Onderzoek naar het chronisch gebruik van benzodiazepine bij rusthuisresidenten 
VRAGENLIJST VERPLEEGKUNDIGE (deel 2) 
Gelieve hieronder de gegevens voor elke geselecteerde resident aan te kruisen of in te vullen.   
Alvast bedankt voor uw medewerking aan dit onderzoek.  
1. INDICATIE EN GEBRUIK VAN BENZODIAZEPINE (BENZO) OF Z-DRUG BIJ DEZE RESIDENT 
1.1. Voor welke indicatie werd de benzo of z-drug bij deze resident voorgeschreven?                             
(meerdere antwoorden zijn mogelijk) 
1 □  slapeloosheid  3 □  depressie      5 □  ik weet het niet  
2 □  angst   4 □  kalmering (acute agitatie)          6 □  andere:…………. 
 
1.2. A. Waar is deze resident met de benzo of z-drug gestart?  
0 □  onbekend (ga naar vraag 1.3) 
1 □  gestart alvorens het verblijf in het wzc  (ga naar vraag B)                  
2 □  gestart tijdens het verblijf in het wzc (ga naar vraag B)                     
3 □  gestart tijdens ziekenhuisopname gedurende het verblijf in het wzc (ga naar vraag B)  
B. Hoelang gebruikt de resident de benzo of z-drug?   
             …… jaren  …… maanden 
 
1.3. Werd er het afgelopen jaar…? 
         1   overwogen om de dosis te verminderen?                           0 □ neen         1 □ ja     
        2   een poging ondernomen om de dosis te verminderen?                  0 □ neen         1 □ ja 
       3   overwogen om te stoppen?                                        0 □ neen         1 □ ja    
       4   een poging ondernomen om te stoppen?                                       0 □ neen         1 □ ja     
 
1.4. Zou volgens u de benzo of z-drug bij deze rusthuisresident kunnen gestopt worden? 
                                            0 □ neen    1 □ ja      
                        reden: …………………………………………….. 
 
1.5. Hebt u de indruk dat het gebruik van benzo of z-drug bij deze resident het gewenste effect geeft? 
(het gewenste effect is goede slaapkwaliteit, minder angstig of minder depressief) 
0 □ neen    1 □ ja       
 
1.6. Zijn er volgens u bijwerkingen van benzo of z-drug merkbaar bij deze resident?                         
(meerdere antwoorden zijn mogelijk) 
1 □ slaperigheid overdag  5 □ apathie    9 □ afhankelijkheid (psychisch) 
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2 □ verwardheid   6 □ geheugenstoornis  10 □ ik weet het niet 
      3 □ spierzwakte   7 □ duizeligheid   11 □ geen 
4 □ concentratiestoornis            8 □ afhankelijkheid (fysisch) 12 □ andere: ……… 
2. MOGELIJKE BARRIÈRES OM EEN AFBOUWPOGING VAN BENZODIAZEPINE (BENZO) OF Z-
DRUG BIJ DEZE RESIDENT TE ONDERNEMEN 
 In dit deel kan u een antwoord geven op de mate waarin u volgende stellingen als een barrière  
 (belemmering) ervaart. Duid met een kruisje aan in welke mate dat overeenkomt met uw ervaring bij deze 
resident; van geen barrière (in geen mate) tot een sterke barrière (in sterke mate). 
Barrière Score 
1. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de initiële problemen bij deze resident zullen terugkomen. 
in geen mate □□□□□□□□□□ in sterke mate 
2. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de zorglast voor het personeel zal toenemen.  in geen mate □□□□□□□□□□ in sterke mate 
3. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
bij deze resident mogelijke ongewenste symptomen zullen 
optreden. 
in geen mate □□□□□□□□□□ in sterke mate 
4. Het afbouwen of stopzetten van benzo of z-drug is niet 
nodig zolang deze resident goed functioneert. in geen mate □□□□□□□□□□ in sterke mate 
5. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de resident zelf niet gemotiveerd is. in geen mate □□□□□□□□□□ in sterke mate 
6. Bij afbouw of stopzetten van benzo of z-drug vrees ik dat 
de familie zich hier tegen zal verzetten. 
in geen mate □□□□□□□□□□ in sterke mate 
7. Bij afbouw of stopzetten van benzo of z-drug bij deze 
resident vrees ik dat het personeel niet gemotiveerd is. 
in geen mate □□□□□□□□□□ in sterke mate 
8. Bij deze resident gaat mijn voorkeur naar medicatie in 
plaats van een niet-medicamenteuze behandeling. 
in geen mate □□□□□□□□□□ in sterke mate 
 Indien u in de praktijk nog andere indicaties of barrières ondervindt en die voor u in dit onderzoek ontbreken, 
mag u dit hier geheel vrijblijvend noteren en beoordelen: 
   ……………………………………………………………………………………………………… 
   ……………………………………………………………………………………………………… 
   ……………………………………………………………………………………………………… 
   ……………………………………………………………………………………………………… 
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7. BENZODIAZEPINE WITHDRAWAL SYMPTOM QUESTION-
NAIRE- BWSQ
reference: Tyrer et al 1990
Wilt u trachten zich te herinneren welke van deze gewaarwordingen u de laatste 
weken hebt gehad en een vinkje zetten in het overeenkomstige vakje? 
Nee Ja, matig Ja, hevig/
ernstig
1. Onwezenlijk gevoel
2. Erg gevoelig voor geluid
3. Erg gevoelig voor licht
4. Erg gevoelig voor geur
5. Erg gevoelig voor aanraking
6. Vreemde smaak in de mond
7. Spierpijnen
8. Spiertrekkingen
9. Schudden en beven
10. ‘Slapen’ van handen, armen of benen
11. Duizeligheid
12. Flauw gevoel
13. Misselijk gevoel
14. Neerslachtig gevoel
15. Irritatie van de ogen
16. Gewaarworden dat de dingen bewegen terwijl ze 
stilstaan
17. Zien of horen van dingen die er in werkelijkheid 
niet zijn (hallucinaties)
18. Niet bij machte uw bewegingen te beheersen
19. Geheugenverlies
20. Verlies van eetlust
Heeft u nog andere nieuwe verschijnselen? (beschrijf 
elk verschijnsel hieronder)
21.
22.
23.
24.
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8. EQ-5D-3L
reference: Euroquol 1990
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7ABBREVIATIO
N
S
ABBREVIATIONS
AD:   Antidepressant
ADL:   Activities of Daily Living
ATC:   Anatomic Therapeutic Chemical
BZD:   benzodiazepines 
BZD/Z:   benzodiazepine and Z-drugs
CBT:   Cognitive Behavioural Therapy
CNS:   Central Nervous System
COPD:   Chronic Obstructive Pulmonary Disease
DDD:   Defined Daily Dose
DSM-IV-TR:  Diagnostic and Statistical Manual of Mental Disorders, 
  4th edition 2000 revision
DSM-V:   Diagnostic and Statistical Manual of Mental Disorders, 5th edition 2013
EMA:   European Medicine Agency
FDA:   Federal Drug Agency (United States)
GABA:   gamma-butyric acid
GDS:   geriatric depression scale
GP:   General Practitioner
GAD:   Generalised Anxiety Disorder
ICSD-2:   International Classification of Sleep Disorders, 2nd edition 2005
ICD-10:   International Classification of Diseases, WHO 1991
MMSE:   Mini Mental State Examination 
MED:   Minimal Effective Dose
NREM sleep:  nonrapid eye movement sleep
NICE:   National Institute for Health and Care Excellence
OBRA-87:  Omnibus Budget Reconciliation Act of 1987 
  (Federal Nursing Home Reform Act in the US)
OCD:   Obsessive Compulsive Disorder
OR:   Odds Ratio
PHEBE:   Prescribing in Homes for the Elderly in Belgium
PDD:   Prescribed Daily Dose
PSG:   polysomnography
PSQI:   Pittsburgh Sleep Quality Index (questionnaire)
RCT:   Randomised controlled trial
REM sleep:  rapid eye movement sleep
SAD:   Social Anxiety Disorder
SNRI:   Selective Norepinephrine Reuptake Inhibitor
SPSS:   Statistical Package for the Social Sciences
SSRI:   Selective Serotonin Reuptake Inhibitor
SWS :   slow wave sleep
TCA:   Tricyclic Antidepressant
US:   United States
UK:   United Kingdom
WHO:   World Health Organisation
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   Jolyce Bourgeois, Robert Vander Stichele 2013 HUISARTS 
   NU. 42(6)
   “Helft rusthuisbewoners aan de slaappil” commentaar
   Majda Azermai, Jolyce Bourgeois, Annemie Somers, Mirko 
   Petrovic (2013) AGEING HEALTH.
   “Inappropriate use of psychotropic drugs in older people: 
   implications for practice.
A3   Azermai M., Bourgeois J., Petrovic M., Minerva 2012; 11(6): 
   75-76 
   “Werkzaamheid en doeltreffendheid van atypische antipsychotica 
   bij volwassenen voor niet-geregistreerde indicaties.” 
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Contribution to conferences
2014   SLEEP 2014, May 31-June 4, Minneapolis USA
   1 poster
   “Evolution of sleep quality in chronic benzodiazepine users 
   compared to nonusers” 
   PHYSPHAR, April 4th and 5th, Maastricht 
   1 poster 
   “Does long-term benzodiazepine use has an impact on cognitive 
   deterioration?”
2013   International Research Conference on Nursing Homes, 
   St Louis USA
   Symposium organisation “Stopping Benzodiazepines: feasibility, 
   barriers and recommendations for practice” 
   European Association for Clinical Pharmacology and 
   Therapeutics (EACPT), Geneva 2013
   1 oral presentation + 1 poster
   “Sleep quality of chronic benzodiazepine users in nursing homes: 
   a comparative study with non-users.”
   “Perceptions about benzodiazepine discontinuation in 
   nursing  homes.”
   Belgian Association for Gerontology & Geriatrics: Wintermeeting
   1 oral presentation
   “Slaapkwaliteit van chronisch benzodiazepine gebruikers in 
   woonzorgcentra: een vergelijkende studie met niet-gebruikers.”
   Dutch Society of Clinical Pharmacology & Biopharmacy:   
   Mededelingendag 
   1 poster
   “SLEEP QUALITY  OF CHRONIC BENZODIAZEPINE USERS IN 
   NURSING HOMES: a comparative study with non-users.”
2012   Belgian Association for Gerontology & Geriatrics: 
   Wintermeeting 
   1 poster
   “Het gebruik van antidepressiva in Belgische rusthuizen: de 
   focus op indicaties en dosissen.”
   Wetenschapsdag, Ghent University
   1 poster
   “Antidepressants in Belgian nursing homes in Belgian nursing 
   homes: indications and dosages.”
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2011   European Association for Clinical Pharmacology and 
   Therapeutics (EACPT), Budapest 2011
   2 posters
   “USE of ANTIDEPRESSANTS IN BELGIAN NURSING HOMES”
   “CHRONIC BENZODIAZEPINE USE IN NURSING HOME RESIDENTS: 
   A CLOSER LOOK INTO INDICATIONS AND DOSAGES”
   International Psychogeriatrics (IPA), 
   Den Hague Sept, 2011
   1 poster
   “Barriers to discontinuation of  chronic use of benzodiazepines in 
   Belgian nursing home residents: A focus group study.”
223
224
9TH
AN
KS
THANKS
To everyone who made this possible…
People may think it is rude not to give special thanks and acknowledge the persons who con-
tributed to this work, and indeed they are right. Therefore, turn the page.
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After my graduation in 2010, I got interested in clinical pharmacology. As this was/is not read-
ily available as a master in Belgium, I started to search for possible education opportunities. 
The clinical pharmacology department led by professor Luc Van Bortel at the university of 
Ghent had such a program. Luckily a PhD position at the same department opened and made 
it possible to combine this education with research. I am very grateful that the two people in 
front of me during my solicitation saw ‘my potential’ and had confidence in me. Therefore I 
thank my promotor Robert ‘Bob’ VanderStichele and copromotor Monique Elseviers for guid-
ing me and being my backbone. In the beginning it was sometimes difficult during the endless 
discussion rounds and paper preparations. But as Bob always says: ‘a diamond in the rough 
needs several polishing turns’. A special thanks to professor Mirko Petrovic, who was officially 
in my steering committee, but appeared to be very close involved in my PhD project. He was 
a great mentor on the benzo level and a great support. I thank professor Luc Van Bortel for 
always seeing the big picture and giving me the opportunity to become a clinical pharmacol-
ogist during my PhD research. 
As every PhD student knows it is a lot of individual work and discipline, so a good work at-
mosphere is essential. And I must say I really liked going to the Heymans Institute, so thank 
you colleagues. As our research department is young and dynamic, the faces in the kitchen 
often change. In order of appearances: Thank you Karen, Ilse, Majda, Jan, Seba, Tine, Sofie, 
Carlos, Elien, Sandrien, Jelle, Isabelle, Katrina, Maarten and Wendy. In addition to our many 
laughs, I appreciated all the help. During my four PhD years I shared an office space with 
equally chaotic persons as myself: Majda, who was there from the beginning and was a great 
congress buddy, and since two years Katrina who gives the best advice and was actually my 
lifelike ‘google translate’. I also got acquainted with a lot of inspiring and helpfull people along 
the way, in the UZ and especially in the nursing homes. This research was not possible with-
out the helping hands of the 5 master thesis students from Antwerp University, who were 
responsible for parts of the data collection in the nursing homes. 
A good group of supporters is necessary to get to the finish. 
Thank you dear mam and dad for supporting me on every possible level. Thank you dear 
friends for the good advice.
A special thanks to my boyfriend, Bram, who forced me to always see everything in perspec-
tive and also helped me with the layout and presentation of this book. I also want to thank 
our fresh baby daughter Clara who kept calm and healthy in my uterus when I was writing 
this book.
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